



Transcranial Magnetic Stimulation as a Treatment of Depression and Other Disorders

Effective: June 1, 2026

Next Review: February 2027

Last Review: April 2026

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Transcranial magnetic stimulation (TMS) is a noninvasive method of delivering electrical stimulation to the brain. The technique involves placement of a small coil over the scalp; a rapidly alternating current is passed through the coil wire, producing a magnetic field that passes unimpeded through the brain. In contrast to electroconvulsive therapy, transcranial magnetic stimulation does not require anesthesia and does not induce convulsions. Transcranial magnetic stimulation is being evaluated as a treatment of depression and other psychiatric/neurologic brain disorders.

MEDICAL POLICY CRITERIA

Note: Clinical documentation to support criteria is required (See Required Documentation)

Medically Necessary

- Transcranial magnetic stimulation (TMS) of the brain may be considered **medically necessary** as a treatment of *major depressive disorder* when either of the following criteria are met:

- A. As initial treatment of a depressive episode (up to 36 rTMS or iTBS treatment sessions, one session per day, including tapering) when all of the following criteria are met (1. - 5.):
1. Confirmed diagnosis of severe major depressive disorder (single or recurrent) when both of the following criteria are met (a. - b.):
 - a. Diagnosis is confirmed by standardized rating scales (see Policy Guidelines) that reliably measure depressive symptoms; and
 - b. Documentation is submitted of both the rating scale that was used and the score.
 2. Age consistent with the device-specific FDA indication (see policy guidelines).
 3. The TMS device is FDA cleared for use in major depressive disorder.
 4. The TMS treatment of the brain is prescribed and supervised by a psychiatrist (MD or DO), psychiatric nurse practitioner or physician assistant/associate with appropriate supervision/collaboration (See policy guidelines).
 5. One of the following conditions is present:
 - a. Symptoms are ongoing despite treatment with the following psychopharmacologic regimens, and each has been ineffective, not tolerated (as evidenced by distinct side effects), or is contraindicated (see Policy Guidelines) as indicated by meeting both of the following (i. and ii.):
 - i. Either of the following:
 - a.) For adults (age 18 or older) either of the following:
 - i.) At least 3 antidepressant medications from at least 2 different classes in separate trials; or
 - ii.) At least 2 different antidepressant medications from at least 2 different classes in separate trials, plus failure with the addition of an augmenting agent to at least one of the failed antidepressants; and
 - b.) For adolescents (age 15 to 18) two separate trials of antidepressant medications.
 - ii. At least four weeks' duration for one or more of the antidepressant agents (unless none of the agents were tolerated).
 - b. History of response to TMS in a previous depressive episode (at least 3 months since the prior episode); or
 - c. Both of the following criteria are met (i. - ii.):
 - i. The individual is a candidate for electroconvulsive therapy (ECT); and
 - ii. The individual does not have psychosis, acute suicidal risk, catatonia, significantly impaired essential function, or other condition for which ECT would be clinically superior to TMS.
- B. Extension of initial therapy when both of the following criteria are met (1. - 2.):
1. The TMS is demonstrating meaningful improvements as documented by a 50% or greater improvement in standardized rating scales (see Policy

- Guidelines) that reliably measure depressive symptoms in the member's clinical status; and
2. There is reasonable expectation that continued treatment will produce improvement.

Not Medically Necessary

- II. Transcranial magnetic stimulation (TMS) of the brain is considered **not medically necessary** as a treatment for major depressive disorder when Criterion I. above is not met.

Investigational

- III. Transcranial magnetic stimulation (TMS) of the brain is considered **investigational** as a treatment for all other indications.
- IV. Accelerated protocols (more than one treatment session per day) for transcranial magnetic stimulation (TMS) of the brain is considered **investigational** for all indications. This includes the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

POLICY GUIDELINES

DEPRESSION RATING SCALES

Assessment tools to diagnose **severe** major depressive disorder may include, but are not limited to the following depression rating scales:

1. **Inventory of Depressive Symptomatology Clinician-related (IDS-C):**
 - Scored 0 - 84 with a score ≥ 39 for severe depression
2. **Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR):**
 - Scored 0 – 27 with a score ≥ 16 for severe depression
3. **Beck Depression Inventory (BDI):**
 - Scored 0 – 63 with a score of ≥ 29 for severe depression
4. **Hamilton Rating Scale (HDRS):**
 - Scored 0 – 52 with a score of ≥ 24 for severe depression
5. **Montgomery-Asberg Depression Rating Scale (MADRS):**
 - Scored 0 – 60 with a score of ≥ 35 for severe depression
6. **Patient Health Questionnaire-9 (PHQ-9):**
 - Scored 0- 27 with a score of ≥ 15 for severe (including moderate severe) depression

PROVIDER TYPES

- A Nurse Practitioner is required to be qualified as a Psychiatric Mental Health Nurse Practitioner (PMHNP) or Advanced Registered Nurse Practitioner (ARNP) with national psychiatric PMHNP certification (e.g., PMHNP board certified).
- Physician Assistants/Associates (PA) are required to have a supervisory/collaborative agreement with a psychiatrist (MD or DO) who has training in TMS and provides direct patient care services with the same organization as the PA.

AGE LIMITATIONS FOR TMS DEVICES

TMS devices listed on this table have been approved for use in patients younger than 18 years of age. All other FDA approved devices are approved for use only in adults (≥ 18 years of age).

Device name and Manufacturer	Indication*	Approved Ages	FDA approval date
Horizon® 3.0 TMS Therapy Systems (Magstim)	Adjunct treatment of MDD Adjunct treatment of OCD Treatment of MDD	15 – 21 Adults Adults	March 2025 2024 2019
Neurostar® TMS therapy system (Neuronetics)	MDD	15- 25 Adult	March 2024 2008
Savi Dual™ Migraine Therapy (ENeura)	Migraine	≥ 12 years old	May 2023
MagVenture TMS Therapy System	Adjunct treatment of MDD Treatment of MDD Adjunct treatment of OCD	15-21 Adults Adults	July 2025
BrainsWay Deep TMS System	Adjunct treatment of MDD Treatment of MDD	15-21 Adults	October 2025 January 2013

*Major Depressive Disorder (MDD); Obsessive Compulsive Disorder (OCD)

CONTRAINDICATIONS

Contraindications to TMS include:

- Seizure disorder or any history of seizure with increased risk of future seizure; OR
- Presence of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode; OR
- Neurologic conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system (CNS); OR
- Significantly impaired essential function, defined as functions necessary to sustain life, such as feeding and hydrating oneself; OR
- Presence of an implanted magnetic-sensitive medical device located 30 centimeters or less from the TMS magnetic coil or other implanted metal items, including but not limited

to a cochlear implant, implanted cardioverter defibrillator (ICD), pacemaker, deep brain stimulator, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents.

REQUIRED DOCUMENTATION

It is critical that the list of information below is submitted for review to determine if the policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome.

- History and Physical/Chart Notes
- Confirmed diagnosis of severe major depressive disorder (single or recurrent) documented by standardized rating scales, including:
 - o Standardized rating scale(s) used
 - o Score
- Psychopharmacologic regimen history with documented response
- Name of FDA approved device to be used for TMS treatment
- Documentation of prescribing provider qualifications (MD or DO, psychiatric nurse practitioner or physician assistant with appropriate supervision/collaboration).
- Documentation of rTMS or iTBS protocol used

CROSS REFERENCES

1. [Spravato, esketamine](#), Medication Policy Manual, Policy No. dru605 (Available 01/01/2027)

BACKGROUND

Transcranial magnetic stimulation (TMS), introduced in 1985 as a new method of noninvasive stimulation of the brain, involves placement of a small coil over the scalp, passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex. TMS was initially used to investigate nerve conduction; e.g., TMS over the motor cortex will produce a contralateral muscular-evoked potential. The motor threshold (RMT), which is the minimum intensity of stimulation required to induce a motor response, is empirically determined for each person by localizing the site on the scalp for optimal stimulation of a hand muscle, then gradually increasing the intensity of stimulation. The stimulation site for the treatment of depression is usually 5 cm anterior to the motor stimulation site.

In contrast to electroconvulsive therapy, TMS does not require general anesthesia and does not generally induce a convulsion. Interest in the use of TMS as a treatment for depression was augmented by the development of a device that could deliver rapid, repetitive stimulation. Imaging studies had shown a decrease in the activity of the left dorsolateral prefrontal cortex in depressed patients, and early studies suggested that high-frequency (e.g., 5-10 Hz) TMS of the left dorsolateral prefrontal cortex had antidepressant effects. Low frequency (1-2 Hz) stimulation of the right dorsolateral prefrontal cortex has also been investigated. The rationale for low-frequency TMS is inhibition of right frontal cortical activity to correct the interhemispheric imbalance. A combination approach (bilateral stimulation), or deep stimulation with an H1 coil, is also being explored, as is thetaburst stimulation.

Standard or conventional repetitive TMS (rTMS) protocols were initially approved by the FDA in 2008 and are typically delivered in one treatment per day for 20 to 30 sessions over 6 weeks with a taper of 6 sessions over 3 additional weeks. Theta burst stimulation (iTBS), a form of

rTMS, was first approved by the FDA in 2018 and delivers high-frequency (50 Hz) TMS in approximately 3-minute sessions. Accelerated TMS typically utilizes iTBS to deliver treatments over a shorter period, usually with ≥ 2 treatments per day; the optimal intertreatment interval and number of daily sessions remains under investigation.^[1] Stanford Neuromodulation Therapy (SNT), also known as SAINT protocol, represents an intensive accelerated approach delivering 10 iTBS sessions per day over 5 consecutive days (50 total sessions) and incorporates functional MRI guidance to individualize targeting based on patient-specific brain connectivity patterns.

Repetitive TMS is also being tested as a treatment for a variety of other disorders. In addition to the potential for altering interhemispheric imbalance, it has been proposed that high-frequency repetitive TMS may facilitate neuroplasticity.

Regulatory Status

The Food and Drug Administration (FDA) granted 510(k) approval for the following devices:

- Brainsway
 - o In 2013 the BrainsWay™ H-Coil Deep TMS System (Brainsway, Ltd.) received FDA clearance for the treatment of depressive episodes in adult patients suffering from major depressive disorder who have failed to respond to antidepressant medications in their current episode of depression (K12228).
 - o The Deep TMS System (Brainsway) was granted a de novo 510(k) classification by FDA (DEN170078) in August 2018. The new classification applies to this device and substantially equivalent devices of this generic type. The Brainsway Deep TMS system is cleared for treatment of adult patients with Obsessive-Compulsive Disorder (approved in 2019). FDA product code: QCI.
 - o In 2019 and 2021 The BrainsWay Deep TMS System received FDA clearance for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode (K210201, K220819).
 - o In 2025 the BrainsWay Deep TMS System add the indication as an adjunct for the treatment of Major Depressive Disorder (MDD) in adolescent patients (age 15-21 years) – K251391.
- Cerena™ TMS device (Eneura Therapeutics) received de novo marketing clearance for the acute treatment of pain associated with migraine headache with aura in 2013. Warnings, precautions, and contraindications include the following:
 - o The device is only intended for use by patients experiencing the onset of pain associated with a migraine headache with aura.
 - o The device should not be used on headaches due to underlying pathology or trauma.
 - o The device should not be used for medication overuse headaches.
 - o The device has not been demonstrated as safe or effective when treating cluster headache or chronic migraine headache.

- o The device has not been shown to be effective when treating during the aura phase.
 - o The device has not been demonstrated as effective in relieving the associated symptoms of migraine (photophobia, phonophobia, and nausea).
 - o Safety and effectiveness have not been established in pregnant women, children under the age of 18, and adults over the age of 65.
- MagVita TMS Therapy System® (approved 2015) and MagVita TMS Therapy System w/Theta Burst Stimulation (approved 2018) are indicated for the treatment of Major Depressive Disorder in adult patients who failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
 - NeuroStar® (formerly known as NeoPulse®) TMS Therapy system (Neuronetics, Inc.) received de novo clearance in 2008 for the treatment of major depressive disorder in adults who have failed a six-week course of one antidepressant medication. NeuroStar Advanced Therapy System (approved in 2022) is indicated as an adjunct for the treatment of adult patients who are suffering from obsessive-compulsive disorder (OCD). In March 2024, the Neurostar® TMS therapy system was approved by the FDA for use in 15 - 25-year-olds (K231926).
 - Rapid² Therapy System from Magstim Company Limited (approved 2015) is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
 - SpringTMS® received FDA clearance for the treatment of migraines, with aura.
 - Neurosoft TMS (TeleEMG) was approved by the FDA in 2016 for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
 - Apollo TMS Therapy System (Mag & More, approved in 2018) is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
 - Nexstim Navigated Brain Therapy (NBT®) System 2 (approved in 2017) is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
 - ALTMS Magnetic Stimulation Therapy System (also Blossom TMS Therapy System, approved in 2022) is indicated for the treatment of Major Depressive Disorder in adult patients, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
 - The Magnus Neuromodulation System (MNS) with SAINT technology - model Number 1001K was FDA approved in 2022 for the treatment of Major Depressive Disorder (MD D) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. (K220177)
 - Horizon 3.0 TMS Therapy System Magstim is indicated for Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior

antidepressant medication in the current episode, as well as an adjunct for the treatment of adult patients suffering from obsessive-compulsive disorder (Cleared 1/13/2023 K222171). The Horizon 3.0 TMS Therapy Systems were cleared for adjunct treatment of adolescents (ages 15 -21) in March 2025 (K243869)

- MagVenture TMS Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. The MagVenture TMS Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from obsessive-compulsive disorder (OCD). (July 2025, K251119) The MagVenture system is also indicated as an adjunct for the treatment of MDD in adolescent patients aged 15 -21. (July 2025, K251125)

The de novo 510(k) review process allows novel products with moderate or low-risk profiles and without predicates which would ordinarily require premarket approval as a class III device to be down-classified in an expedited manner and brought to market with a special control as a class II device.

EVIDENCE SUMMARY

Systematic reviews (SRs) and well-designed randomized controlled trials (RCTs) comparing active transcranial magnetic stimulation (TMS) to sham devices are needed in order to establish safety and efficacy of this treatment for any condition.

MAJOR DEPRESSIVE DISORDER (MDD)

Systematic Reviews and Technology Assessments

Lefaucheur (2025) published a systematic review (SR) examining accelerated transcranial magnetic stimulation (aTMS) compared to standard or sham repetitive TMS (rTMS) for treating major depressive disorder and treatment-resistant depression.^[2] The review included 23 studies and analyzed the efficacy of aTMS protocols along with the impact of various stimulation parameters including pattern, intersession interval, dosage, and cortical targeting methods. While some studies showed no significant differences between aTMS and standard protocols, others suggested potential advantages of aTMS, particularly with twice-daily high-frequency rTMS of the left dorsolateral prefrontal cortex or more intensive intermittent theta burst stimulation protocols with longer intervals between sessions and personalized cortical targeting. The results suggest that the number of sessions or pulses per session, duration of intervals between sessions, and precision of target localization using image-guided neuronavigation influenced therapeutic efficacy. Limitations included small sample sizes, few independent replication studies, and variability in clinical profiles of treated patients with different definitions of treatment resistance and presence of comorbidities, preventing definitive conclusions.

Gamboa (2025) published a SR comparing accelerated TMS to repetitive TMS in major depressive disorder.^[3] The review included four studies (n = 219). Results showed symptom improvement across all groups, with accelerated protocols demonstrating faster response in some cases, though long-term efficacy varied and no study provided conclusive superiority of one protocol over the other. The authors suggested that aTMS demonstrated efficacy,

tolerability, and cost-effectiveness, suggesting non-inferiority to rTMS while highlighting the need for further research to define optimal accelerated protocols and evaluate long-term outcomes. Study limitations included small sample sizes, variability in aTMS protocols (frequency, intensity, and number of sessions), inconsistency in depression rating scales, diagnostic heterogeneity, and short follow-up durations.

Gallop (2025) published a SR of transcranial magnetic stimulation for pediatric major depressive disorder that identified 28 studies (n = 640 participants), including four double-blind, sham-controlled RCTs, one additional trial which compared low-frequency versus high-frequency rTMS, six open-label cohort studies, and multiple case reports.^[4] The largest RCT (n=103) found no significant difference between active and sham rTMS on clinician-rated depression severity or remission rates, while another RCT (n =100) showed that rTMS combined with a selective serotonin reuptake inhibitor (SSRI) produced significantly greater reductions in HAM-D, children's depression rating scale-revised (CDRS-R) scores, and higher response rates than SSRI alone. A smaller sham-controlled RCT (n=55) reported reductions in depression severity and fewer self-injury impulses in non-medicated adolescents who received rTMS. Open-label cohorts (n=8 to 32) generally reported significant reductions in both clinician-rated and self-reported depression severity, with some effects maintained up to 6 months. A meta-analysis was not performed due to heterogeneity in study design, comparators, and stimulation protocols.

Lan (2023) published a SR examining the efficacy and safety of Stanford Neuromodulation Therapy (SNT) for treatment-resistant depression (TRD).^[5] The review included one randomized controlled trial (n = 29) and three single-arm prospective studies (n = 34). In the RCT, active SNT demonstrated significantly higher antidepressant response rates compared to sham (71.4% versus 13.3%) and remission rates (57.1% versus 0%). The single-arm studies reported response rates ranging from 83.3% to 90.5% and remission rates from 66.7% to 90.5%. No severe adverse events occurred across all four studies. The review concluded that SNT significantly improved depressive symptoms in patients with TRD within 5 days without severe adverse events. Limitations include the small number of studies and participants, lack of long-term follow-up data, and limited diversity in study designs with only one RCT available.

Cai (2023) published a SR and meta-analysis (MA) evaluating the effectiveness of accelerated intermittent theta burst stimulation (aiTBS) in MDD or bi-polar depression (BD).^[6] Five double-blind randomized controlled trials (RCTs) with 239 MDD or BD patients with a major depressive episode were included. Active aiTBS overperformed sham stimulation in the study-defined response. The authors concluded that preliminary evidence that active aiTBS resulted in a greater response in treating major depressive episodes in MDD or BD patients than sham stimulation.

Qin (2023) published a SR of RCTs with meta-analysis evaluated efficacy and safety of bilateral theta-burst stimulation (TBS) as a type of repetitive TMS (rTMS) intervention for patients with mood disorders.^[7] Analyses included six RCTs with 285 participants with major depressive disorder (MDD) (n = 233) or a depressive episode in the course of bipolar disorder (BD) (n = 52) who had undergone active bilateral TBS (n = 142) versus sham stimulation (n = 143). Active bilateral TBS outperformed sham stimulation with respect to study-defined improvements (55.1 % versus 20.3 %, 4 RCTs, n = 152, 95%CI: 1.63 to 4.39, p < 0.0001; I² = 0 %) and remission rates (37.2 % versus 14.3 %, 2 RCTs, n = 85, 95%CI: 1.13 to 5.95, p = 0.02; I² = 0 %) in MDD patients but not those with bipolar or unipolar mixed depression. Superiority of active bilateral TBS over sham stimulation was confirmed for improvements in

depressive symptoms at post-bilateral TBS assessments and 8-week follow-ups in patients with either MDD or mixed depression (all $p < 0.05$). Discontinuation rates due to any reason and adverse events (i.e., headache, dizziness) were similar between TBS and sham stimulation groups with MDD or mixed depression (all $p > 0.05$). The authors conclude that bilateral TBS targeting the dorsolateral prefrontal cortex (DLPFC) appears to be a well-tolerated form of rTMS that has substantial antidepressant effects, particularly in patients with MDD.

Neuteboom (2023) published a SR evaluating the efficacy, safety and tolerability of accelerated intermittent theta burst stimulation (aiTBS) in patients with MDD.^[8] aiTBS was defined as at least three iTBS treatment sessions per day, during at least four days for one week. Six articles from five unique studies met eligibility criteria; two open-label studies and three RCTs [two double blind and one quadruple blind]. Response rates directly after treatment ranged from 20.0% to 86.4% and remission rates ranged from 10.0 to 86.4%. Four weeks after treatment response rates ranged from 0.0% to 66.7% and remission rates ranged from 0.0% to 57.1%. Three articles described a significant reduction in suicidality scores. aiTBS was well tolerated and safe, with no serious adverse events reported. The studies included small sample sizes and differed in frequency, intersession interval, neuro localization and stimulation intensity. Replication studies and larger RCTs are warranted to establish efficacy, safety and long-term effects.

A systematic review conducted by Voigt (2021) focused on theta burst stimulation for treatment-resistant depression (TRD).^[9] The reviewers included eight RCTs comparing theta burst stimulation to sham treatment and one comparing theta burst stimulation to conventional rTMS. As measured by the HAM-D, theta burst stimulation was superior to sham on response (RR 2.4; 95% CI 1.27 to 4.55; $p=0.007$; $I^2 = 40\%$). There was no statistically significant difference between theta burst stimulation and conventional rTMS (RR 1.02; 95% CI 0.85 to 1.23; $p=0.80$; $I^2 = 0\%$). There was no difference between theta burst stimulation and rTMS in the incidence of adverse events.

Chu (2020) published an SR on theta-burst stimulation for major depression.^[10] A total of 10 studies met inclusion criteria. Six, including 294 participants, were RCTs, and four, including 297 participants, were uncontrolled. According to the meta-analysis, the overall effect size of response rate was 0.38 (95% confidence interval [CI] 0.29 to 0.48) and the overall effect size of remission rate was 0.20 (95% CI 0.13 to 0.29).

In 2019, the Canadian Agency for Drugs and Technologies in Health (CADTH) published an updated review of rTMS for depression, previously published in 2015.^[11] The report addressed the clinical safety and effectiveness of TMS for treatment-resistant depression and the cost-effectiveness. This summary will focus on the safety and effectiveness review. The review includes three SRs (the Health Quality Ontario SR described below and two more recent SRs) and five RCTs on the safety and effectiveness of rTMS. Two of the SRs included only sham comparators, while the third included pharmacological, ECT, and sham comparators. One SR reported separately on unilateral and bilateral stimulation, although both resulted in greater rates of response and remission (with weighted mean differences [WMDs] of 3.36 and 2.67 for unilateral and bilateral, respectively). The second and third SRs did not do separate analyses of unilateral and bilateral rTMS. The second reported a difference in Montgomery-Asberg Depression Rating Scale (MADRS) score of -3.6 points (95% credible interval [CrI], -7.6 to 0.3) between rTMS and sham and the third reported a WMD in HDRS scores between rTMS and sham of 2.31 points (95% CI 1.19 to 3.43,

$p < 0.001$) in favor of rTMS. In the analysis of rTMS versus ECT in the third SR, the WMD in HDRS scores was 5.97 (95% CI 10.94 to 11.0) in favor of ECT, with a 72% higher response rate and 44% higher remission rate. The review concluded that the effect of rTMS would be considered clinically relevant in two systematic reviews, but not in the third. Additionally, the review stated that based on one SR, the benefit of ECT versus rTMS would be considered clinically relevant.

Hung (2020) performed an SR evaluating the use of deep TMS for treatment-resistant depression.^[12] A total of 15 studies met inclusion criteria, including three RCTs and 12 uncontrolled studies. Results of the meta-analysis including all 15 studies indicated that dTMS significantly improved the depressive (Hedges' $g = -1.323$, 95% CI -1.651 to -0.995, $p < 0.001$) and anxiety symptoms (Hedges' $g = -1.282$, 95% CI -1.514 to -1.051, $p < 0.001$) in patients with treatment-resistant depression. A subgroup analysis was performed of RCTs versus uncontrolled studies that indicated there was a larger effect size in the uncontrolled studies (-1.461 for uncontrolled studies vs -0.756 for RCTs).

In 2019, Voigt published an SR that reviewed the efficacy of repetitive TMS (rTMS) in non-treatment resistant patients with major depressive disorder.^[13] Ten studies were included in the analysis. The quality of these studies was assessed with GRADE and CEBM. Only one study was a double-blind RCT (quality rating 1B). This RCT compared medication resistant patients (two or more medication trials) with non-medication resistant patients (one unsuccessful medication trial). The likelihood of responding to rTMS was four times higher in the group with only one unsuccessful medication trial before rTMS compared to the group that received two or more unsuccessful trials ($p = 0.021$). Of the remainder of the studies, four were RCTs. They were all single-center RCTs conducted in China and all had a quality rating of 1B. Two addressed treatment of the first episode of depression. One reported significantly greater numbers of early improvers in rTMS plus antidepressant compared to sham plus antidepressant at two weeks ($p = 0.031$) but not four weeks ($p = 0.586$). The other reported that the rate of relapse/recurrence at 12 months was significantly lower in rTMS plus antidepressant compared to antidepressant alone ($p = 0.033$). Two RCTs addressed treatment naïve patients. One reported significantly greater response and remission rates in active versus sham rTMS (both in combination with antidepressant; $p < 0.05$). The other reported a significantly greater number of patients achieving a $\geq 50\%$ reduction in HAM-D-17 score in the active versus sham rTMS (both in combination with antidepressant; $p < 0.05$). Limitations of this analysis were heterogeneity of the included studies and a lack of risk of bias assessment.

Martin (2017) published an SR that evaluated the cognitive effects of rTMS used for the treatment of depression. Eighteen studies were included in the analysis.^[14] Using the Cochrane Collaboration's tool for assessing risk of bias in randomized trials, the authors determined that the majority of studies had a low risk of bias across most standard criteria, but had an unclear risk of bias for allocation concealment and selective reporting of results. One study, which was not randomized, had a high risk of selection bias. Measures of attention and working memory, processing speed, executive function, and learning and memory were examined. Significant differences were found between rTMS and sham for the Trail Making Test Parts A and B, measures of attention/working memory and processing speed. A lack of significant differences was found for the remainder of measures analyzed.

Kedzior (2017) published an SR assessing cognitive outcomes following high-frequency rTMS versus electroconvulsive therapy (ECT).^[15] Due to high heterogeneity with respect to cognitive

assessment, no meta-analyses were performed. Cognitive functioning was assessed in six studies including 111 high-frequency rTMS-treated and 94 ECT-treated patients. All but one study reported similar acute cognitive impairments were reported following ECT and high-frequency rTMS. Three studies reported outcomes that favored ECT over high-frequency rTMS based on acute mood outcomes. The review concluded that more studies are needed to be able to reliably compare the effects of these treatments on cognitive outcomes.

In 2016, the Health Quality Ontario published a meta-analysis of left DLPFC rTMS for treatment-resistant depression (TRD).^[16] Reviewers included 23 RCTs (n=1156 patients) that compared rTMS with sham and six RCTs (n=266 patients) that compared rTMS with ECT. In 16 studies, patients received rTMS in addition to antidepressant medication. Seven studies used intensities of less than 100% motor threshold and the definition of remission in the included studies varied (from ≤ 7 to ≤ 10 on the HAM-D). A meta-analysis showed a statistically significant improvement in depression scores when compared with sham, with a weighted mean difference (WMD) of 2.31. However, this was smaller than the prespecified clinically important difference of 3.5 points on the HAM-D, and the effect size was small (0.33; 95% confidence interval [CI], 0.17 to 0.5; $p < 0.001$). Subgroup analysis showed a larger and clinically significant treatment effect in the rTMS studies using 20 Hz with shorter train duration compared with other rTMS techniques (WMD=4.96; 95% CI 1.15 to 8.76; $p = 0.011$). Secondary analyses showed rTMS demonstrated statistically greater rate of response among 20 studies (pooled relative risk, 1.72; 95% CI 1.13 to 2.62; $p = 0.11$) as well as statistically greater rate of remission among 13 studies (pooled relative risk=2.20; 95% CI 1.44 to 3.38, $p < 0.001$).

For the six trials that compared rTMS with ECT, the WMD of 5.97 was both statistically and clinically significant in favor of ECT. The relative risk for remission and response rates favor ECT but was not statistically significant. Remission and relapse rates at the six-month follow-up were reported in two studies including 40 and 46 subjects, comparing rTMS and ECT. While one study reported slightly higher remission rate for ECT (27.3%) compared with rTMS (16.7%), the other study did not find significant difference between ECT and rTMS for mean depression scores at three or six months, but did note relapses were less frequent for ECT. Statistical comparisons were either not significant or not available, limiting the interpretation of these findings. The authors concluded there is little data to evaluate the long-term effects of rTMS and that ECT was more effective in improving depression.

Kedzior (2016) published a SR that evaluated cognitive function i.e. memory, attention, and psychomotor coordination after dTMS, using the H-coil system for patients with major psychiatric disorders.^[17] Thirteen studies were included, with most being of poor quality. Patients had either unipolar or bipolar depression or schizophrenia and showed short-term improvements. Although short-term cognitive function improved, more long-term sham-controlled studies are needed beyond the daily stimulation phase.

In 2014, the Washington State Health Care Authority conducted a Technology Assessment and updated review of the current literature comparing TMS to sham and ECT.^[18] The review included the AHRQ assessment noted below plus three additional RCTs. The WA TEC review came to the following conclusions:

Although the three RCTs published after the AHRQ report did not consistently detect statistically significant differences between rTMS and sham stimulation, the overall body of evidence is consistent with regard to direction of the results. A small quantity of data

suggested that the durability of effect, i.e., the continued advantage of active rTMS over sham rTMS, may not last beyond two or three weeks after the end of treatment; rTMS may serve primarily to accelerate recovery (low-quality evidence).

In addition, the WA TEC assessment concluded that a review of five RCTs, “suggested that rTMS may be as effective as ECT under certain circumstances, but under other circumstances, ECT may be superior; this evidence is based on low quality evidence because of unexplained inconsistency in study results.”

Randomized Controlled Trials

Liu (2026) published a randomized, double-blind, sham-controlled study evaluating the efficacy and safety of accelerated intermittent theta burst stimulation for adolescents with major depressive disorder.^[19] The study included 74 adolescents with non-treatment-resistant major depressive disorder randomly assigned to accelerated intermittent theta burst stimulation or sham group, with the active group undergoing 5 sessions of 1800-pulse intermittent theta burst stimulation per day targeting the left dorsolateral prefrontal cortex using neuronavigation for 10 consecutive days. Results showed that the accelerated intermittent theta burst stimulation group demonstrated significantly greater reduction in 17-item Hamilton Depression Rating Scale scores than the sham group at day 11 ($p < 0.001$, Cohen's $d = 0.86$, 95% CI = 0.38 to 1.33) and the 1-month follow-up (Cohen's $d = 0.72$, 95% CI = 0.24 to 1.18), though no statistically significant difference was observed at the 3-month follow-up ($p = 0.17$, Cohen's $d = 0.33$, 95% CI = -0.13 to 0.79).

Qin (2026) published a randomized, sham-controlled trial examining intermittent theta burst stimulation for non-suicidal self-injury in adolescents with major depressive disorder.^[20] The study included 60 participants (mean age 14.2 years, standard deviation 1.5 years; 55 female patients, 91.7%) randomly allocated to active or sham treatment groups in a 1:1 ratio, receiving active or sham intermittent theta burst stimulation over the left dorsolateral prefrontal cortex for five sessions daily for five days, with 85% completing the intervention. Results demonstrated that at 4 weeks post-intervention, the active treatment group showed greater Deliberate Self-Harm Inventory-Adolescent Revised version score reduction than the sham treatment group (mean difference = -18.66, 95% CI = -28.35 to -8.97). Active treatment led to greater decline in Deliberate Self-Harm Ideation Scale for Adolescents Revised ideation scores (mean difference = -9.23, 95% CI = -14.41 to -4.05) and Ottawa Self-Injury Inventory-addiction subscale scores (mean difference = -6.16, 95% CI = -10.58 to -1.74) compared with sham treatment. Longer-term follow-up is needed to assess durability of treatment effects.

Dalhuisen (2024) published a multicenter randomized controlled trial comparing repetitive Transcranial Magnetic Stimulation (rTMS) with pharmacological treatment in treatment-resistant depression.^[21] The study included 89 patients with unipolar nonpsychotic depression who had failed at least two previous treatments. Patients were randomized to receive either 25 sessions of high-frequency rTMS to the left dorsolateral prefrontal cortex or a medication switch following Dutch treatment guidelines, with both groups receiving psychotherapy for eight weeks. Results showed rTMS was significantly more effective, with higher response (37.5% vs. 14.6%) and remission rates (27.1% vs. 4.9%) compared to medication switches. The rTMS group also showed greater improvement in anxiety and anhedonia symptoms. Treatment expectations correlated with Hamilton Depression Rating Scale score changes. Limitations include a relatively small sample size and moderate treatment resistance levels in the patient population.

The ASCERTAIN-TRD study was a 3-arm, open-label study in which patients with TRD (failed ≥ 2 antidepressants) were randomized to augmentation with either aripiprazole or rTMS or were switched to venlafaxine XR.^[22] The study was open-label and limited to eight weeks duration and 235 individuals completed the study. Montgomery-Åsberg Depression Rating Scale (MADRS) response rates were numerically improved with rTMS augmentation compared with either aripiprazole augmentation or switching to venlafaxine/duloxetine (52.2% vs 38.1% and 35.8%, respectively). MADRS remission rates were also better among rTMS-treated individuals (34.2% vs 25.3% and 24.9%, respectively). MADRS score changes were significantly improved with rTMS (-17.39; $p = 0.015$) compared with switch (-13.22); however, augmentation with aripiprazole (-14.9; $p = 0.069$) was not significantly better.

Wang (2023) published a RCT to explore the effect of rTMS on brain-derived neurotrophic factor (BDNF) levels and cognitive function in the treatment of middle-aged and elderly MDD.^[23] The patients ($n=120$) were randomly divided into control group ($n = 60$, patients received simple oral treatment with escitalopram and sham rTMS) and study group ($n = 60$, patients received oral treatment with escitalopram combined with rTMS) according to the random number table method. We compared the clinical efficacy, serum BDNF levels, and cognitive function between the two groups. After treatment, the HAMD-17 score in the study group was lower than that in the control group [13.00 (12.00-16.00) vs 17.00 (15.00-19.00), $p < .05$], and the RBANS score was higher than that in the control group [166.00 (161.25-171.75) vs 133.00 (130.00-136.75), $p < .05$]. The total effective rate of the research group was 95.0%, which was higher than the 82.0% of the control group ($p < .05$). The serum BDNF levels [36.00 (33.00-38.00) vs 30.00 (28.00-32.00), $p < .05$] and MoCA scores [24.00 (22.00-26.75) vs 23.00 (21.00-25.00), $p < .05$] of the study group were higher than those of the control group. There were no significant adverse reactions during the treatment of both groups. The authors concluded that compared with oral escitalopram alone, repeated transcranial magnetic stimulation in the treatment of middle-aged and elderly patients with major depressive disorder can further improve the efficacy, and can more effectively improve the BDNF level and cognitive function, with ideal safety.

Zangen (2023) published a prospective, multicenter, randomized to evaluate if Deep TMS targeting the medial prefrontal cortex (MPFC) is noninferior to targeting the lateral prefrontal cortex (LPFC) and whether electrophysiological or clinical markers for patient selection can be identified.^[24] They enrolled 169 patients with MDD for whom antidepressants failed in the current episode. Patients were randomized to receive 24 Deep TMS sessions over 6 weeks, using either the H1 coil or the H7 coil. The primary efficacy endpoint was the change from baseline to week 6 in Hamilton Depression Rating Scale scores. Clinical efficacy and safety profiles were similar and not significantly different between groups, with response rates of 60.9% for the H1 coil and 64.2% for the H7 coil. Moreover, brain activity measured by EEG during the first treatment session correlated with clinical outcomes in a coil-specific manner. This study provides a treatment option for MDD, using the H7 coil, and initial guidance to differentiate between patients likely to respond to LPFC versus MPFC stimulation targets. This study needs validation by additional research.

Bulbeau (2022) published a RCT comparing rTMS with iTBS in participants ($n=54$) with treatment resistant depression.^[25] The protocols were as follows: for rTMS: 110% of RMT; 10 Hz pulses; 20-min session; 4 s per train; 28-s intertrain interval; 1600 pulses per day (40 trains of 40 pulses each). For iTBS: 80% of RMT; 50 Hz pulses; 600 pulses per day. In both trial arms, participants had one session each weekday for 4 weeks, for a total of 20 sessions. A total of 54 completed the stimulation sessions (10 Hz rTMS: 27 [90%]; iTBS: 27 [90%]). Response rates were 36.7% and 33.3%, and remission rates were 18.5% and 14.8%, in the

iTBS and 10 Hz rTMS groups respectively. Both groups showed a similar significant reduction in depression scores and quality of life improvement at six months. The authors reported that they did not find any clinical predictive factor of therapeutic response for either modality. Two adverse effects of moderate to severe intensity were reported: asthenia (10 Hz rTMS: 2 [6%]; iTBS: 4 [13%]) and headaches (10 Hz rTMS: 1 [3%]; iTBS: 5 [17%]). Fisher's exact test detected no significant difference between groups for asthenia (OR: 0.47; 95% CI: 0.0394 to 3.600; $p = 0.6708$) or headaches (OR: 0.1769; 95% CI: 0.0035 to 1.7331; $p = 0.1945$). Limitations include a small sample size, possibility of unblinding and a few patients received lamotrigine (off label use) which may modify TMS affects.

The STAR*D study and recent update by Rush (2020) has demonstrated that patients with a major depressive episode who have failed to respond to their initial pharmacologic treatment show less and less response and remission rates with subsequent medication trials.^[26, 27] Rush stated that after non-efficacy with an initial failed SSRI trial, only 21% of patients achieved remission and 58% of patients achieve no meaningful benefit with a second step switch to another antidepressant. Over four levels of treatment, 1/3 of patients will not respond. In the Deep TMS pivotal trial, patients were shown to have a remission rate of 32.6% vs 14.6% sham and a response rate of 38.4% vs. 21.4% sham after the initial 4 weeks (20 sessions).^[28] Patients who failed 1 or 2 medications had a remission rate of 36.6% vs 16.7% while patients who failed 3+ medications had a remission rate of 28.9% vs. 12.2% in the sham treatment. Additionally, approximately 64% of the acute phase (initial 20 sessions) non-responders, achieved remission during the continuation phase (24 sessions over 12 weeks).

Blumberger (2018) published a multicenter, randomized noninferiority trial (THREE-D) comparing 10 Hz rTMS with intermittent theta burst stimulation (iTBS).^[29] Between 2013 and 2016, 414 patients with treatment-resistant major depressive disorder were enrolled and randomized to four to six weeks of MRI-guided rTMS ($n=205$) or iTBS ($n=209$). Treatment resistance was defined as failure to tolerate two or more antidepressant trials of adequate dose and duration or no clinical response to an adequate dose of an antidepressant. Patients who failed more than three antidepressant trials of adequate dosage were excluded from the study. Patients could alter their medication through the trial. Treatment with rTMS (37 minutes) and iTBS (3 minutes) was delivered five times a week for four to six weeks. The primary outcome measure was the 17-item HAM (HAM-17), for which scores for patients treated with rTMS improved by 10.1 points and scores for patients treated with iTBS improved by 10.2 points, indicating noninferiority of iTBS (adjusted difference, 0.103; lower 95% CI -1.16; $p=0.001$). Treatment with iTBS resulted in a higher self-rated intensity of pain (mean score, 3.8; $SD=2.0$) than treatment with rTMS (mean score, 3.4; $SD=2.0$; $p=0.011$). Headache was the most common treatment-related adverse event for both groups (rTMS 131/204 [64%]; iTBS 136/208 [65%]). Serious adverse events were noted in patients treated with rTMS ($n=1$; myocardial infarction) and iTBS ($n=3$; agitation, worsening suicidal ideation, worsening depression); there was no significant difference in the number of adverse events in the two groups. The study was limited by absence of a treatment group with placebo.

Several RCTs not discussed above or included in the above systematic reviews also had significant limitations which did not allow reliable conclusions to be made about the effectiveness of TMS as a treatment for depression. Limitations of individual studies and the body of literature as a whole include one or more of the following:

- Standardized optimal treatment parameters for TMS have not been established. Studies varied with respect to frequency, location, intensity, and duration. Many studies did not

mention repeat treatments using TMS after their intervention phase or in the follow-up assessments.^[30-37]

- There were significant (greater than 10%) or unclear loss to follow-up and/or poorly defined intention-to-treat (ITT) analyses.^[30-36, 38, 39]
- Use of co-therapies such as antidepressants, unequal distribution of co-therapies between treatment and sham groups, sham devices in which potential for some therapeutic effect was possible, and mental health counseling were allowed but not quantified in the results, potentially confounding the findings.^[30-35, 38, 40-42]
- Follow-up of all study subjects was over a short period of time, less than six months, so durability of the results is unknown.^[30-40, 42-45]
- Study populations were small, less than 100 patients total, making results unreliable and difficult to apply to patients requiring treatment in the general population.^[30-35, 37-40, 42-44, 46-53]
- Statistical power calculations were inadequate or unclear, and/or the study failed to enroll a sufficient number of participants in order to have adequate statistical power to reliably detect differences between the treatment groups.^[37]
- Randomization methods were not clearly stated or weak methods of randomization were used (e.g. one provider randomly assigned patients to groups using their own personal judgment).^[31-33, 37, 38, 40, 43, 44]
- Strict inclusion/exclusion criteria were used which were not representative of patients requiring treatment in the general population, for example, a mild to moderate level of depression or illness, no comorbidities (or only a few that were well controlled), and treatment resistance to standard therapies to name a few.^[30-33, 35, 38, 40, 44]
- Studies used previously published unreliable data for new and/or further analyses.^[54, 55]

Adolescents

Zheng (2023) published a systematic review of randomized controlled trials (RCTs) to explore the therapeutic effects and safety of active low-frequency repetitive transcranial magnetic stimulation (LF-rTMS) versus sham LF-rTMS in children and adolescent patients with first-episode and drug-naïve (FEDN) major depressive disorder (MDD).^[56] A systematic search of the literature yielded 442 references, of which 3 RCTs (130 children and adolescents with FEDN MDD, 50.8% male, and mean age range from 14.5 to 17.5 years) met the inclusion criteria. Among the two RCTs (66.7%, 2/3) examining the effects of LF-rTMS on study-defined response and remission and cognitive function, active LF-rTMS was more efficacious than sham LF-rTMS in terms of study-defined response rate and cognitive function (all $p < 0.05$) but not regarding study-defined remission rate (all $p > 0.05$). The authors reported that LF-rTMS could benefit children and adolescents with FEDN MDD in a relatively safe manner, although further studies are warranted.

Sun (2023) published a meta-analysis examining the therapeutic effects, tolerability, and safety of adjunctive repetitive transcranial magnetic stimulation (rTMS) in adolescents with first-episode major depressive disorder (FE-MDD).^[57] The study included six randomized controlled trials (RCTs) involving 562 adolescents with FE-MDD. Results showed that adjunctive rTMS was superior to control groups in improving depressive symptoms (standardized mean difference [SMD] = -1.50, 95% confidence interval [CI]: -2.16, -0.84; $I^2 = 89\%$, $p < 0.00001$), with significantly greater response rates (risk ratio [RR] = 1.35, 95% CI: 1.04, 1.76; $I^2 = 56\%$, $p = 0.03$) and remission rates (RR = 1.35, 95% CI: 1.03, 1.77; $I^2 = 0\%$, $p = 0.03$). All-cause discontinuations were similar between groups (RR = 0.79, 95% CI: 0.32, 1.93; $I^2 = 0\%$, $p =$

0.60), and no significant differences were found in adverse events including headache, loss of appetite, dizziness, and nausea ($p = 0.14 - 0.82$). Four of six studies (66.7%) demonstrated improved neurocognitive function with adjunctive rTMS ($p < 0.05$). Limitations include sample sizes and short duration follow-up periods.

Majumder (2021) performed a systematic review of the safety and efficacy of rTMS in adolescents and children (ages 10 and over) with major depressive disorder.^[58] A total of 18 publications, including case reports, met inclusion criteria. Most studies included treatment-resistant depression, defining it as one, two or several failed antidepressant trials depending on the study. The multi-subject trials allowed comorbid anxiety disorder, dysthymia, attention deficit hyperactivity disorder (ADHD) but excluded schizophrenia, bipolar disorder, substance use disorder, post-traumatic stress disorder (PTSD), intellectual disability, pervasive developmental disorders, and eating disorders. There was heterogeneity in inclusion criteria, number of rTMS sessions, and various other parameters. No meta-analysis was completed due to heterogeneity. Overall, the included studies indicated that in children and adolescents rTMS is safe but did not show that it is superior to placebo as a stand-alone treatment for resistant depression. The results were more promising for rTMS as an add-on treatment.

A RCT included in the above systematic review was performed by Croarkin (2021), which TMS for adolescents with treatment-resistant depression.^[59] Individuals aged 12 to 21 years with treatment-resistant depression (defined as an antidepressant treatment record level of 1 to 4 in a current episode of depression) were randomized to receive active NeuroStar TMS monotherapy ($n=48$) or sham TMS ($n=55$). Treatment was delivered daily for 30 days. At the end of treatment, there was no statistically significant difference in improvement in the least-squares mean (SE) HAM-D-24 between groups (active -11.1 [2.03]; sham -10.6 [2.00]; $p = 0.8$; difference [95% CI], -0.5 [-4.2 to 3.3]). There were also no statistically significant differences between groups in response rates (active 41.7%; sham 36.4%; $p=0.6$) or remission rates (active 29.2%; sham 29.0%; $p=0.95$).

Durability of rTMS

Systematic Reviews

Kedzior (2015) examined the durability of the antidepressant effect of high-frequency rTMS on the left DLPFC in the absence of maintenance treatment.^[60] Included were 16 double-blind, sham-controlled randomized trials (total $n=495$ patients). The range of follow-up was 1 to 16 weeks, but most studies only reported follow-up to two weeks. The overall effect size was small with a standardized mean difference (SMD; Cohen's d) of -0.48, and the effect sizes were lower in RCTs with 8 to 16 weeks of follow-up ($d=-0.42$) than with 1 to 4 weeks of follow-up ($d=-0.54$). The effect size was larger when an antidepressant medication was initiated concurrently with rTMS (five RCTs, $d=-.56$) than when patients were on a stable dose of medication (nine RCTs, $d=-0.43$) or were unmedicated (two RCTs, $d=-0.26$).

Observational Studies

Dunner (2014) reported a one-year follow-up with maintenance therapy from a large multicenter observational study (42 sites) of rTMS for patients with TRD.^[61] A total of 257 patients agreed to participate in the follow-up study of 307 who were initially treated with rTMS. Of them, 205 completed the 12-month follow-up, and 120 patients had met the Inventory of Depressive Symptoms-Self Report response or remission criteria at the end of treatment. Ninety-three (36.2%) of the 257 patients who enrolled in the follow-up study received additional

rTMS (mean, 16.2 sessions). Seventy-five (62.5%) of the 120 patients who met response or remission criteria at the end of the initial treatment phase (including a two-month taper phase) continued to meet response criteria through a one-year follow-up.

A variety of tapering schedules are being studied. For example, Richieri (2013) used propensity-adjusted analysis of observational data and found that patients who had rTMS tapered over 20 weeks (from three times per week to once a month) had a significantly reduced relapse rate than patients who had no additional treatment (37.8% vs 81.8%).^[62] Connolly (2012) reported that in the first 100 cases treated at their institution, the response rate was 50.6% and the remission rate was 24.7%.^[63] At six months after the initial rTMS treatment, 26 (62%) of 42 patients who received tapered maintenance therapy (from two sessions per week for the first three weeks to monthly) maintained their response. In another study, Janicak (2010) evaluated patients who met criteria for a partial response during either a sham-controlled or an open-label phase of a prior study were tapered from rTMS and simultaneously started on maintenance antidepressant monotherapy.^[41] During the 24-week follow-up, 10 of 99 patients relapsed, 38 had symptom worsening, and of these 32 (84%) had symptomatic benefit with adjunctive rTMS.

Section Summary

There are a large number of sham-controlled randomized trials and meta-analyses of these RCTs evaluating the use of rTMS for depression. The meta-analyses found a clinical benefit associated with rTMS for TRD, with improved response rates and remission rates compared with sham. There is some evidence that rTMS, when given in conjunction with the initiation of pharmacologic therapy, improves the response rate compared with pharmacologic therapy alone, while the effect of rTMS is less robust when it is given in combination with a stable dose of antidepressant medication. There is limited evidence to compare the effects of these treatments on cognition, although the adverse events of rTMS appear to be minimal. While the most recent meta-analyses have found that the effect of rTMS is smaller than the effect of ECT on TRD, given that rTMS does not require general anesthesia or induce seizures and some individuals may not elect ECT, the balance of incremental benefits and harms associated with rTMS may be reasonable compared with ECT.

BIPOLAR DISORDER AND BIPOLAR DEPRESSION

Systematic Review

Konstantinou et al (2022) conducted a systematic review of 31 RCTs of rTMS for the treatment of bipolar disorder; meta-analysis was not performed.^[64] Most included studies were in the setting of bipolar depression (n=24). Only 8 studies had a low risk of bias. Overall, rTMS seems safe and well-tolerated but efficacy results are mixed and there is no consensus about the optimal rTMS regimen. The authors noted limitations of the available literature including heterogeneity among studies, differences in sham treatments, and small sample sizes. They also stated that adequately powered sham-controlled studies are needed to verify the efficacy of rTMS in patients with bipolar disorder.

Tee (2020) conducted a systematic review of sham-controlled RCTs of rTMS for bipolar disorder.^[65] A total of 11 RCTs met inclusion criteria, of which seven included only patients with bipolar depression, three included only patients with bipolar mania, and one included both unipolar and bipolar depression. Of the 345 included bipolar patients, 257 were treated for bipolar depression, 85 for mania, and 2 for mixed episodes. Risk of bias was assessed with

the Cochrane Risk of Bias Tool. Of the studies of bipolar depression, one study was classified as good quality, two were classified as fair quality, and five were classified as poor quality. Of the studies of bipolar mania, one study was classified as fair quality and two were classified as poor quality. Results of the meta-analysis showed a statistically significant improvement in depressive symptoms in rTMS-treated versus sham-treated patients (standardized mean difference = 0.302, 95% CI 0.055 to 0.548, $p=0.016$). There was no statistically significant heterogeneity. There was also a statistically significant difference between groups in favor of rTMS for remission rate (risk difference = 0.14, $p<0.05$). There were no significant differences between groups for patients treated for bipolar mania. No serious adverse events were reported.

Randomized Controlled Trials

Dellink (2024) published a randomized controlled trial that studied the effectiveness of continuous theta burst stimulation (cTBS) in treating bipolar depression (BD-D) and the potential of plasma kynurenine pathway metabolites as biomarkers to predict treatment outcome.^[66] The study included 37 patients with BD-D who underwent either active or sham cTBS treatment. Active cTBS did not demonstrate greater symptom alleviation compared to sham. Higher baseline quinolinic acid levels significantly predicted symptom improvement in the active treatment group. The study limitations including small sample size and a short follow-up period of 10-11 days.

Novak (2024) published a randomized, double-blind, sham-controlled trial that studied the effectiveness of 10 Hz repetitive transcranial magnetic stimulation (rTMS) as an add-on treatment for bipolar depression (BDE).^[67] The study included 60 patients who were randomly assigned to receive either right ventrolateral (RVL) rTMS, left dorsolateral (LDL) rTMS, or sham treatment. Only 46 patients completed the double-blind phase. Although the results showed a greater mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to Week 4 in both active groups compared to the sham, the differences did not achieve statistical significance (RVL vs sham: $p = 0.3$; LDL vs sham: $p = 0.4$). Limitations include small sample size and attrition bias.

Sheline (2024) published a randomized clinical trial that studied the effectiveness of accelerated intermittent theta-burst stimulation (aiTBS) for treatment-refractory bipolar disorder (BD).^[68] The study included 24 participants with treatment-resistant BD who were randomly assigned to receive either active or sham aiTBS treatment. The results showed that the active group had significantly lower Montgomery-Åsberg Depression Rating Scale (MADRS) scores after treatment (mean difference: -14.75, 95% CI: -19.73 to -9.77, $P < 0.001$, Cohen d: -2.19) compared to the sham group. All participants completed the treatment and 1-month follow-up. Limitations include small sample size and short follow-up period.

Mallik (2023) published an RCT for to study the effect of novel continuous theta burst stimulation (cTBS) targeting right dorsolateral prefrontal cortex in a randomized rater blinded placebo control design.^[69] Nineteen patients aged 18 to 59 years (baseline Hamilton Depression Rating Scale [HAM-D] 17 severity score >18) were randomly allocated to active cTBS ($n = 11$) and sham cTBS ($n = 9$) groups using block randomization method. They received 15 cTBS sessions (burst of 3 pulses delivered at 50 Hz, repeated every 200 ms at 5 Hz, 600 pulses per session), 3 sessions per day (total of 1800 pulses) for 5 days in a week at 80% resting motor threshold. On repeated measures analysis of variance, a significant within-group time effect (from pretreatment to 2 weeks after TBS) for HAM-D ($F = 15.091$, $P <$

0.001), Beck Depression Inventory ($F = 22.376$, $P < 0.001$), Hamilton Anxiety Rating Scale ($F = 18.290$, $P < 0.001$), Changes in Sexual Functioning Questionnaire ($F = 9.281$, $P = 0.001$), and World Health Organization's abbreviated quality of life assessment ($F = 24.008$, $P < 0.001$). The authors concluded that although safe and well tolerated, the therapeutic efficacy of intensive intermittent TBS in acute-phase bipolar depression is inconclusive.

Torres (2023) published a randomized sham-controlled trial where 16 patients received active Intermittent theta burst stimulation (iTBS) to the Left Dorsolateral Prefrontal Cortex (DLPF) and 15 patients received sham stimulation across four weeks.^[70] No significant improvements were observed in any cognitive variables in the active relative to the sham group; however, there was a trend for increased left hippocampal volume in the former. Left hippocampal volume increases were associated with improvements in nonverbal memory in the active group. Larger studies are required to determine the effects of iTBS for bipolar disorder.

Zengin (2022) performed an RCT to investigate the efficacy and safety of Transcranial magnetic stimulation (TMS) treatment, a non-invasive brain stimulation technique, on depressive symptoms in treatment-resistant bipolar depression (TRBD).^[71] The study included 29 patients between the ages of 18-65, with bipolar disorder depressive episode. Patients were divided into two groups double-blind-randomly, 20 sessions of TMS and 20 sessions of sham TMS were applied crossover. In both groups, the severity of depression was decreased significantly according to HAM-D and BDI scores after the procedure. As well as active stimulation, some positive placebo effects were observed with sham stimulation. But the decreases seen in HAM-D and BDI scores and response to the treatment were higher during the weeks when the groups received active stimulation (respectively $p=0.000$, $p=0.001$, $p=0.005$). The authors concluded that TMS treatment is an effective and safe treatment for patients with treatment-resistant bipolar depression.

Myczkowski (2018) performed an RCT to evaluate the cognitive effects of H1-coil (deep) transcranial magnetic stimulation (TMS) in patients with treatment-resistant bipolar depression.^[72] Forty-three patients were randomized to receive 20 sessions of active (55 trains, 18 Hz, 120% resting motor threshold intensity) or sham rTMS within a double-blind, sham-controlled trial. : Cognitive improvement was shown for all cognitive domains. It occurred regardless of intervention group and depression improvement. For the language domain, greater improvement was observed in the sham group over time. No correlations between depression (at baseline or during treatment) and cognitive improvement were found. The authors comment that Putative pro-cognitive effects of rTMS in BD were not observed and thus should be further investigated.

Tavares (2017) published a randomized sham-controlled trial that examined the safety and efficacy of deep (H1-coil) TMS (dTMS) for treatment-resistant bipolar depression patients.^[73] Fifty patients were randomized to 20 sessions of active or sham dTMS over the left dorsolateral prefrontal cortex. Two patients in the sham and five patients in the active group dropped out during the study. Assessments using the 17-item Hamilton Depression Rating Scale (HDRS-17) were completed at baseline, week four (end of treatment), and week eight. Patients were also assessed using the dTMS adverse effects questionnaire and the Young Mania Rating Scale, which would identify treatment-emergent mania switch. Changes in HDRS-17 from baseline (25.32 and 25.8 in sham and dTMS groups, respectively) were

statistically superior in the active versus sham dTMS group at the end of treatment (difference at four weeks favoring dTMS=4.88; 95% CI 0.43 to 9.32, $p=0.03$) but not at follow-up (difference favoring dTMS=2.76; 95% CI 1.68 to 7.2, $p=0.22$). Response and remission rates were not significantly different between groups. No incidences of treatment-emergent mania were reported.

McGirr (2016) performed a meta-analysis to assess the efficacy of TMS for bipolar depression.^[74] The analysis included randomized, double-blind, sham-controlled trials of rTMS involving five or more sessions that randomized patients with bipolar depression to both active and sham rTMS arms. Many of the studies did not include enough patients with bipolar depression to analyze them separately within the study. Data from a total of 19 studies were included. Study quality was not evaluated. There was high methodological heterogeneity, but there was no statistical evidence of heterogeneity. A funnel plot revealed an asymmetrical distribution. According to the meta-analysis, significantly more patients who received active rTMS achieved clinical response at study end compared to those who received sham rTMS (47/106, 44.3%, vs. 19/75, 25.3%; RD=0.18, 95% CI: 0.06 to 0.30, $p<0.01$).

Fitzgerald (2016) published a two arm parallel design RCT evaluating rTMS for patients with refractory bipolar depression.^[75] Forty-nine patients participated in the study and received rTMS or sham stimulation. The authors concluded there was no difference in depression between the groups. The study was limited in size.

Nahas (2003) performed an RCT and carried out the following left prefrontal rTMS study to determine the safety, feasibility, and potential efficacy of using TMS to treat the depressive symptoms of bipolar affective disorder (BPAD).^[76] They enrolled 23 depressed BPAD patients (12 BPI depressed state, nine BPII depressed state, two BPI mixed state). Patients were randomly assigned to receive either daily left prefrontal rTMS (5 Hz, 110% motor threshold, 8 sec on, 22 sec off, over 20 min) or placebo each weekday morning for 2 weeks. The authors failed to find a statistically significant difference between the two groups in the number of antidepressant responders ($>50\%$ decline in HRSD or HRSD <10 - 4 active and 4 sham) or the mean HRSD change from baseline over the 2 weeks ($t = -0.22$, $p = 0.83$). The authors concluded that further studies are needed to fully investigate the potential role, if any, of TMS in BPAD depression.

POST TRAUMATIC STRESS DISORDER AND ANXIETY

Systematic Reviews

Brown (2024) published a Cochrane systematic review of rTMS for posttraumatic stress disorder.^[77] The search was conducted through January 2023, and the authors identified 13 RCTs ($N = 577$). Notably, five studies were conducted in the US, primarily enrolling white, male veterans. The authors found that rTMS probably makes little to no difference on posttraumatic stress disorder severity immediately following treatment (SMD, -0.14; 95% CI, -0.54 to 0.27; 3 studies, 99 participants; moderate-certainty evidence); however, there was significant heterogeneity amongst the studies.

Cui (2019) included 21 studies ($n=1481$ patients) in a meta-analysis of rTMS plus drug therapy compared to drug therapy alone for the treatment of generalized anxiety disorder.^[78] Results of the analysis showed that rTMS improved anxiety symptoms as measured by the

Hamilton Anxiety Scale, (standardized mean difference = -0.68 , 95% CI -0.89 to -0.46). The conclusions that could be drawn from the body of evidence were limited by significant heterogeneity across studies, and the authors concluded that additional high-quality studies are needed to confirm the results.

An SR by Cirillo (2019) evaluated the safety and efficacy of TMS as a treatment for anxiety and trauma-related disorders.^[79] The authors identified 17 studies that met inclusion criteria. Nine were for post-traumatic stress disorder (PTSD) (six double-blind, randomized, sham-controlled, one open-label, and two retrospective), four were for generalized anxiety disorder (two double-blind, randomized, sham-controlled, and two uncontrolled open-label), two were for specific phobias (one double-blind, randomized, sham-controlled, and single-blind, randomized, sham-controlled), and two were for panic disorder (both double-blind, randomized, sham-controlled). According to the meta-analysis including all nine PTSD studies, the overall effect size for PTSD was -0.88 (95% CI -1.42 to -0.34), favoring TMS. According to the meta-analysis for generalized anxiety disorder, which included all four studies meeting inclusion criteria, the effect size for generalized anxiety disorder was -2.06 (95%CI -2.64 to -1.48), favoring TMS. No meta-analyses were performed for panic disorder and specific phobia due to an insufficient number of studies and patients.

Trevizol (2016) published a SR to evaluate the effects of rTMS on PTSD.^[80] The five studies included showed rTMS statistically superior to sham stimulation (standard mean difference [SMD] $=0.74$; 95% CI 0.06 to 1.42), although heterogeneity of the trials was high. Despite improvements, the authors concluded this SR was limited in size and additional RCTs are needed to determine clinical impact.

Randomized Control Trials

Yuan (2023) published a RCT comparing the two forms of TMS (iTBS and rTMS) in 75 participants with post-traumatic stress disorder (PTSD).^[81] Participants were randomly assigned to groups in a ratio of 1:1:1, receiving either 10 Hz rTMS, iTBS, or sham-controlled iTBS. Participants in the two treatment groups underwent 15 therapies which consisted of 1800 pulses and targeted the right dorsolateral prefrontal cortex (DLPFC). The main outcomes included changes in scores on the Posttraumatic Stress Disorder Checklist (PCL-C) and the Post-Traumatic Growth Inventory (PTGI). After intervention, the PCL-C and PTGI scores in iTBS and rTMS groups were significantly different from those in sham-controlled iTBS group. No significant differences in PCL-C and PTGI were found between the two active treatment groups. They concluded that iTBS, with a shorter treatment duration, can effectively improve the symptoms of PTSD, with no significant difference in effect from that of rTMS. Future studies are needed to further elucidate the mechanisms, optimize the parameters and investigate the therapeutic potential and efficacy of iTBS in PTSD.

Isserles (2021) reported a multisite randomized sham-controlled trial of deep TMS combined with exposure therapy for the treatment of PTSD.^[82] A total of 125 patients were randomly assigned to receive deep TMS or sham during 12 sessions administered over four weeks. The primary endpoint was change in five-week Clinician-Administered PTSD Scale for DSM-5 score. While both groups improved significantly, the improvement in the sham group was significantly greater than the improvement in the active treatment group (20.52 vs. 16.32; $p=0.027$). This remained true at the nine-week follow-up ($p=0.024$).

SCHIZOPHRENIA

Systematic Reviews and Technology Assessments

Chen (2026) published a meta-analysis of randomized controlled trials examining the efficacy of high-frequency transcranial magnetic stimulation to improve negative symptoms in patients with schizophrenia.^[83] The analysis included 23 randomized controlled trials involving 1024 participants (mean age 39.7 years, range 29.8 to 54.1 years; mean proportion of female patients 28.02%, range 0% to 70.0%), with the primary outcome being change in negative symptoms scores from baseline to post-treatment as measured by the Positive and Negative Syndrome Scale or the Scale for the Assessment of Negative Symptoms. Results showed that compared to sham, high-frequency repetitive transcranial magnetic stimulation demonstrated a pooled effect size of -0.47 (95% CI = -0.71 to -0.24) in favor of high-frequency repetitive transcranial magnetic stimulation strategies that were associated with significantly reduced negative symptoms of schizophrenia. High-frequency repetitive transcranial magnetic stimulation demonstrated improvement across all symptom dimensions (Hedge's g = -0.30, 95% CI = -0.46 to -0.13). The findings indicated that a protocol applying stimulation at 110% of the motor threshold over the left dorsolateral prefrontal cortex for at least 15 sessions was associated with improvement in negative symptoms. Study limitations included heterogeneity in stimulation protocols across included studies and the need for standardization of treatment parameters.

Blyth (2025) included 126 studies (N=4122 participants) in a meta-analysis of rTMS safety in schizophrenia.^[84] Results showed that active rTMS was associated with higher rates of headache or scalp pain, dizziness or syncope, facial twitching, and nausea compared to sham ($p < .05$). The prevalence of seizure was low (1.39 per 1000) and not different from sham or from the general population. No increased risk of cognitive impairment, worsening psychosis, depression, or mania was observed.

Marzouk (2019) published an SR evaluating the use of TMS for positive symptoms in schizophrenia.^[85] Thirty studies met the inclusion criteria, of which 25 investigated auditory verbal hallucinations. Twelve studies reported significant beneficial effects of TMS while 18 reported no significant beneficial effects. The SR concluded that further research with larger sample sizes is needed.

A 2019 SR published by Limori evaluated the effect of rTMS on cognitive function when used for depression, schizophrenia, and Alzheimer's disease.^[86] A total of 31 studies met inclusion and exclusion criteria, of which 15 were conducted in patients with depression, 11 in patients with schizophrenia, and 5 in patients with Alzheimer's disease. Six studies reported positive effects of rTMS on executive function while the rest reported no significant cognitive effects. A small number of studies also reported positive effects on verbal memory, working memory, and attention. No studies reported adverse cognitive effects. Conclusions were limited by heterogeneity between studies in terms of cognitive measures applied, stimulation parameters, and participants.

He (2017) published a meta-analysis of the effects of 1-Hz (low frequency) and 10-Hz rTMS (high frequency) for auditory hallucinations and negative symptoms of schizophrenia, respectively.^[87] For 1-Hz rTMS, 13 studies were included. Compared with sham, the rTMS group showed greater improvement in auditory hallucinations (SMD = -0.29; 95% CI -0.57 to -0.01). However, significant heterogeneity between the studies was found ($p = 0.06$). In the seven studies included for 10-Hz rTMS, the overall effect size for improvement in negative symptoms was -0.41 (95% CI -1.16 to -0.35); again, there was significant heterogeneity

between studies ($p < 0.001$). The study was further limited by the small number of articles included and by the unavailability of original data for some studies.

Dollfus (2016) published a SR to evaluate the impact of the placebo effect in studies involving rTMS on visual hallucinations for patients with schizophrenia.^[88] Twenty-one articles with 303 patients were reviewed. The authors concluded that the placebo in rTMS studies cause bias and that the design of such studies should be carefully evaluated.

A 2015 Cochrane SR included 41 studies with a total of 1473 participants.^[89] Based on very low-quality evidence, there was a significant benefit of temporoparietal TMS compared to sham for global state (seven RCTs) and positive symptoms (five RCTs). The evidence on cognitive state was equivocal. For prefrontal rTMS compared to sham, the evidence on global state and cognitive state was of very low quality and equivocal. The authors concluded that there is insufficient evidence to support or refute the use of TMS to treat symptoms of schizophrenia, and although there is some evidence to suggest that temporoparietal TMS may improve certain symptoms such as auditory hallucinations and positive symptoms of schizophrenia, the results were not robust enough to be unequivocal.

A 2011 BCBSA TEC Assessment evaluated TMS as an adjunct treatment for schizophrenia.^[90] Five meta-analyses were reviewed, along with RCTs in which measurements were carried out beyond the treatment period. A meta-analysis of the effect of TMS on positive symptoms of schizophrenia (hallucinations, delusions, and disorganized speech and behavior) did not find a significant effect of TMS. Four meta-analyses that looked specifically at auditory hallucinations showed a significant effect of TMS. It was noted that outcomes were evaluated at the end of treatment, and the durability of the effect was unknown. The Assessment concluded that the available evidence is insufficient to demonstrate that TMS is effective as a treatment of schizophrenia.

Randomized Controlled Trials

Several additional small, single center RCTs of rTMS for the treatment of schizophrenia have been published since the systematic reviews described above.^[91-96] These studies were limited by their small sample sizes (28 to 50), very high loss to follow-up, and inadequate duration of followup. Due to these limitations, these studies do not provide sufficient evidence to draw conclusions about the effectiveness of the technology in patients with schizophrenia.

Section Summary

The evidence on TMS for the treatment of auditory hallucinations in schizophrenia consists of a number of small RCTs. Evidence to date shows small to moderate effects on hallucinations when measured at the end of treatment, but evidence suggests that TMS does not produce a durable treatment effect in patients with schizophrenia.

OBSESSIVE COMPULSIVE DISORDER

Systematic Reviews

Joseph (2025) published a systematic review and meta-analysis evaluating the efficacy and safety of accelerated TMS for obsessive-compulsive disorder.^[97] The review screened 97 records and included 7 randomized controlled trials, with 6 analyzed quantitatively (total n not specified in abstract). The meta-analysis demonstrated that aTMS significantly reduced OCD symptoms (standardized mean difference = 0.63), depressive symptoms (standardized mean

difference = 0.52), and increased response rate (odds ratio = 4.28) compared to sham aTMS. Adverse effects were higher in the aTMS group (odds ratio = 5.16) but were mild, and dropout rates were similar between groups (odds ratio = 0.74). At follow-up assessments, aTMS sustained significant reductions in depressive symptoms (standardized mean difference = 0.74) but not in OCD or anxiety symptoms. Risk of bias assessment showed "some concerns" for all included studies, and GRADE assessment indicated moderate certainty for the primary outcome. Study limitations included heterogeneity of protocols and lack of data on long-term effects.

Tseng (2025) published a network meta-analysis examining the efficacy and acceptability of non-invasive brain stimulation interventions for obsessive-compulsive disorder management across 24 different stimulation methods. The analysis included 34 randomized controlled trials with 1,089 participants and found that three interventions significantly improved overall OCD severity compared with sham controls: high-frequency repetitive transcranial magnetic stimulation over the dorsolateral prefrontal cortex (mean difference = -10.81, 95% CI = -20.80 to -0.82), high-frequency deep TMS over the dorsal medial prefrontal cortex/anterior cingulate cortex (mean difference = -9.74, 95% CI = -16.42 to -3.06), and low-frequency rTMS over the right DLPFC (mean difference = -4.70, 95% CI = -8.84 to -0.57). The study concluded that excitatory stimulation over the dmPFC/ACC and bilateral DLPFC, or inhibitory stimulation over the right DLPFC, was associated with significant improvements in overall OCD severity, though the authors noted that further large-scale randomized controlled trials with longer follow-up periods are needed to investigate the true impact of NIBS-based interventions.

Figueiredo (2025) published a systematic review and meta-analysis examining the effects of repetitive transcranial magnetic stimulation on obsessive-compulsive disorder. The analysis incorporated 31 trials and revealed substantial reductions in the left dorsolateral prefrontal cortex (mean difference: -4.63, 95% CI: -7.73, -1.52) and medial prefrontal/anterior cingulate cortex (mean difference: -3.92, 95% CI: -6.93, -0.90), with frequencies ranging from less than 1 Hz to more than 5 Hz found to be effective, though continuous theta burst stimulation did not demonstrate efficacy. Repeated rTMS reduced Yale-Brown Obsessive-Compulsive Scale scores (mean difference: -3.30, 95% CI: -4.55, -2.04), although this was below the minimal clinically important difference of 4.9 points, with a number needed to treat for response of 6 and dropout rates comparable to the sham group. The analysis comparing scores from the end of treatment to follow-up showed no significant change (mean difference: 0.07, 95% CI: -0.60 to 0.75, $p = 0.83$), indicating maintenance of the achieved effect, while the analysis from baseline to follow-up confirmed a significant and sustained benefit (mean difference: -3.17, 95% CI: -4.68 to -1.65, $p < 0.0001$), with baseline severity moderating outcomes. The study concluded that rTMS constitutes an effective treatment for OCD when administered to specific targets and frequencies, though the mean clinical impact is negligible, indicating the necessity of optimized protocols and pragmatic maintenance strategies.

Vecheva 2024 published a SR of RCTs which utilized TMS in obsessive compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) to analyse its therapeutic benefits and explore the relationship between cortical target and psychopathophysiology.^[98] The SR included 47 randomised controlled trials (35 for OCD) and found a 22.7 % symptom improvement for OCD and 29.4 % for PTSD. Eight cortical targets were investigated for OCD and four for PTSD, yielding similar results. Bilateral dlPFC-TMS exhibited the greatest symptom change (32.3 % for OCD, N = 4 studies; 35.7 % for PTSD, N = 1 studies), followed by right dlPFC-TMS (24.4 % for OCD, N = 8; 26.7 % for PTSD, N = 10), and left dlPFC-TMS (22.9 % for OCD, N = 6; 23.1 % for PTSD, N = 1). mPFC-TMS showed promising results,

although evidence is limited (N = 2 studies each for OCD and PTSD) and findings for PTSD were conflicting. The included studies lacked a consistent rationale for cortical target selection, which complicates the interpretation of findings and hinders TMS development and optimisation. Limitations include heterogeneity of methodology and potential author bias.

Ramakrishnan (2024) published a systematic review and individual participant data meta-analysis that studied the optimal Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) thresholds for response and remission in obsessive-compulsive disorder (OCD).^[99] The study included individual participant data from 25 randomized-controlled trials (RCTs) out of 94 eligible studies, involving a total of 1,235 participants. The optimal threshold for response was a $\geq 30\%$ Y-BOCS reduction, and for remission was a ≤ 15 posttreatment Y-BOCS score. The authors reported that the differences in sensitivity and specificity between the optimal and nearby thresholds were small, indicating some uncertainty. The study's limitations include the potential for author bias, participant selection and inconsistent methodology.

Kar (2024) published an umbrella review that studied the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in treating obsessive-compulsive disorder (OCD).^[100] The review included 12 meta-analyses, which analyzed a total of 282 to 791 participants across 10 to 27 studies. The results showed that the majority of the meta-analyses consistently supported the effectiveness of rTMS in reducing OCD symptoms when applied to the dorsolateral prefrontal cortex (DLPFC) and supplementary motor area (SMA). Specifically, the review found that rTMS targeting the DLPFC and SMA consistently reduced OCD symptoms, with a moderate to large effect size. Additionally, encouraging results were observed when targeting the medial prefrontal cortex (mPFC) and anterior cingulate cortex (ACC) through deep transcranial magnetic stimulation (dTMS). Limitations include a high level of heterogeneity of methods including TMS protocols and heterogeneity of findings in nine out of 12 meta-analyses, indicating a need for further research and standardization in the field.

Grassi (2023) systematic review and meta-analysis of the available open and sham-controlled trials for the treatment of obsessive compulsive disorder (OCD) focused on neural pathways and protocols.^[101] The primary analysis included a pairwise meta-analysis (over 31 trials), and subgroup analyses were performed for each targeted brain area. Meta-regression analyses explored the possible moderators of effect size. The pairwise meta-analysis showed a significant reduction in OCD symptoms following active rTMS ($g = -0.45$ [95%CI: $-0.62, -0.29$]) with moderate heterogeneity ($I^2 = 34.9\%$). Subgroup analyses showed a significant effect of rTMS over the bilateral pre-SMA (supplementary motor area), the DLPFC (dorsolateral prefrontal cortex), the ACC/mPFC (anterior cingulate cortex and medial prefrontal cortex), and the OFC (orbitofrontal cortex). No moderators of the effect size emerged. All the TMS protocols were well tolerated and no serious side effects occurred with mild and transient headache as the most frequently reported side effect. Limitations to the studies include small sample size, heterogeneity of TMS protocols and devices. Future studies should define the sufficient number of sessions and stimuli for each patient as well as define clinical features or biomarkers to predict the most promising TMS target for a single patient. In addition, defining strategies to augment the TMS effects should be investigated.

Pellegrini (2022) attempts to explain some of this heterogeneity in trials for testing the efficacy of r-TMS as a treatment for OCD by comparing the efficacy of r-TMS in patients with or without resistance to treatment with selective serotonin reuptake inhibitors (SSRI), defined using standardized criteria.^[102] Twenty-five independent comparisons (23 studies) were included. Overall, r-TMS showed a medium-sized reduction of Yale-Brown Obsessive-

Compulsive Scale (Y-BOCS) scores (Hedge's g : -0.47; 95%CI - 0.67 to -0.27) with moderate heterogeneity ($I^2 = 39.8\%$). Subgroup analysis found that those studies including patients non-resistant to SSRI (stage 1) (g : -0.65; 95%CI -1.05 to -0.25, $k = 7$) or with low SSRI-resistance (stage 2) (g : -0.47; 95%CI -0.86 to -0.09, $k = 6$) produced statistically significant results with low heterogeneity, while studies including more highly resistant patients at stage 3 (g : -0.39; 95%CI: -0.90 to 0.11, $k = 4$) and stage 4 (g : -0.36; 95%CI: -0.75 to 0.03, $k = 8$) did not. The authors conclude that r-TMS is an effective treatment for OCD, but largely for those not resistant to SSRI or failing to respond to only one SSRI trial. As a consequence, r-TMS may be best implemented earlier in the care pathway.

Fitzsimmons (2022) reported results of a systematic review and pairwise/network meta-analysis of randomized, sham-controlled studies of rTMS for obsessive compulsive disorder (OCD).^[103] A total of 21 studies including 662 participants met inclusion criteria. Studies were generally small and there was heterogeneity in study protocols. Overall, rTMS for OCD was found to be efficacious across all protocols according to the pairwise meta-analysis (Hedges' g = -0.502 [95%CI -0.708 to -0.296]). rTMS remained efficacious in analyses where stimulation protocols were clustered only by anatomical location, including both dorsolateral prefrontal cortex (dlPFC) stimulation and medial frontal cortex stimulation, and in analyses of each unique combination of frequency and location separately, including low frequency (LF) pre-supplementary motor area (preSMA) stimulation, high frequency (HF) bilateral dlPFC stimulation, and LF right dlPFC stimulation.

Suhas (2021) conducted a network meta-analysis [NMA] to compare the efficacy of all interventions in SRI-resistant OCD from published RCTs from all modalities of treatments; pharmacological, psychological, neuromodulation, neurosurgery including deep brain stimulation.^[104] 55 RCTs examining 19 treatments or placebo involving 2011 participants were included in the NMA. Ondansetron [Standardized mean difference -2.01 (95% CI -3.19, -0.83)], deep TMS [- 1.95 (-3.25, -0.65)], therapist administered Cognitive Behavioral Therapy [CBT-TA] [-1.46 (-2.93, 0.01)] and aripiprazole [-1.36 (-2.56, -0.17)] were ranked as the best four treatments on using the Surface Under the Cumulative Ranking [SUCRA] percentage values (85.4%, 83.2%, 80.3%, 67.9% respectively). The authors concluded that deep TMS, ondansetron, CBT, and aripiprazole may be considered a first-line intervention for SRI-resistant OCD in adults. The small number of subjects in individual studies, higher confidence interval limits, and wider prediction interval for most agents warrant a cautious interpretation.

Pereyra (2021) conducted a systematic review and meta-analysis of rTMS in the treatment of OCD.^[105] All RCTs in the analysis ($n=26$) had a low risk of bias. A random effects model was used to compare pre- and post-stimulation YBOCS scores, with effect sizes reported as Hedges' g . The analysis found that rTMS had a significant effect on YBOCS scores compared to sham (effect size, 0.64; 95% CI, 0.39 to 0.89; $p < .0001$). Raw mean difference in standardized mean difference for the primary outcome (YBOCS score) between treatments was 4.04 (95% CI, 2.54 to 5.54; $p < .001$). The effect size was still significant when 2 dominant trials were removed. Effect sizes with rTMS appeared to be significant until 4 weeks after treatment, and low- and high-frequency rTMS had similar efficacy to each other. The authors performed several subgroup analyses (cortical target, stimulation frequency, total pulses per session, total duration of treatment) but none of the effect sizes were significant between rTMS and sham.

Liang (2021) conducted a systematic review and meta-analysis of different TMS modalities for the treatment of OCD.^[106] Three of the five protocols assessed were significantly more

efficacious than sham TMS, and all treatment strategies were similar to sham TMS regarding tolerability. Transcranial magnetic stimulation was not more effective than sham TMS, but there was direct evidence from only one RCT for this comparison (Carmi, 2019, discussed in the next section).^[107] The overall quality of the evidence was rated very low for efficacy and low for tolerability, and the reviewers concluded that high quality RCTs with low selection and performance bias are needed to further verify the efficacy of specific rTMS strategies for OCD treatment.

Zhou (2017) published an SR that analyzed 20 sham-controlled studies with 791 patients examining the effect of rTMS on obsessive-compulsive disorder (OCD).^[108] Treatments targeted the bilateral DLPFC, left DLPFC, right DLPFC, supplementary motor area (SMA), and the orbitofrontal cortex. The majority of studies did not use intention to treat analyses and only three studies assessed the effectiveness of the blinding procedures used. Results of a meta-analysis indicated a large effect size for therapeutic effect ($g=0.71$; 95%CI 0.55 to 0.87; $p<0.001$). Significant improvements over sham treatment were seen for rTMS targeting the supplementary motor area, left dorsolateral prefrontal cortex (DLPFC), bilateral DLPFC, and right DLPFC, excluding the orbitofrontal cortex. High-frequency and low-frequency treatments were significantly better than sham treatment, with no differences found between frequencies.

A systematic review by Trevizol (2016) included 15 RCTs (total $n=483$) that compared active with sham rTMS for obsessive-compulsive disorder (OCD).^[109] All studies were sham-controlled and double-blinded. Sample sizes in the trials ranged from 18 to 65 patients. Mean age of participants was 31.9 (SD = 7.6) years. The duration of the studies was between one and six weeks. Seven studies used low-frequency stimulation and eight studies used high-frequency stimulation. The cortical regions varied among the studies, targeting the supplementary motor area, orbitofrontal cortex, or left, right, or bilateral DLPFC. The researchers calculated the YBOCS score. Response rates were not reported. The pooled mean difference between groups on the YBOCS was 2.94 (95% CI 1.26 to 4.62), translating to a small to moderate effect size for active stimulation of 0.45 (95% CI 0.20 to 0.71). Individual adverse effects were not assessed due to a lack of reporting in the primary studies, but there was no difference between groups in the dropout rate. Intervention protocols were heterogeneous across the studies, but regression analysis did not identify any treatment protocol or other variables as predictors of TMS response.

Randomized Controlled Trials

Ozer (2024) published a double blind, placebo controlled RCT evaluating high-frequency deep transcranial magnetic stimulation (dTMS) targeting the medial prefrontal cortex (mPFC) and the anterior cingulate cortex (ACC) with an H-coil compared to a sham coil treatment in patients ($n = 29$) with OCD.^[110] Patients in the active TMS group ($n = 14$) underwent stimulation of the mPFC and ACC twice daily at a frequency of 20 Hz for three weeks, using a double-cone coil. The same procedure was applied to the sham control group ($n = 15$) using a placebo coil. Throughout the study, the patients continued their antidepressant and/or antipsychotic treatments at the same dose. Following treatment, the active TMS group exhibited a more significant reduction in Yale-Brown Obsessive-Compulsive Scale scores (pre-treatment: 25.36 ± 5.4 , post-treatment: 18.43 ± 6.86) and Hamilton Anxiety Rating Scale scores (pre-treatment: 10.6 ± 3.5 , post-treatment: 6.7 ± 2.7) compared to the sham TMS group. However, there was no statistically significant reduction in symmetry-related obsessive-compulsive symptoms in the TMS group compared to the sham TMS group.

Jiang (2023) investigated whether an accelerated high-dose theta burst stimulation (ahTBS) protocol significantly improves the efficacy of OCD compared to traditional 1-Hz repetitive transcranial magnetic stimulation (rTMS) in the routine clinical setting.^[111] Patients diagnosed with OCD (n = 45) were randomized into two groups and treated with ahTBS or 1-Hz rTMS for 5 days. Patients were assessed at baseline at the end of treatment using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). After 5 days of treatment, there was a significant decrease in Y-BOCS scores in both groups ($p < 0.001$), and the difference between the two groups was not statistically significant (group $\times$ time interaction, $F = 1.90$, $p = 0.18$). There was also no statistically significant difference in other secondary outcome indicators, including depression, anxiety symptoms, and response rate. Neuropsychological testing showed no negative cognitive side effects of either treatment. Limitations include small sample size, possible medication interference with TMS treatment, lack of sham control and high loss to follow-up.

Roth (2021) published the efficacy of Deep transcranial magnetic stimulation (dTMS) with the H7-coil was for obsessive-compulsive disorder (OCD) based on multicenter sham-controlled studies.^[112] The primary outcome measure was response, defined by at least a 30% reduction in the Yale Brown Obsessive Compulsive Scale (YBOCS) score from baseline to endpoint. Secondary outcome measures included first response, defined as the first time the YBOCS score has met response criteria, and at least one-month sustained response. Twenty-two clinical sites with H7-coils provided data on details of treatment and outcome (YBOCS) measures from a total of 219 patients. First response was achieved in average after 18.5 sessions (SD = 9.4) or 31.6 days (SD = 25.2). Onset of sustained one-month response was achieved in average after 20 sessions (SD = 9.8) or 32.1 days (SD = 20.5). Average YBOCS scores demonstrated continuous reduction with increasing numbers of dTMS sessions. The authors reported that the majority of OCD patients benefitted from dTMS, and the onset of improvement usually occurs within 20 sessions.

A more recent RCT, Carmi (2019) was addressed in the 2021 Liang systematic review, above.^[107] The trial was submitted to FDA as part of the de novo classification request, to establish a reasonable assurance of safety and effectiveness of the deep TMS device for OCD.^[107] Adults ages 22 to 68 years with a diagnosis of OCD as a primary disorder, who were receiving treatment in an outpatient setting, and have a YBOCS score >20 were included. In addition, patients were either in maintenance treatment with a therapeutic dosage of a serotonin reuptake inhibitor (SRI) for at least two months before randomization or, were in maintenance treatment on cognitive-behavioral therapy (CBT) and had failed to respond adequately to at least one past trial of an SRI. A total of 99 patients were randomized to active treatment or sham. The primary outcome was the difference between groups in the mean change from baseline to six weeks on the YBOCS. Secondary outcomes included the response rate (defined as a 30% or greater improvement from baseline on the YBOCS), the Clinical Global Impression of Improvement (CGI-I), the Clinical Global Impression of Severity (CGI-S), and the Sheehan Disability Scale, a patient-reported measure of disability and impairment. Results at 10 weeks were also reported as secondary outcomes.

The primary efficacy analysis used a modified intention to treat analysis (n=94), excluding five patients who were found to not meet eligibility criteria following randomization. There was a greater decrease from baseline in the active treatment group (-6.0 points) than the sham group (-2.8 points), translating to a moderate effect size of 0.69. At six weeks, the response rate was 38.1% in the active treatment group compared to 11.1% in the sham group ($p = 0.003$). The FDA review provides data from the ITT analysis of the mean change in YBOCS score (n=99).

In the ITT data set, the YBOCS score decreased by -6.0 points (95% CI -3.8 to -8.2) in the active group and by -4.1 points (95% CI -1.9 to -6.2) in the sham group. Although the decreases were both statistically significant from baseline, the difference of 1.9 points between the treatment arms was not statistically significant ($p=0.0988$). Results on the secondary outcomes were mixed. More patients in the active treatment group were considered improved based on the Clinical Global Impression of Improvement (CGI-I) and the Clinical Global Impression of Severity (CGI-S) at six weeks, but there was no significant difference between groups on the Sheehan Disability Scale. The number of adverse events and dropouts were similar between groups (73% vs. 69% for adverse events and 12.5% vs. 12.0% for dropouts, for TMS and sham, respectively).

Additional small, single center RCTs of rTMS for the treatment of OCD have been published since the systematic reviews described above.^[113] These studies were limited by their small sample sizes (under 50), very high loss to follow-up, and inadequate duration of followup.

OTHER PSYCHIATRIC DISORDERS

Systematic Reviews

Fu (2025) published a systematic review and meta-analysis examining the efficacy and safety of Transcranial Magnetic Stimulation (TMS) for attention-deficit hyperactivity disorder (ADHD).^[114] The study analyzed eight randomized controlled/crossover trials including 325 ADHD patients. Results showed significant improvements in both inattention (SMD = -0.94, 95% CI = -1.33 to -0.56, $p < 0.001$) and hyperactivity/impulsivity symptoms (SMD = -0.98, 95% CI = -1.27 to -0.69, $p < 0.001$) after 3-6 weeks of TMS compared to non-TMS interventions. Benefits persisted at one-month follow-up for inattention (SMD = -0.67, $p < 0.001$) and total symptoms (SMD = -0.48, $p = 0.005$). Adverse events were minor, primarily including headache and scalp discomfort. Limitations included a relatively small number of included studies and the need for further research to better understand the relationship between brain regions and specific ADHD symptoms for optimal stimulation targeting.

Smith (2023) published a SR and meta-analysis examining the use of TMS in the treatment of pediatric and young adult autism spectrum disorder in intellectually capable persons (IC-ASD).^[115] Sixteen studies were identified and twelve were included in the meta-analysis. Seven were open-label or used neurotypical controls for baseline cognitive data, and nine were controlled trials. In the latter, waitlist control groups were often used over sham TMS. Only one study conducted a randomized, parallel, double-blind, and sham controlled trial. Favorable safety data was reported in low frequency repetitive TMS, high frequency repetitive TMS, and intermittent theta burst studies. Compared to TMS research of other neuropsychiatric conditions, significantly lower total TMS pulses were delivered in treatment and neuronavigation was not regularly utilized. The meta-analysis results report improvement in cognitive outcomes (pooled Hedges' $g = 0.735$, 95% CI = 0.242, 1.228; $p = 0.009$) and primarily Criterion B symptomology of IC-ASD (pooled Hedges' $g = 0.435$, 95% CI = 0.359, 0.511; $p < 0.001$) with low frequency repetitive TMS to the dorsolateral prefrontal cortex. The authors conclude that TMS may offer a promising and safe treatment option for pediatric and young adult patients with IC-ASD. Future work should include use of neuronavigation software, theta burst protocols, targeting of various brain regions, and robust study design before clinical recommendations can be made.

Westwood (2021) published an SR and meta-analysis of noninvasive brain stimulation for the treatment of attention-deficit/hyperactivity disorder (ADHD).^[116] A total of 18 studies met

inclusion criteria, of which four addressed rTMS and 14 addressed tDCS. The meta-analysis showed no statistically significant improvements following rTMS or tDCS in any measures.

A 2020 SR on noninvasive brain stimulation for alcohol craving published by Mostafavi identified 34 eligible studies, of which 23 addressed rTMS and 11 addressed tDCS.^[117] Twenty-seven of the studies included a control group. According to the meta-analysis, the pooled standardized mean differences in alcohol cravings based on tDCS or rTMS treatment were not statistically significant (- 0.13 [-0.34 to 0.08] and - 0.43 [-1.02 to 0.17], respectively).

A 2018 SR published by Barahona-Corrêa assess the use of rTMS for the treatment of Autism Spectrum Disorder (ASD).^[118] A total of 23 studies met inclusion criteria, including four case-reports, seven non-controlled clinical trials, and 12 controlled clinical trials. The controlled trials compared the effects of real TMS with waiting-list controls (n=6) or sham-treatment (n=6). Four of the controlled trials were not randomized. Meta-analyses indicated moderate, statistically significant effects on repetitive and stereotyped behaviors, social behavior, and number of errors in executive function tasks. However, most studies had a moderate to high risk of bias and outcomes were not reported long-term.

A 2014 Cochrane review identified two RCTs with a total of 40 patients that compared low frequency rTMS with sham rTMS for the treatment of panic disorder.^[119] The larger of the two studies was a randomized, double-blind, sham-controlled trial in 21 patients with panic disorder with comorbid major depression. Response was defined as a 40% or greater decrease on the Panic Disorder Severity Scale and a 50% or greater decrease on HAM-D. After four weeks of treatment, the response rate for panic was 50% with active rTMS and 8% with sham. The study had a high risk of attrition bias. The overall quality of evidence for the two studies was considered to be low, and the sample sizes were small, precluding any conclusions about the efficacy of rTMS for panic disorder.

Additional SRs have been published exploring the efficacy of TMS for a variety of psychiatric disorders like borderline personality disorder and addiction.^[120-123] All of these SRs had one or more significant methodological limitations, including but not limited to small patient populations, short follow-up times, continued use of concurrent therapies, and/or significant loss to follow-up in the included studies, heterogeneous treatment parameters between studies, and limited management of study bias and conflict of interest. Generally, the authors agreed that larger, long-term RCTs are needed, along with better defined optimal treatment parameters for administering TMS.

Randomized Controlled Trials

A number of additional RCTs explored the efficacy of TMS for a variety of mental health disorders other than depression, including, but not limited to, bipolar mania, panic disorder, alcohol dependence, and ADHD. Many of these studies are preliminary (feasibility) studies and/or have serious methodological limitations that render outcomes unreliable. Some limitations of these studies include:

- Poorly defined or unmet endpoints^[124-129]
- Significant or unclear loss to follow-up and poorly defined intention-to-treat (ITT) analyses^[126, 128, 130-132]
- Lack of long-term follow up^[124-138]
- Small patient populations^[124-134, 139-149]

- Lack of standardized optimal treatment parameters^[124-127, 129-133, 139, 150-152]
- Use of co-therapies^[124-134]
- Strict inclusion/exclusion criteria which were not representative of patients requiring treatment in the general population^[124-127, 130, 133, 134, 139]

Section Summary

Current evidence is insufficient to determine the efficacy of TMS in patients with the psychiatric disorders discussed here. Well-designed RCTs are needed which address the methodological limitations of current studies, noted above.

NEURODEGENERATIVE DISEASES

Systematic Reviews

Wang (2025) published a meta-analysis examining the effects of repetitive transcranial magnetic stimulation on immediate and long-term cognitive functions in Alzheimer's dementia and mild cognitive impairment.^[153] The analysis included 31 randomized controlled trials for immediate cognition assessment and nine trials for long-term cognition evaluation, with participants tested on Mini-Mental State Examination, Montreal Cognitive Assessment, and Alzheimer's Disease Assessment Scale-Cognitive Section. Results demonstrated that rTMS significantly improved immediate cognition (SMD = 0.93, 95% CI = 0.64 to 1.22, $p < 0.001$) and long-term cognition (SMD = 0.42, 95% CI = 0.13 to 0.70, $p = 0.004$) across all patients. Moderator analysis revealed that targeting the dorsolateral prefrontal cortex, using intensities of 80% or less of motor threshold, total treatment time of 800 minutes or more, and stimulation sessions greater than 20 significantly enhanced immediate cognitive performance. Study limitations included heterogeneity in stimulation protocols and the need for standardization of treatment parameters.

Xiu (2024) evaluated the efficacy of HF-rTMS in improving global cognitive function rehabilitation in elderly patients with mild to moderate Alzheimer's Disease (AD) in a SR with meta-analysis.^[154] Seventeen RCTs, with a total of 1161 elderly patients with mild to moderate AD, were included in the meta-analysis. Compared to the control group, HF-rTMS could increase MMSE (mean difference [MD] = 3.64; 95%CI 1.86-5.42; $p < 0.0001$), MoCA (MD = 3.69; 95%CI 1.84-5.54; $p < 0.0001$), P300 amplitude (MD = 1.09; 95%CI 0.45-1.72; $p = 0.0008$), and total effective rate scores (MD = 3.64; 95% CI 2.14-6.18; $p < 0.00001$) while decreasing ADAS-Cog (MD = - 3.53; 95%CI - 4.91- - 2.15; $p < 0.00001$) and P300 latency scores (MD = - 38.32; 95%CI - 72.40- - 4.24; $P = 0.03$). The authors concluded that HF-rTMS could improve the global cognitive function of elderly patients with mild to moderate AD.

Huang (2024) published a SR with meta-analysis evaluating the efficacy of repeated transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS) using neuropsychological assessments as a potential treatment option for Alzheimer's disease (AD).^[155] A total of 17 eligible studies were included. Repetitive TMS improved cognition of patients with AD (immediate post-treatment WMD of MMSE score: 2.06, $p < 0.00001$; short-term follow-up WMD of MMSE score: 2.12, $p = 0.006$; WMD of ADAS-Cog score in single-arm studies: -4.97, $p = 0.001$). DBS did not reverse the progression of cognitive decline (WMD of ADAS-Cog score in single-arm studies: 7.40, $p < 0.00001$). Furthermore, tDCS demonstrated no significant efficacy in improving cognition in random clinical trials or single-arm studies.

Miller (2023) published a SR to evaluate the efficacy and moderators of repetitive transcranial magnetic stimulation (rTMS) targeted over the dorsolateral prefrontal cortex (DLPFC) as an intervention to treat cognitive decline in people with age-related neurodegenerative diseases.^[156] Sixteen studies involving 474 participants met the inclusion criteria, of which eight studies measured global cognitive function. The results from the random-effects meta-analysis showed rTMS significantly improved global cognitive function relative to control groups shown by a large, significant effect size ($g = 1.39$, 95% CI, 0.34-2.43; $p = 0.017$). No significant effects were found between subgroups or for individual cognitive domains. The authors concluded that high-frequency rTMS, targeted over the DLPFC, appears to improve global cognitive function in people with age-related neurodegenerative diseases. This research is limited by the small number of studies with high between-study heterogeneity.

Teselink (2021) performed an SR and meta-analysis of non-invasive brain stimulation for Alzheimer's disease and mild cognitive impairment.^[157] A total of 19 studies measuring cognition and nine measuring neuropsychiatric symptoms met inclusion criteria. There was no evidence of publication bias. Overall, noninvasive stimulation was found to significantly improve global cognition ($p=0.001$) and neuropsychiatric symptoms ($p=0.019$) compared to sham stimulation. According to subgroup analyses, these effects were driven by TMS treatment in Alzheimer's disease and there was no significant effect of tDCS or in dementia patients. A meta-regression analysis showed Meta-regression showed that age was significantly associated with global cognition response ($p=0.02$). There was substantial heterogeneity across all subgroup analyses and meta-regressions (all $I^2 > 50\%$).

Wang (2020) published an SR and meta-analysis of rTMS and tDCS for the behavioral and psychological symptoms of dementia.^[158] A total of 10 studies were identified. Seven of the studies included patients with Alzheimer's disease. The meta-analysis included both forms of stimulation and the results indicated that stimulation resulted in a statistically significant improvement in the behavioral and psychological symptoms of dementia immediately following stimulation (SMD, 0.31; 95% CI 0.10 to 0.52; $p=0.005$). The improvement was not statistically significant at the last follow-up visit for stimulation overall (0.15; 95% CI -0.11 to 0.41; $p=0.25$), but was statistically significant in the subgroup analysis for rTMS (0.57; 95% CI 0.18 to 0.96; $p=0.004$). The subgroup analysis for Alzheimer's disease patients did not indicate any significant differences from the group overall.

Vacas (2018) published an SR and meta-analysis of rTMS and tDCS for the behavioral and psychological symptoms of dementia.^[159] Three RCTs and two open-label clinical trials of rTMS were identified as well as two RCTs of tDCS. A meta-analysis with four RCTs did not show significant efficacy of noninvasive brain stimulation techniques, but a meta-analysis of the rTMS RCTs alone showed a statistically significant positive effect on behavioral and psychological symptoms of dementia (overall effect = -0.58; 95% CI -1.02 to -0.14; $I^2 = 0\%$). The adverse effects reported were mild and not clinically relevant.

A 2017 SR published by Cheng analyzed studies that used rTMS for patients with mild to moderate Alzheimer's disease.^[160] Seven RCTs (including 107 active and 87 sham rTMS patients) were included in a meta-analysis analyzing a primary outcome of cognitive function as measured by the Mini-Mental State Examination or the Alzheimer's Disease Assessment Scale-cognitive subscale. Active rTMS was found to be significantly more effective than sham for improving cognition.

Randomized Controlled Trials

Koch (2025) published 52-week results from a double-blind, sham-controlled RCT that assessed the long-term efficacy of personalized precuneus-targeted rTMS in 48 patients with mild-to-moderate Alzheimer's disease, consisting of 31 patients continuing treatment from a previous 24-week trial published by Koch (2022).^[161] Treatment included a two-week intensive course of rTMS or sham treatment applied daily to the precuneus five times per week, followed by a 50-week maintenance phase in which the same stimulation was applied once weekly. Personalization of rTMS treatment was established using neuro-navigated TMS in combination with electroencephalography (TMS-EEG). The primary outcome measure was change from baseline to week 52 in the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB). Secondary outcomes included score changes in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Mini Mental State Examination (MMSE), Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL) and Neuropsychiatric Inventory (NPI). Thirty-two of the 48 participants completed the study (68%, mean age 72.8 years; 56% women). The estimated mean change in CDR-SB after week 52 was 1.36 for precuneus rTMS (95% CI, 0.68 to 2.04) and 2.45 for sham-rTMS group (95% CI, 1.85 to 3.05). There were also statistically significant effects for the secondary outcomes ADAS-Cog, ADCS-ADL and NPI scores. This study is limited by a high dropout rate (32%), small sample size, and single-center design.

Koch (2022) published a double-blind, sham-controlled RCT that evaluated the efficacy of precuneus-targeted rTMS in 50 patients with mild-to-moderate Alzheimer's disease.^[162] Participants were randomly assigned in a 1:1 ratio to receive either precuneus or sham rTMS (mean age 73.7 years; 52% female). The 24-week treatment protocol included an intensive two-week phase, in which stimulation was applied once per week, followed by maintenance therapy consisting of once weekly stimulation. The primary outcome was change from baseline in the CDR-SB. Secondary outcomes included score changes in the ADAS-Cog, MMSE, and ADCS-ADL. Participants who received precuneus rTMS maintained stable cognitive performance while the sham group deteriorated (mean CDR-SB change: -0.25 vs -1.42, $p=0.009$, 68% vs 35% responder rate). Secondary outcomes including ADAS-Cog, MMSE, and activities of daily living also favored active treatment. Neurophysiological measures revealed preserved cortical excitability in the rTMS group and enhanced gamma oscillations. This study is limited by small sample size, single-center design, and a 10% dropout rate.

CEREBRAL PALSY

Systematic Reviews

No SRs were identified.

Randomized Controlled Trials

Gupta (2016) published a RCT that evaluated motor function, after rTMS for cerebral palsy (CP) patients.^[163] Forty-one spastic CP children who completed the study and were randomly assigned to receive physical therapy ($n=12$) alone, 5hz rTMS followed by physical therapy ($n=15$), or 10hz rTMS, ($n=14$) followed by physical therapy for 20 days. The gross motor function measure (GMFM) test was applied at baseline and after 20 treatments. Although the study showed improved motor function for the rTMS plus physical therapy groups, the authors concluded the results should not be interpreted as a final outcome, especially with previous studies showing lack of progress from this treatment. Larger studies evaluating long-term effects are needed.

EPILEPSY

Systematic Reviews

A meta-analysis conducted by Mishra and colleagues (2020) included seven RCTs that compared rTMS with sham or placebo controls in patients with epilepsy.^[164] Two of the included studies showed statistically significant reductions in the seizure rate from baseline, three trials failed to show any statistically significant difference in seizure frequency, and two had unclear results due to inadequate power. In a meta-regression, when adjusted for other potential variables such as the type of coil used, stimulation frequency, and the total duration of the active intervention, seizure frequency worsened by 2.00 ± 0.98 ($p=0.042$) for each week of lengthening of the posttreatment follow-up period. These results suggested that rTMS exerted only a short-term effect. The reviewers concluded that although the procedure may be a therapeutic alternative for patients with drug-resistant epilepsy, further RCTs using standardized protocols and with adequate sample sizes and duration are still needed.

Walton (2021) published an update to a Cochrane SR that included eight RCTs to evaluate the effects of rTMS on health outcomes for patients with drug-resistant epilepsy.^[165] All studies were randomized and seven were blinded. However, a meta-analysis could not be conducted due to differences in the design, interventions, and outcomes of the studies. Therefore, a qualitative synthesis was performed. For the outcome of seizure rate, two studies showed a significant reduction and six studies did not. Of the four studies evaluating the mean number of epileptic discharges, three showed a statistically significant reduction in discharges. Adverse effects were uncommon and mild, involving headache, dizziness, and tinnitus. There were no significant changes in medication use. The authors noted low quality of evidence and that more studies are needed to evaluate reduction in seizure activity, quality of life, and adverse outcomes.

Pereira (2016) published an update to a 2007 SR that evaluated the safety of rTMS for patients with epilepsy and how well the procedure was tolerated.^[166] Sixteen new studies were identified totaling 48, for this SR. The authors concluded the risk of increased seizure activity with rTMS was small and adverse events for patients with epilepsy were similar to healthy patients. They also questioned data control, stated results should be interpreted with caution and more studies are needed.

Randomized Control Trials

Wang (2025) published a single-center, randomized, sham-controlled, crossover clinical trial investigating the effectiveness of cerebellar transcranial magnetic continuous theta burst stimulation (cTBS) for drug-resistant epilepsy (DRE).^[167] The study included 44 patients with DRE (≥ 2 seizures per month for ≥ 2 years), with 38 completing the final analysis (18 in active-first, 20 in sham-first groups). Results showed active cTBS significantly reduced seizures compared to sham treatment, with a 25% greater reduction (95% CI = 5%-46%, $p = .018$) and a significantly higher 50% responder rate (difference = 24%, 95% CI = 11%-40%, $p = .029$). Minor adverse events included headache (5%), tinnitus (3%), and dizziness (3%), all resolving spontaneously. Limitations included the single-center design and relatively small sample size, with authors noting the need for further studies to confirm effectiveness and understand mechanisms of action.

FIBROMYALGIA

Systematic Review

Ahmed (2025) included 43 RCTs (N=2120) in a network meta-analysis evaluating noninvasive brain stimulation for fibromyalgia.^[168] Low-frequency rTMS reduced pain intensity more than sham (SMD, -1.20; 95% CI -1.82 to -0.58), with high-frequency rTMS showing a smaller effect (SMD, -0.58; 95% CI -1.00 to -0.17). Low-frequency rTMS over the right dorsolateral prefrontal cortex (DLPFC) produced the most pronounced effects (SMD, -1.42; 95% CI -2.69 to -0.15) and maintained short-term improvements. High-frequency rTMS over the left primary motor cortex (M1) also reduced pain (SMD, -0.78; 95% CI -1.39 to -0.18). rTMS was well tolerated and achieved clinically meaningful pain reductions.

Su (2021) conducted a meta-analysis of 18 RCTs (n=643) with rTMS in patients with fibromyalgia.^[169] Reduction in disease influence according to the Fibromyalgia Impact Questionnaire showed a significant effect of rTMS (SMD, -0.7; 95% CI -1.173 to -0.228). The effect of rTMS on disease influence, pain, depression, and anxiety lasted for at least 2 weeks after the last session. Older patients were most likely to experience reduced Fibromyalgia Impact Questionnaire scores. The authors concluded that larger RCTs are needed to confirm these findings.

Sun (2022) performed a systematic review and meta-analysis of the effectiveness of rTMS for fibromyalgia.^[170] A total of 14 studies, including 433 participants, met inclusion criteria. The mean study quality was rated 8.5/10 on the PEDro scale. The analysis found that rTMS resulted in a greater improvement than sham treatment in the Numerical Pain Rating Scale (NPRS) (standardized mean difference = -0.49; 95% CI -0.86 to 0.13; p=0.0008) and the Fibromyalgia Impact Questionnaire (FIQ) (standardized mean difference = -0.50, 95% CI -0.75 to -0.25; p=0.0001). No significant differences between groups were identified for the Beck Depression Inventory (BDI), Hospital Anxiety and Depression Scale (HADS) anxiety score, Pain Catastrophizing Scale (PCS), or Fatigue Severity Scale (FSS).

In 2017, Saltychev and Laimi published a meta-analysis of rTMS for the treatment of patients with fibromyalgia.^[171] The meta-analysis included seven sham-controlled double-blinded RCTs with low risk of bias. The sample size of the trials ranged from 18 to 54. Five of the studies provided high-frequency stimulation to the left primary motor cortex, the remaining two were to the right DLPFC or left DLPFC. The number of sessions ranged from 10 to 24, and follow-up ranged from immediately after treatment to three months after treatment. In the pooled analysis, pain severity decreased after the last simulation by 1.2 points (95% CI -1.7 to -0.8) on a 10-point numeric rating scale, while pain severity measured at one week to one month after the last simulation decreased by 0.7 points (95% CI -1.0 to -0.3 points). Both were statistically significant but not considered to be clinically significant, with a minimal clinically important difference of 1.5 points.

Kninik (2016) published a SR that determined the effects repetitive transcranial magnetic stimulation (rTMS) versus a sham stimulation had on fibromyalgia, depression and/or quality of life.^[172] The SR included five RCTs of moderate quality. The authors concluded that rTMS had a superior effect on quality of life after 30 days, but more studies are needed to determine why and how rTMS impacts health outcomes and what treatment protocols are appropriate.

A 2012 SR included four studies on transcranial direct current stimulation (tDMS) and five on TMS for treatment of fibromyalgia pain.^[173] Four of the five TMS studies were double-blind RCTs, however the fifth included study was a case series of four patients who were blinded to

treatment. Quantitative meta-analysis was not conducted due to variability in brain site, stimulation frequency/intensity, total number of sessions, and follow-up intervals. Results of four out of five of these studies reported significant decreases in pain and greater durability of pain reduction was observed overall, with stimulation of the primary motor cortex compared to the dorsolateral prefrontal cortex. However, all five TMS trials used in this analysis were limited by small sample size ($n \leq 40$), continued use of concomitant medications and four had short-term follow-up (≥ 8 weeks) which preclude the ability to reach conclusions regarding the ability of TMS to effect pain reduction scores in patients suffering with fibromyalgia.

Randomized Controlled Trials

Badr (2024) published a randomized controlled trial examining the effects of low-frequency repetitive Transcranial Magnetic Stimulation (rTMS) on sleep problems in fibromyalgia patients.^[174] The study included 42 patients randomly assigned to receive either real or sham rTMS treatment over the right dorsolateral prefrontal cortex for 20 sessions. Results showed significant improvements in the real rTMS group compared to sham across all measures, including the Fibromyalgia Impact Questionnaire ($F = 237.645$, $P = 0.001$), Pittsburgh Sleep Quality Index ($F = 64.005$, $P = 0.001$), and Medical Outcomes Study Sleep Scale ($F = 28.938$, $P = 0.001$). Polysomnography parameters also showed significant improvements, with large effect sizes in both subjective and objective measures. A significant negative correlation was found between changes in MOS-SS and periodic limb movements index ($r = -0.643$, $P = 0.002$). Limitations included a relatively small sample size and the need for longer follow-up periods to assess long-term effectiveness.

Section Summary

Additional studies are needed to establish effective treatment parameters in a larger number of subjects and to evaluate the durability of tDMS or TMS treatment effect in patients with fibromyalgia.

HEADACHES/MIGRAINES

Systematic Reviews and Technology Assessments

Saltychev (2022) conducted a systematic review and meta-analysis of 8 RCTs from 2004-2021 that studied that compared rTMS to sham stimulation in patients with migraine ($n=339$).^[175] All RCTs used high-frequency rTMS to the left dorsolateral prefrontal cortex and all studies except 1 included patients with chronic migraine. The treatment duration was three to 12 sessions over three to eight days. All studies except 1 had a low risk of bias and the risk of publication bias was nonsignificant. Results for the frequency of migraine days per month and the intensity of migraine pain both favored rTMS; however, the authors stated that the difference in migraine pain intensity was clinically insignificant.

A 2020 the Canadian Agency for Drugs and Technologies in Health (CADTH) rapid response report evaluated the use of non-invasive nerve stimulation for migraine pain.^[176] The six included publications assessed a variety of stimulation methods, including but not limited to TMS, tDCS, and trigeminal nerve stimulation. The review concluded that the evidence is limited in quality and quantity. Based on the limited evidence identified, the review concluded that there is a lack of evidence of the effectiveness of non-invasive nerve stimulation for migraine pain.

Feng (2019) performed an SR of non-invasive brain stimulation (rTMS and transcranial direct current stimulation [tDCS]) for the treatment of migraine.^[177] Nine RCTs met inclusion criteria, of which five used rTMS and four used tDCS. Several studies overlapped with the WA HCA technology assessment below. Results of a meta-analysis of outcomes following excitatory stimulation of the primary motor cortex of migraine patients showed a significant reduction in headache intensity (Hedges' $g = -0.94$; 95% CI -1.28 to -0.59 ; $p < 0.001$, $I^2 = 18.39\%$) and frequency (Hedges' $g = -0.88$; 95% CI -1.38 to -0.38 ; $p = 0.001$, $I^2 = 57.15\%$). Stimulation of the dorsolateral prefrontal cortex also showed a significant effect on headache intensity (Hedges' $g = -1.14$; 95% CI -2.21 to -0.07 ; $p = 0.04$, $I^2 = 61.86\%$), but did not significantly alter the frequency of headaches.

In 2017, the Washington State Health Care Authority (WA HCA) published a technology assessment of treatments for chronic migraine and chronic tension-type headache.^[177, 178] The authors identified two small RCTs that evaluated the efficacy of TMS for the treatment of chronic migraine using a sham control. One RCT was considered to be at moderately low risk of bias and the other moderately high risk of bias due to multiple methodological concerns. One of the RCTs found that at four weeks post-treatment, TMS resulted in statistically significant improvement in outcomes compared to sham (low quality of evidence). With regard to safety, this study reported no statistical difference between the TMS and sham group in frequency of study withdrawal due to adverse events, but more TMS-treated patients experienced discomfort compared to sham. In the other RCT, eight weeks-results were reported. At this time-point, no statistical differences were reported between TMS and sham for reduction in migraine attacks or reduction in migraine days and no differences were reported in the frequency of minor adverse events or study withdrawal due to adverse events. The assessment authors concluded that the data in the second RCT was of insufficient quality to draw conclusions.

A 2019 SR published by Stilling evaluated the use of TMS and tDCS for the treatment of headache.^[179] A total of 34 studies met inclusion criteria, including 16 rTMS, 6 TMS, and 12 tDCS studies. The quality of the studies was assessed using GRADE and ranged from very low to high. rTMS was found to be the most promising, but few studies reported changes from active treatment greater than sham.

Lan (2017) performed a meta-analysis that included five RCTs and 313 migraine patients.^[180] Only one study was identified that assessed the efficacy of TMS on migraine with aura. This study found a significant effect of TMS after the first attack. The remaining four RCTs assessed the effect of TMS on chronic migraine. These studies were found to have statistically significant heterogeneity. The analysis showed no significant effect of TMS on chronic migraine.

Randomized Control Trials

A 2019 RCT published by Granato evaluated the effects of high-frequency rTMS in patients with chronic migraine and medication overuse headache.^[181] Of the 26 patients enrolled, 14 completed the study. Half of these received high-frequency rTMS and half received sham treatment. Outcome measures were changes in headache days (HD), headache hours (HH) and symptomatic drug intake (SDI). These were recorded for 30 days before the beginning of stimulation and during the three following months. There were reductions in all measures in both groups but no significant differences between groups.

Leung (2015) published an RCT that evaluated how rTMS improved headaches for military patients with mild traumatic brain injury (MTBI).^[182] Twenty-four patients received rTMS or sham rTMS at the left motor cortex (LMC). Patients were evaluated one week and one-month post treatment. Although the authors concluded rTMS is an effective treatment for MTBI headaches, this study did not evaluate whether the outcomes were sustained long-term.

Rapinesi (2016) published an RCT that evaluated the impact of dTMS on chronic migraines (CM).^[183] Fourteen treatment-resistant patients were randomized to receive add-on high-frequency dTMS (n=7) or standard abortive or preventive antimigraine treatment (n=7). Twelve sessions were received over one-month time. Depression symptoms were evaluated during treatment and one month later. Although the authors concluded add-on dTMS is effective in decreasing the intensity and frequency of migraines, this study was limited in size and did not evaluate long-term effects.

PAIN

Systematic Reviews

Che (2021) reported the results of a systematic review of rTMS over the DLPFC for the treatment of chronic and provoked pain.^[184] A total of 26 studies met inclusion criteria. A publication bias was identified in the studies of provoked pain but not for chronic pain conditions. Overall, no significant effect was found for TMS across chronic pain conditions. However, there was a significant short-term analgesia effect in neuropathic pain conditions (SMD = -0.87). There was an overall pain reduction identified in the midterm (SMD = -0.53, 24.6 days average) and long-term (SMD = -0.63, three months average) post DLPFC stimulation across pain conditions, but not within specific chronic pain conditions.

A 2019 SR by Ramger analyzed the efficacy of non-invasive brain stimulation for the treatment of central post-stroke pain.^[185] Six studies met inclusion criteria. These included one RCT of direct current stimulation and five studies of TMS (three within-subject randomized cross-over studies, one case series, and one prospective cohort). Only one of the cross-over studies was rated as “good/excellent” quality, while the remainder of included studies were rated as “fair” or “poor”. Four studies reported significant decreases in VAS ($p<0.05$). Overall, the authors concluded that there may be a beneficial effect of non-invasive brain stimulation for central post-stroke pain, but that the evidence is limited.

An SR published by Hamid (2019) evaluated the efficacy of TMS for chronic pain. Twelve RCTs met inclusion criteria.^[186] Risk of bias was assessed for the included studies and ranged from low to high. Limitations of the studies include that not all clearly specify sham blinding, inconsistent reporting of the type of control, and heterogeneity in treatment protocols. A meta-analysis demonstrated a statistically significant improvement in pain measured by the pain VAS associated with rTMS ($p<0.001$).

Randomized Control Trials

Attal (2021) conducted a multicenter sham-controlled randomized trial of rTMS for neuropathic pain.^[187] A total of 152 patients were randomized to receive rTMS to the primary motor cortex (M1; n=49), rTMS to the dorsolateral prefrontal cortex (DLPFC; n=52), or sham rTMS (n=48). The primary end point was the comparison between active M1-rTMS, active DLPFC-rTMS and sham-rTMS for the change over the 25 weeks (Group $\times$ Time interaction)

in average pain intensity (from 0 no pain to 10 maximal pain) on the Brief Pain Inventory in patients who received at least one rTMS session (modified intention-to-treat population). Compared to sham, M1-rTMS significantly improved pain intensity, pain relief, sensory dimension of pain, self-reported pain intensity and fatigue, Patient and Clinician Global Impression of Change (PGIC and CGIC). DLPFC-rTMS did not result in outcomes that were significantly different than sham. rTMS to either brain region resulted in no differences from sham for quality of pain, mood, sleep, or quality of life. The most commonly reported side effect was headache, which did not occur at significantly different rates between groups.

Ambriz-Tututi (2016) published a RCT that evaluated the impact of rTMS on patients with chronic low back pain.^[188] Eighty-two patients received rTMS, sham stimulation, or physical therapy (PT) for one week and were evaluated with the visual analogue scale (VAS), Short Form McGill pain questionnaire (SF-MPQ), and the Short Form 36 Health Survey. The authors concluded long-term reduction of pain in the rTMS group, but there was no apparent long-term outcome documented.

Malavera (2016) published a randomized, double-blinded, parallel group, single-center RCT to evaluate the impact of rTMS on phantom limb pain (PLP), for land mine victims.^[189] Fifty-four patients received rTMS (n=27) or sham stimulation (n=27) five days a week for two weeks and were evaluated 15 and 30 days after treatments. The rTMS group showed significant PLP improvement up to 15 days after treatment, but as the authors noted the study was limited in size and may not have included enough assessment data, nor were the long-term effects evaluated.

Additional studies are not discussed here due to methodological limitations, including low patient numbers and lack of long-term follow-up.^[190]

PARKINSON'S DISEASE

Systematic Reviews

Conte (2025) published an overview of systematic reviews with meta-analysis examining the effects of transcranial magnetic stimulation on motor symptoms of Parkinson's disease.^[191] The overview synthesized evidence from 21 systematic reviews with meta-analyses, including 107 unique primary studies. Results suggested with low to moderate certainty that high-frequency stimulation of the primary and supplementary motor cortex significantly improved general motor impairment, gait, functional mobility, and balance in patients with Parkinson's disease, with minimal side effects. Additional findings indicated that a higher number of sessions, greater number of pulses per session, and use of the F8 coil type appeared to enhance treatment effects. Study limitations included the need for further research to strengthen findings regarding optimal stimulation parameters and the influence of patient characteristics on treatment outcomes.

Li (2022) conducted a meta-analysis of 32 sham-controlled RCTs of rTMS in patients with Parkinson disease and motor dysfunction (n=1048 patients).^[192] Motor dysfunction was assessed using the United Parkinson's Disease Rating Scale part III score. Overall, rTMS had a significant effect on motor symptoms compared to sham (SMD, 0.64; 95% CI, 0.47 to 0.80; p<.0001; I²=64%). High-frequency rTMS to the primary motor cortex was the most effective intervention. Significant benefit of rTMS was also demonstrated for akinesia, rigidity, and tremor.

2022 systematic review and meta-analysis by Cheng evaluated the efficacy of TBS on motor and nonmotor symptoms of Parkinson's disease.^[193] A total of eight studies met inclusion criteria. Of these, two evaluated only in the "off" medicine status (under the anti-Parkinsonism medicine withdrawal status for at least 12 hours), two evaluated only in the "on" anti-Parkinsonism medicine state, and four assessed both the "on" and "off" medicine states. According to the meta-analysis, TBS significantly improved the Unified Parkinson's Disease Rating Scale part III (UPDRS-III) score compared to sham in the "off" medicine state (SMD = -0.37; 95% CI -0.65 to -0.09; $p < 0.01$; $I^2 = 19\%$) but not the "on" medicine state (SMD = -0.06; 95% CI -0.37 to 0.25; $p = 0.69$; $I^2 = 0\%$). Statistically significant effects were also reported for improved slowing of gait in the "off" medicine status (SMD = -0.37; 95% CI -0.71 to -0.03; $p = 0.03$; $I^2 = 0\%$) and therapeutic effect on PD depression (mean difference = -2.93; 95% CI -5.52 to -0.33; $p = 0.03$). The authors concluded that large, high-quality RCTs are needed to confirm these findings.

Jiang (2020) performed a systematic review and meta-analysis of the effect of rTMS on cognitive function in Parkinson's disease patients.^[194] A total of 14 studies (173 participants) met inclusion criteria. Significant effects of rTMS were identified for the mini-mental state examination (MMSE) for the global cognitive outcome, and executive function. No significant effects were identified for the rest of the cognitive domains (memory, attention, and language ability).

A 2019 SR by Kim evaluated the effect of non-invasive brain stimulation (NIBS), including repetitive transcranial magnetic stimulation and transcranial direct current stimulation, for freezing of gait in parkinsonism.^[195] Seven studies met inclusion criteria. A meta-analysis was performed on the data from the 102 included patients. It showed a significant improvement in freezing of gait questionnaire scores (SMD=0.28; 95% CI 0.01 to 0.55) and turning time (SMD = 0.30; 95% CI 0.02 to 0.58). The effect size was greater when only Parkinson's disease patients were included.

Qin (2018) published a meta-analysis of RCTs examining high-frequency rTMS for Parkinson's disease (PD).^[196] The primary outcome measure was changes in depressive symptoms in Parkinson's disease patients and the secondary outcome was changes in motor symptoms. Nine RCTs, with data from 332 participants, were analyzed. Results were reported as mean difference (MD) or standard mean difference (SMD). For the primary outcome, changes in depressive symptoms, rTMS was not better than sham-rTMS (SMD = -0.33, 95% CI -0.83 to 0.17) or selective serotonin re-uptake inhibitors (SSRIs) (SMD = 0.07, 95% CI -0.52 to 0.18). The changes in motor symptoms were greater, both compared to sham-rTMS (MD = -2.80, 95% CI -5.45 to -0.15) and SSRIs (MD = -2.70, 95% CI -4.51 to -0.90).

Wagle (2016) published a SR that evaluated how rTMS improved motor symptoms in patients with Parkinson's disease.^[197] Twenty-one clinical trials with an active and control arm were reviewed. The authors concluded that rTMS can improve motor function as an adjunct therapy, but had insufficient data to evaluate specific clinical conditions related to Parkinson's disease i.e. dyskinesia, bradykinesia, and gait. Larger studies are needed to evaluate clinical features that will have a positive long-term response.

A 2015 SR included 20 sham-controlled RCTs with a total of 470 patients with PD.^[198] Sample sizes ranged from 8 to 102. The total effect size of rTMS on Unified Parkinson's Disease Rating Scale (UPDRS) part III score was 0.46, which is considered a small to medium effect size, and the mean change in the UPDRS-III score (-6.42) was considered to be a clinically

important difference. The greatest effect on motor symptoms was from high frequency rTMS over the primary motor cortex (standardized mean difference [SMD] of 0.77, $p < 0.001$) and low-frequency rTMS over other frontal regions (SMD: 0.50, $p = 0.008$). High frequency rTMS at other frontal regions and low frequency rTMS over the primary motor cortex did not have a statistically significant benefit. The largest study (described below) included in the SR was an exploratory, multicenter, double-blind trial that randomized 106 patients to eight weeks of 1-Hz rTMS, 10 Hz rTMS, or sham stimulation over the supplementary motor area.^[199] At nine weeks, all groups showed a similar amount of improvement. It cannot be determined from these results if the negative results of the largest trial are due to a lack of effect of rTMS on motor symptoms in general or to the location of stimulation. Additional study with a larger number of subjects and longer follow-up is needed to determine if high frequency rTMS over the primary motor cortex improves motor symptoms in patients with Parkinson disease.

A SR from 2009 included 10 RCTs with a total of 275 patients with PD.^[200] Seven of the studies were double-blind, one was not blinded and two of the studies did not specify whether the raters were blinded. In studies that used high frequency TMS there was a significant improvement on the Unified Parkinson's Disease Rating Scale (UPDRS) with a moderate effect size of -0.58. For low frequency TMS the results were heterogeneous and did not significantly reduce the UPDRS. The analyzed studies varied in outcomes reported, TMS protocol, patient selection criteria, demographics, stages of Parkinson's disease and duration of follow-up, which ranged from immediate to 16 weeks after treatment.

Randomized Controlled Trials

Feng (2025) published a single-center double-blind controlled study evaluating the efficacy and safety of low-frequency repetitive transcranial magnetic stimulation targeting the dorsolateral prefrontal cortex for improving sleep disturbances in patients with early-stage Parkinson disease.^[201] The study included 80 patients with Parkinson disease (Hoehn-Yahr grades 1-3) with sleep disorders randomized into a treatment group ($n = 40$) that received 1 Hz repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex (90% motor threshold, 20 minutes per day for 10 days) and a control group ($n = 40$) that received sham stimulation. Results demonstrated that compared to baseline, the treatment group exhibited significant improvements in Hamilton Depression, Hamilton Anxiety, Pittsburgh Sleep Quality Index, and Parkinson's Disease Sleep Scale scores (all $p < 0.001$). Polysomnography data revealed prolonged total sleep time ($p < 0.001$), reduced sleep latency ($p < 0.001$), fewer nighttime awakenings ($p < 0.001$), enhanced sleep efficiency ($p < 0.001$), and shortened rapid eye movement sleep latency. Between-group comparisons demonstrated superior outcomes in the treatment group for all sleep and mood metrics ($p < 0.001$), with improvements persisting for at least 1 month. Study limitations included the single-center design, relatively short follow-up period, and the need for longer-term studies to assess durability of treatment effects.

Romero (2024) published a randomized, single-blinded controlled trial examining the effects of repetitive Transcranial Magnetic Stimulation (rTMS) and EEG-guided neurofeedback, both alone and in combination, on Parkinson's disease symptoms.^[202] The study included 40 participants (27 males, mean age 63 years) with Parkinson's disease, divided into four groups: rTMS alone, EEG-guided neurofeedback alone, combined therapy, and a control group. The combined therapy group showed the greatest improvements in motor symptoms, health-related quality of life, and cortical silent periods, followed by the rTMS-only and neurofeedback-only groups. Statistical significance was demonstrated through longitudinal analysis of covariance mixed-effects models. Limitations included a relatively small sample

size, and while overall motor symptoms improved, the study found no significant differences between treatment groups and controls in functional mobility or postural stability measures. The study was also limited by its single-blinded design and short follow-up period of two weeks.

He (2021) conducted a randomized sham-controlled study on the effect of iTBS on mild cognitive impairment in Parkinson's disease.^[203] A total of 35 PD patients were randomly assigned to receive iTBS (n=20) or sham (n=15) over the left dorsolateral prefrontal cortex for 10 consecutive weekdays. Statistically significant differences in improvement in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and Montreal Cognitive Assessment (MoCA) were reported immediately post-intervention for both the iTBS and sham groups and at the three-month follow-up for only the iTBS group ($p<0.05$).

Cohen (2018) reported a double-blind, randomized, sham-controlled study to assess repetitive deep TMS for PD.^[204] Forty-eight patients were randomized to sham or real repetitive deep TMS to the primary motor cortex and prefrontal cortex. The primary outcome measures were the total and motor scores of the Unified Parkinson's Disease Rating Scale, and secondary measures were rating of depression and quantitative motor tasks. Both groups improved significantly over the trial period. There was no significant effect of treatment. Side effects were reported to be more common in the repetitive deep TMS group. These effects were transient and reported to be tolerable.

Makkos (2016) published a double-blinded placebo-controlled RCT to determine if rTMS can improve depression for patients with PD.^[205] Forty-six patients with mild to moderate depression received rTMS (n=23) or sham stimulation (n=23) for 10 days. Patients were evaluated by the Montgomery-Åsberg Depression Rating Scale at baseline, one day into treatment and 30 days after treatment. The authors concluded results were promising for the rTMS group, but rTMS trials should further evaluate the effects of rTMS on PD patients with severe depression.

A 2013 exploratory multicenter double-blind trial randomized 106 patients to eight weeks of 1 Hz TMS, 10 Hz TMS, or sham stimulation over the supplementary motor area.^[199] At nine weeks all groups showed a similar amount of improvement. At the 20-week follow-up only the 1 Hz group showed a significant improvement (6.84 points) in the primary outcome measure, the UPDRS. There was no significant improvement in other outcome measures.

In 2012, Benninger reported a double-blind sham-controlled RCT of brief (six sec) very high frequency (50 Hz) TMS over the motor cortex in 26 patients with mild to moderate Parkinson's disease.^[206] Eight sessions of 50 Hz TMS did not improve gait, bradykinesia, or global and motor scores on the UPDRS compared to the sham-treated group. Activities of daily living were significantly improved a day after the intervention, but the effect was no longer evident at one month after treatment. Functional status and self-reported well-being were not affected by the treatment. No adverse effects of the very high frequency stimulation were identified.

In another study from 2012, Yang randomized 20 patients with Parkinson's disease to 12 brief sessions (six min) of high frequency (5-Hz) TMS or sham TMS over the leg area of the motor cortex followed by treadmill training.^[207] Blinded evaluation showed a significant effect of TMS combined with treadmill training on neurophysiological measures, and change in fast walking speed and the timed up and go task. Mean treadmill speed improved to a similar extent in the active and sham TMS groups.

Section Summary

The current evidence is mixed regarding the treatment benefits of TMS in patients with Parkinson's disease. Additional well-designed, RCTs, which control for treatment effect and include a larger number of subjects and longer follow-up, is needed to determine if TMS improves motor symptoms in patients with Parkinson's disease.

STROKE REHABILITATION

Systematic Reviews

Zhang (2026) published a systematic review and meta-analysis of randomized controlled trials examining theta burst stimulation effects on post-stroke aphasia.^[208] The review included 12 randomized controlled trials (combined $n = 524$). Results demonstrated that theta burst stimulation significantly improved overall speech function ($SMD = 0.97$, 95% CI = 0.51 to 1.43, $p < 0.001$), particularly effective in enhancing naming, auditory comprehension, repetition, and spontaneous speech abilities. Subgroup analyses revealed that selecting stimulation of Broca's area, the intermittent theta burst stimulation protocol, early-stage (acute or subacute) patients, and multiple interventions (10 or more sessions) can significantly improve post-stroke aphasia.

Zhang (2025) published a systematic review and meta-analysis examining the effects of repetitive Transcranial Magnetic Stimulation (rTMS) on motor recovery after stroke.^[209] The study analyzed 37 randomized controlled trials (RCTs) with low risk of bias, encompassing 48 unique comparisons. Results showed significantly higher Fugl-Meyer Assessment for Upper Extremity (FMA-UE) scores in the rTMS group compared to controls (mean difference = 5.4, $P < 0.001$ post-intervention; mean difference = 5.2, $P = 0.031$ at follow-up). Subgroup analyses revealed greater benefits for patients treated within six months post-stroke and those with more severe baseline motor impairment. Both contralesional and ipsilesional stimulation showed immediate improvements, while bilateral rTMS benefits were only significant at follow-up. The modified Rankin Scale also showed significant improvements in the rTMS group. Limitations included potential publication bias (corrected MD = 10.7) and the need for larger sample sizes in future studies to better clarify rTMS's role in post-stroke rehabilitation.

Duan (2024) published a systematic review and meta-analysis examining the effectiveness of repetitive Transcranial Magnetic Stimulation (rTMS) in treating post-stroke dysfunction.^[210] The study analyzed 33 studies comprising 2,682 patients. Results showed an overall effective strength (ES) of 0.53, with varying effectiveness across different stroke stages (acute: 0.69, subacute: 0.45, chronic: 0.52). The analysis revealed similar effectiveness between high-frequency (ES=0.56) and low-frequency stimulation (ES=0.53), and comparable outcomes across different symptoms (sensory: 0.50, upper limb: 0.52, swallowing: 0.51, aphasia: 0.54). Treatment effectiveness was similar whether rTMS was applied to affected (ES=0.51) or unaffected sides (ES=0.54), and whether used alone or in combination therapy (both ES=0.53). Limitations included heterogeneity of methods including lack of standardized protocols.

Ahmed (2023) completed a SR with network meta-analysis (NMA) to compare the efficacy of non-invasive brain stimulation (NiBS) including transcranial direct current stimulation (tDCS), repetitive transcranial magnetic stimulation (rTMS), theta-burst stimulation (TBS), and transcutaneous vagus nerve stimulation (taVNS) in upper limb stroke rehabilitation.^[211] A total of 87 RCTs (3750 participants) were included. Pairwise meta-analysis showed that all NiBS except continuous TBS (cTBS) and cathodal tDCS were significantly more efficacious than

sham stimulation for motor function (standardized mean difference [SMD] range 0.42-1.20), whereas taVNS, anodal tDCS, and both low and high frequency rTMS were significantly more efficacious than sham stimulation for ADLs (SMD range 0.54-0.99). The NMA showed that taVNS was more effective than cTBS (SMD:1.00; 95% CI (0.02-2.02)), cathodal tDCS (SMD:1.07; 95% CI (0.21-1.92)), and physical rehabilitation alone (SMD:1.46; 95% CI (0.59-2.33)) for improving motor function. The taVNS ranked highest in improving motor function (SMD: 1.20; 95% CI (0.46-1.95)) and ADLs (SMD:1.20; 95% CI (0.45-1.94)) after stroke. After taVNS, excitatory stimulation protocols (intermittent TBS, anodal tDCS, and HF-rTMS) are most effective in improving motor function and ADLs after acute/sub-acute (SMD range 0.53-1.63) and chronic stroke (SMD range 0.39-1.16).

Chen (2023) published a SR with meta-analysis to summarize the current effectiveness of noninvasive brain stimulation (NIBS) in the treatment of post-stroke sensory dysfunction.^[212] A total of 14 RCTs were included (combined n = 804). Moderate-quality evidence suggested that NIBS significantly improved sensory function after stroke, and significant effects were observed up to one year after the intervention. In subgroup analysis, treatment with transcranial direct current stimulation (tDCS) or repetitive transcranial magnetic stimulation (rTMS) was significantly more effective than controls for recovery of sensory function in stroke patients. Stimulation of the primary motor cortex (M1), primary somatosensory cortex (S1) or M1 + S1 stimulation sites significantly improved sensory function. NIBS for sensory dysfunction showed significant therapeutic potential in patients with different stages of stroke. No significant effects were observed in subjects with less than 10 NIBS stimulations. Significant therapeutic effects were observed with either high-frequency or low-frequency rTMS.

Qiao (2022) performed a meta-analysis of RCTs that assessed the effect of rTMS in 433 patients with post-stroke dysphagia.⁵⁵ Twelve trials that used dysphagia severity rating scales (Dysphagia Grade and Penetration Aspiration Scale) were included. The specific controls used in each study were not specified. Study characteristics included duration of treatment of 1 to 10 days, stimulation frequency of 1 to 10 Hz, and duration of stimulation of 5 to 20 minutes. The analysis favored rTMS (SMD, -0.67; 95% CI -0.88 to -0.45; $p < .001$; $I^2 = 42\%$). Subgroup analyses identified treatment duration > 5 days and rTMS during the subacute phase after stroke as potential situations with greater clinical benefit, but there was no difference in efficacy according to stimulation frequency, location, or duration of each stimulation. The authors noted that publication bias was present and there may be limited clinical applicability of the dysphagia rating scales.

Xie (2021) published an SR and network meta-analysis of rTMS for lower extremity motor function recovery in stroke patients.^[213] A total of 18 RCTs met inclusion criteria. The meta-analysis indicated high-frequency rTMS was superior to sham in promoting lower extremity motor function recovery. Based on the five relevant studies, the meta-analysis also indicated that high-frequency rTMS resulted in higher amplitudes of motor evoked potentials than low-frequency rTMS or sham stimulation.

Dionísio (2018) published an SR on the efficacy of rTMS for recovery of nonmotor functions following stroke.^[214] A total of 38 studies met the inclusion criteria on the topics of aphasia, dysphagia, neglect, and visual extinction. No meta-analysis was completed. Most of the included studies had small patient numbers. The authors concluded that the variability that was present in terms of patient selection, treatment protocols, and outcome measures, limits the conclusions that can be drawn.

Zhang (2017) published an SR and meta-analysis evaluating the effects of rTMS on upper-limb motor function after stroke.^[215] A search for studies published before October 2016 was performed, yielding 34 RCTs with a total of 904 participants (range, 6 to 108 participants). Pooled estimates found improvement with rTMS for both short-term (SMD=0.43; $p<0.001$) and long-term (SMD=0.49; $p<0.001$) manual dexterity. Of the 28 studies reporting on adverse events, 25 studies noted none. Mild adverse events, such as headache and increased anxiety were reported in three studies. The review was limited by variation in TMS protocols between studies.

Sebastianelli (2017) published an SR including 67 studies on the use of low-frequency rTMS of the unaffected hemisphere in stroke patients.^[216] No meta-analyses were included. The SR concluded that rTMS applied to the unaffected hemisphere following stroke appears to be safe and has potential to be a useful adjuvant strategy for neurorehabilitation but that further research is needed.

McIntyre (2017) published an SR on the use of rTMS for spasticity post-stroke. Ten studies met the inclusion criteria, two of which were RCTs.^[217] The RCTs were rated on the Physiotherapy Evidence Database with scores of eight to nine. Meta-analyses were conducted separately for the uncontrolled studies and the RCTs. Whereas the uncontrolled pre-post studies found significant improvements in spasticity, the RCTs did not.

A 2017 SR published by Fan included 12 studies total examining the effect of noninvasive brain stimulation in the recovery of unilateral neglect in poststroke patients.^[218] Eleven RCTs were included in the meta-analysis. Techniques of noninvasive brain stimulation included transcranial direct current stimulation, theta-burst TMS, and rTMS. The quality of included RCTs was good to excellent, with PEDro scores of eight or nine in seven studies and six to eight in the remainder. A moderate degree of heterogeneity was identified in rTMS and cTBS studies. The meta-analysis showed a significant effect of rTMS immediately following treatment and at follow-up.

In 2016, Graef reported a meta-analysis of rTMS combined with upper-limb training for improving function after stroke.^[219] Included were 11 sham-controlled randomized trials with 199 patients that evaluated upper-limb motor/functional status and spasticity; eight RCTs with sufficient data were included in the meta-analysis. These studies were considered to have a low-to-moderate risk of bias. In the overall analysis, there was no benefit of rTMS on upper-limb function or spasticity (SMD=0.03; 95% CI -0.25 to 0.32).

Liao (2016) published a SR that evaluated the impact of rTMS on dysphagia in stroke patients.^[220] Six RCTs with a total of 163 patients were reviewed. The authors concluded that patients had improved, four weeks after treatment with low or high frequency rTMS. High frequency rTMS may be more beneficial than low frequency rTMS. This SR did not include long-term outcomes.

A 2015 meta-analysis by Li included four RCTs on rTMS over the right pars triangularis for patients ($n=137$) with aphasia after stroke.^[221] All of the studies used double-blinding, but therapists were not blinded. Every study used a different outcome measure, and the sample sizes were small (range from 12 to 40). Meta-analysis showed a medium effect size for naming ($p=0.004$), a trend for a benefit on repetition ($p=0.08$), and no significant benefit for comprehension ($p=0.18$). Additional study in a larger number of patients is needed to determine with greater certainty the effect of this treatment on aphasia after stroke.

A 2014 meta-analysis by Le assessed the effect of rTMS on recovery of hand function and excitability of the motor cortex after stroke.^[222] Eight RCTs with a total of 273 participants were included in the review. The quality of the studies was rated moderate to high, although the size of the studies was small. There was variability in the time since stroke (five days to 10 years), in the frequency of rTMS applied (1 Hx to 25 Hx for one sec to 25 mins per day), and the stimulation sites (primary motor cortex or premotor cortex of the unaffected hemisphere). Meta-analysis found a positive effect on finger motor ability (four studies, n=79, standardized mean difference of 0.58) and hand function (three studies, n=74, standardized mean difference of -0.82), but no significant change in motor evoked potential (n=43) or motor threshold (n=62).

A 2013 Cochrane review included 19 trials with a total of 588 participants on the effect of TMS for improving function after stroke.^[223] The two largest trials included in the review showed that TMS was not associated with a significant improvement in the Barthel Index score. Four trials (n=73) found no significant effect for motor function. Subgroup analysis for different stimulation frequencies or duration of illness also did not show a significant benefit of rTMS when compared to sham rTMS or no treatment. The review concluded that current evidence does not support the routine use of TMS for the treatment of stroke.

Randomized Controlled Trials

Liu (2024) published a randomized, double-blinded, sham-controlled trial examining the effects of high-frequency repetitive Transcranial Magnetic Stimulation (rTMS) on post-stroke working memory impairment.^[224] The study included 123 stroke patients, with 82 completing the trial, who received either 10 Hz rTMS or sham treatment to the left dorsolateral prefrontal cortex for 14 days. Results showed significant working memory improvements in the rTMS group at both 2 weeks ($t = 5.55$, $P < 0.001$) and 6 weeks ($t = 2.11$, $P = 0.045$) compared to sham treatment. The rTMS group demonstrated increased oxygenated hemoglobin content and stronger functional connectivity in specific brain regions. Both groups had equal dropout rates (18%), with headaches being the most common side effect (36% rTMS, 30% sham). Limitations included a moderate sample size and a relatively short follow-up period of four weeks post-treatment.

Dai (2023) published a single-blinded, randomized controlled trial, to evaluate the effectiveness of 10-Hz cerebellar rTMS in poststroke dysphagia (PSD) patients with infratentorial stroke (IS).^[225] Patients (n = 42) with PSD with subacute in infratentorial stroke (IS) were allocated to three groups: bilateral cerebellar rTMS (biCRB-rTMS), unilateral cerebellar rTMS (uniCRB-rTMS), or sham-rTMS. The stimulation parameters were 5 trains of 50 stimuli at 10 Hz with an interval of 10 s at 90% of the thenar resting motor threshold (RMT). The Functional Oral Intake Scale (FOIS) was assessed at T0 (baseline), T1 (day 0 after intervention), and T2 (day 14 after intervention), whereas the Dysphagia Outcome and Severity Scale (DOSS), Penetration Aspiration Scale (PAS), and neurophysiological parameters were evaluated at T0 and T1. Significant time and intervention interaction effects were observed for the FOIS score ($F = 3.045$, $p = 0.022$). The changes in the FOIS scores at T1 and T2 were both significantly higher in the biCRB-rTMS group than in the sham-rTMS group ($p < 0.05$). The uniCRB-rTMS and biCRB-rTMS groups demonstrated greater changes in the DOSS and PAS at T1, compared with the sham-rTMS group ($p < 0.05$). Bilateral corticobulbar tract excitability partly increased in the biCRB-rTMS and uniCRB-rTMS groups at T1, compared with T0. The percent changes in corticobulbar tract excitability parameters at T1 showed no difference among three groups.

Zhong (2023) published an RCT to evaluate the effect of high-frequency cerebellar rTMS on poststroke dysphagia.^[226] This was a randomized, sham-controlled, double-blind trial. A total of eighty-four study participants were randomly assigned into the cerebellum and control groups. The cerebellum group received bilateral 10Hz rTMS treatment of the pharyngeal motor area of the cerebellum. The control group was administered with sham rTMS of the pharyngeal motor area of the cerebellum. All patients underwent the same conventional swallowing rehabilitation training after the intervention 5 days a week for a total of 10 days. The interaction between time and intervention had a significant effect on PAS ($P<0.001$) and Fiberoptic Endoscopic Dysphagia Severity Scale (FEDSS) ($P<0.001$). Compared to the control group, the cerebellum group exhibited significantly improved clinical swallowing function scores (PAS: $P=0.007$, FEDSS: $P=0.002$). Bilateral cerebellar rTMS is a potential new neurorehabilitation technique for post-stroke dysphagia. The authors comment on the need for more studies investigating the therapeutic mechanism for cerebellar rTMA.

Wang (2020) conducted an RCT to determine the efficacy of high-frequency TMS over the contralesional motor cortex for motor recovery in severe hemiplegic stroke patients. Patients with ischemic or hemorrhagic stroke in the territory of the middle cerebral artery were randomized to receive 10 Hz rTMS ($n=15$), 1 Hz rTMS ($n=15$) or sham ($n=15$). Treatment was applied over the contralesional motor cortex (M1) prior to physiotherapy daily for two weeks. Clinical efficacy was assessed by the FMA score (a standardized motor impairment scale) and the Barthel Index (BI; a measure of daily life ability). According to a repeated-measures mixed analysis of variance, all patients had a significant recovery from impairment and improvement in activities of daily living postintervention compared to pre-treatment. There were no statistically significant differences between the 1 Hz rTMS group and the sham group. The 10 Hz rTMS group FMA and BI scores were significantly higher than the 1 Hz rTMS group and the sham group ($p<0.05$ and $p<0.005$, respectively). Neurophysiological measures and muscle activation were also improved in all groups, but significantly greater in the 10 Hz rTMS group ($p<0.05$ for both).

An RCT published by Ren (2019) assessed the use of rTMS over the right pars triangularis of the posterior inferior frontal gyrus (pIFG) and the right posterior superior temporal gyrus (pSMG) for the treatment of poststroke global aphasia. A total of 45 patients were randomized to receive one of three treatments: rTMS over the right triangular part of the pIFG, rTMS over the right pSTG, or sham stimulation. Outcomes reported were aphasia quotient (AQ) scores obtained from the Chinese version of the Western Aphasia Battery (WAB), spontaneous speech, auditory comprehension, and repetition. These were measured at baseline and immediately after three weeks (15 days) of experimental treatment. There were statistically significant increases in the right pSTG rTMS group compared to sham for auditory comprehension, repetition, and AQ ($p<0.05$). There were statistically significant increases in the pIFG rTMS group compared with sham for repetition, spontaneous speech, and AQ ($p<0.05$).

Choi (2018) examined the effects of high frequency rTMS on hemiplegic shoulder pain in patients with chronic stroke.^[227] A total of 24 chronic stroke patients with chronic hemiplegic shoulder pain were randomly assigned to receive real rTMS (10 sessions of high-frequency stimulation) or sham rTMS. Pain was evaluated using the Numeric Rating Scale (NRS) at one day and one, two, and four weeks after treatment. Additional measures were changes the Motricity Index (MI-UL) and modified Brunnstrom Classification (MBC), which were used to evaluate changes in upper-limb motor function. There was a significant improvement in

the NRS score at all time points in the real rTMS but not sham group. No significant changes were observed in the measures of upper-limb motor function.

Forogh (2017) performed a randomized double-blind sham-controlled trial on TMS for stroke recovery.^[228] Twenty-six patients were evaluated. Patients received five days of low-frequency rTMS or sham rTMS. Follow-up was conducted at 12 weeks. Static postural stability, balance, muscle strength, and motor recovery were assessed. Significant differences between real and sham treatment groups were observed for static postural stability, balance, and muscle strength. There was significant improvement in muscle recovery compared to baseline in the real rTMS group. However, the groups were different in this measure at baseline, and they were not significantly different at three or 12 weeks.

Huang (2017) reported results of an RCT on the use of rTMS for the recovery of lower extremities after stroke.^[229] Thirty-eight subacute stroke patients with significant leg disabilities received real or sham rTMS followed by 45 minutes of physical therapy for three weeks. Real rTMS consisted of 15 minutes of 1-Hz treatment over the contralesional motor cortex representing the quadriceps muscle. Recovery in ambulation, balance, motor functions, and activities of daily living were assessed. No significant differences between groups were identified.

Guan (2017) performed a prospective, double-blind, randomized, sham-controlled study to assess the effectiveness of rTMS on motor recovery after stroke.^[230] Forty-two were assessed and found eligible for the study and following dropout during the study, 27 were included in the final analysis. Patients were randomized to receive real or sham high-frequency rTMS treatment. Treatment consisted of 10 consecutive days of 5 Hz rTMS applied to the ipsilesional M1. Motor functional scores, including the National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI), Fugl-Meyer Assessment Upper Limb/Lower Limb (FMA-UL/LL), modified Rankin Score (mRS), and the resting motor threshold (RMT) of the hemiplegic limb, were assessed. At one month following treatment, there were significant differences in score improvement from baseline in NIHSS, BI, and FMA-UL. At three months, six months, and one year the only score for which a significant difference in improvement was seen was FMA-UL, representing a lasting improvement in upper extremities function.

Additional RCTs of the efficacy of TMS for post-stroke recovery have been published that are preliminary (feasibility) studies and/or have serious methodological limitations, such as very small patient populations or lack of a sham control, that render outcomes unreliable.

Section Summary

Evidence consists of a number of RCTs and SRs of the effect of TMS on recovery from stroke. Results are conflicting, and efficacy may depend on the location of the stroke and frequency of the TMS. Additional study is needed to determine whether TMS facilitates standard physiotherapy in patients with stroke.

TINNITUS

Systematic Reviews

The Washington HTA published a technology assessment in 2020 that reviewed non-invasive, non-pharmacological treatments for tinnitus. The authors identified a total of 10 parallel-assignment RCTs and 9 crossover RCTs from 19 publications describing results of rTMS stimulation interventions compared to sham stimulation. Intervention protocols were

heterogeneous. Most of the 18 RCTs reporting measures of tinnitus distress or disability did not report a significant difference between active and sham rTMS. No significant differences between groups were reported for depression, anxiety, and sleep outcomes in the five RCTs reporting on psychological measures or quality of life in the one reporting RCT. A total of 14 studies reported on adverse events. In five, no adverse events were reported and in three, results were not reported by group. Of the six studies that reported differences by group, three reported similar incidence between groups, two reported higher incidence of adverse events in the active rTMS group and one reported a higher incidence of adverse events in the sham rTMS group.

Randomized Control Trials

In 2017, Sahlsten published a prospective randomized placebo-controlled study to investigate the effects of rTMS using electric field navigation for tinnitus.^[232] Thirty-nine patients were randomized to receive 10 sessions of 1 Hz rTMS or placebo targeted to the region of the left auditory cortex corresponding to tonotopic representation of tinnitus pitch. Primary outcomes were tinnitus intensity represented by the visual analogue scores (VAS 0-100), annoyance and distress, and the Tinnitus Handicap Inventory (THI). These were evaluated immediately following treatment and one, three, and six months later. All measures tested decreased significantly in both groups. No significant differences between groups were reported.

Landgrebe (2017) reported a multicenter randomized, sham-controlled trial that investigated the efficacy and safety of rTMS for chronic tinnitus.^[233] A total of 163 patients were randomized to receive real or sham rTMS. Treatment consisted of 10 sessions of 1 Hz to the left temporal cortex. Tinnitus questionnaire scores were taken at baseline and at the end of treatment. The primary outcome was change in this score and secondary outcome measures were depression and quality of life. There were no significant differences in any measures between groups at the end of the trial.

Lehner (2016) published a two-arm parallel group RCT that evaluated 74 patients who received ten sessions of triple-site stimulation (n=25), single-site stimulation (n=24) or placebo (n=25).^[234] Patients answered a tinnitus questionnaire day one and 12 and at follow-up three and six months later. The authors concluded rTMS reduces tinnitus severity in both groups the single and triple site groups, with no differences between them. Larger RCTs are needed to determine long-term effects, objective outcomes and appropriate treatment protocols.

OTHER MEDICAL INDICATIONS

SRs and RCTs have been published exploring the efficacy of TMS for a variety of central nervous system-related disorders such as central pain related to spinal cord injury, dysphagia, blepharospasm, amyotrophic lateral sclerosis (ALS), multiple sclerosis, chronic pain, substance abuse, burning mouth syndrome, phantom limb sensations, cravings, traumatic brain injury, concussion, symptom management in breast cancer, and treatment of obesity.^[211, 235-304] All of these studies had one or more significant methodological limitations, including but not limited to small patient populations, short follow-up times, heterogeneous treatment parameters, continued use of concurrent therapies, and/or significant loss to follow-up. Generally, the authors agreed that larger, long-term RCTs are needed, along with better defined optimal treatment parameters for administering TMS.

MOVEMENT DISORDER SOCIETY

The Movement Disorder Society (MDS) published an evidence-based review of treatments for motor (updated in 2018) and non-motor (updated in 2019) symptoms of Parkinson's disease.^[305, 306] The reviews found insufficient evidence to make adequate conclusions on the efficacy of rTMS for the treatment of motor symptoms or depression in Parkinson's disease. The MDS did note that evidence regarding TMS treatment of depression in the general population is growing; therefore, it concludes that the practice implication is "possibly useful."

In 2008, the society also conducted a literature review describing current management practices for tic disorder and noted that study results regarding the use of TMS as a treatment for tics varied.^[307]

AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY (AACAP)

The AACAP (2023) published a Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders.^[308] The recommendations include that selective serotonin reuptake inhibitor medication (except paroxetine), preferably fluoxetine, could be offered to adolescents and children with major depressive disorder. The guideline also indicates that there is insufficient evidence for other classes of antidepressants for this age group. The guidelines state that the "Use of interventional treatments (eg, neurofeedback, transcranial magnetic stimulation, electroconvulsive therapy)" are areas where the AHRQ review yielded insufficient information to draw conclusions about benefits or harms. As of the publication, there was not enough rigorous evidence to make formal recommendations about TMS as a treatment option for depression in children and adolescents.

AMERICAN PSYCHIATRIC ASSOCIATION

In 2018, the American Psychiatric Association published consensus recommendations on rTMS for the treatment of depression.^[309] The guidelines state, "Multiple randomized controlled trials and published literature have supported the safety and efficacy of rTMS antidepressant therapy." The recommendations include information on the following variables: clinical environment, operator requirements, documentation, coils, cortical targets, coil positioning methods, determination of motor threshold, number of treatment sessions for acute treatment, and allowable psychotropic medications during TMS treatment.

The APA's guidelines on the treatment of patients with obsessive-compulsive disorder (2007, reaffirmed in 2012) state that "findings of the four published trials of repetitive TMS (rTMS) are inconsistent, perhaps because the studies differed in design, stimulation sites, duration, and stimulation parameters. The available results and the technique's non-invasiveness and good tolerability should encourage future research, but the need for daily treatment may limit the use of TMS in practice."

AMERICAN ACADEMY OF NEUROLOGY

The American Academy of Neurology published an evidence-based practice guideline in 2016 on the treatment of restless legs syndrome (RLS) in adults.^[310] It stated, "For patients or clinicians wanting to use nonpharmacologic approaches to treat RLS...clinicians may consider

prescribing near-infrared spectroscopy (NIRS) or repetitive transcranial magnetic stimulation (rTMS) (where available) (Level C).” This recommendation is based on one Class II study.

DEPARTMENT OF VETERANS AFFAIRS/DEPARTMENT OF DEFENSE

The 2023 VA/DoD guideline for management of bipolar disorder states “for individuals with bipolar disorder who have demonstrated partial or no response to pharmacologic treatment for depressive symptoms, we suggest offering repetitive transcranial magnetic stimulation [rTMS] as an adjunctive treatment.”^[311] However, the recommendation was rated as weak and the confidence in the evidence was very low. For the management of PTSD, the 2023 guideline found insufficient evidence for or against rTMS.^[312]

The 2022 Veteran's Affairs/Department of Defense guideline for management of major depressive disorder recommends offering rTMS to patients who have experienced partial response or no response to an adequate trial of 2 or more pharmacologic treatments (strength of recommendation: weak).^[313] Recommended options for the second treatment attempt after the initial therapy tried include switching to another antidepressant or adding augmentation therapy with a second-generation antipsychotic. The recommendation for rTMS was graded as weak due to limitations of the available literature including small study effects, high rates of discontinuation, lack of allocation concealment, and the practical limitations of the need for daily treatment and lack of widespread access to facilities that offer this therapy. The guideline also concluded that there is limited evidence to recommend for or against theta-burst stimulation for treatment of depression.

In 2019, the Department of Veterans Affairs (VA)/Department of Defense (DoD) published an update to its 2010 evidence-based clinical practice guideline for the management of stroke rehabilitation.^[314] The guideline includes the following recommendation regarding TMS:

There is insufficient evidence to recommend for or against repetitive transcranial magnetic stimulation to improve upper or lower extremity motor function.
(Recommendation rating: Neither For Nor Against; Reviewed, New-added)

A clinical practice guideline on the primary care management of headache published in 2020 by the VA/DoD states that there is insufficient evidence to recommend for or against Transcranial magnetic stimulation for headache (Recommendation rating: Neither For nor Against; Reviewed, New-added).^[315]

A clinical practice guideline on management and rehabilitation of post-acute mild traumatic brain injury published in 2021 by the VA/DoD recommends against the use of rTMS for the treatment of symptoms attributed to mild traumatic brain injury (Recommendation rating: Weak Against; Reviewed, New-added).^[316]

SUMMARY

Medically Necessary

It appears that transcranial magnetic stimulation (TMS) delivered as repetitive TMS (rTMS) or Theta Burst TMS (iTBS) may improve depression for some people with major depressive disorder. Despite the weaknesses in the published clinical evidence and limited guideline support, TMS has become a recognized standard of care for treatment resistant major depressive disorder. Therefore, TMS may be considered medically necessary for up to 36

sessions, one session per day as a treatment of major depressive disorder when policy criteria are met. Additional sessions may be considered medically necessary when continuation criteria are met.

Not Medically Necessary

Transcranial magnetic stimulation (TMS) is not clinically indicated for major depressive disorder except in the clinical scenarios addressed in the criteria. Therefore, TMS is considered not medically necessary when Criterion I. is not met.

Investigational

There is not enough research to show that transcranial magnetic stimulation (TMS) improves health outcomes for any condition other than major depressive disorder. Therefore, TMS is considered investigational as a treatment of all other conditions.

There is not enough evidence to show that treatment using an accelerated transcranial magnetic stimulation (TMS) protocol is superior to conventional protocols to improve health outcomes. Therefore, the use of accelerated TMS protocols is considered investigational for all indications. This includes the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol.

REFERENCES

1. Conroy SK, Holtzheimer PE. Neuromodulation Strategies for the Treatment of Depression. *Am J Psychiatry*. 2021;178(12):1082-88. PMID: 34855452
2. Lefaucheur JP, Colzi C, Hollander E, et al. Comparison between accelerated and standard or sham rTMS in the treatment of depression: A systematic review. *Neuroscience and biobehavioral reviews*. 2025;173:106140. PMID: 40252882
3. Gamboa L, Palha-Fernandes E, Bragança M. Non-inferiority of Accelerated vs. Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder: A Systematic Review. *Clin Psychopharmacol Neurosci*. 2025;23(4):551-59. PMID: 41139590
4. Gallop L, Westwood SJ, Hemmings A, et al. Effects of repetitive transcranial magnetic stimulation in children and young people with psychiatric disorders: a systematic review. *Eur Child Adolesc Psychiatry*. 2025;34(2):403-22. PMID: 38809301
5. Lan XJ, Cai DB, Liu QM, et al. Stanford neuromodulation therapy for treatment-resistant depression: a systematic review. *Front Psychiatry*. 2023;14:1290364. PMID: 38161728
6. Cai DB, Qin ZJ, Lan XJ, et al. Accelerated intermittent theta burst stimulation for major depressive disorder or bipolar depression: A systematic review and meta-analysis. *Asian J Psychiatr*. 2023;85:103618. PMID: 37201381
7. Qin ZJ, Huang SQ, Lan XJ, et al. Bilateral theta burst stimulation for patients with acute unipolar or bipolar depressive episodes: A systematic review of randomized controlled studies. *J Affect Disord*. 2023;340:575-82. PMID: 37579881
8. Neuteboom D, Zantvoord JB, Goya-Maldonado R, et al. Accelerated intermittent theta burst stimulation in major depressive disorder: A systematic review. *Psychiatry Res*. 2023;327:115429. PMID: 37625365

9. Voigt JD, Leuchter AF, Carpenter LL. Theta burst stimulation for the acute treatment of major depressive disorder: A systematic review and meta-analysis. *Transl Psychiatry*. 2021;11(1):330. PMID: 34050123
10. Chu HT, Cheng CM, Liang CS, et al. Efficacy and tolerability of theta-burst stimulation for major depression: A systematic review and meta-analysis. *Progress in neuro-psychopharmacology & biological psychiatry*. 2021;106:110168. PMID: 33166668
11. Pohar R, Farrah K. Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines—An Update. 2019. PMID:
12. Hung YY, Yang LH, Stubbs B, et al. Efficacy and tolerability of deep transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis. *Progress in neuro-psychopharmacology & biological psychiatry*. 2020;99:109850. PMID: 31863873
13. Voigt J, Carpenter L, Leuchter A. A systematic literature review of the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) in non-treatment resistant patients with major depressive disorder. *BMC Psychiatry*. 2019;19(1):13. PMID: 30621636
14. Martin DM, McClintock SM, Forster JJ, et al. Cognitive enhancing effects of rTMS administered to the prefrontal cortex in patients with depression: A systematic review and meta-analysis of individual task effects. *Depression and anxiety*. 2017;34(11):1029-39. PMID: 28543994
15. Kedzior KK, Schuchinsky M, Gerkenmeier I, et al. Challenges in comparing the acute cognitive outcomes of high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) vs. electroconvulsive therapy (ECT) in major depression: A systematic review. *Journal of psychiatric research*. 2017;91:14-17. PMID: 28288306
16. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Ontario health technology assessment series*. 2016;16(5):1-66. PMID: 27099642
17. Kedzior KK, Gierke L, Gellersen HM, et al. Cognitive functioning and deep transcranial magnetic stimulation (DTMS) in major psychiatric disorders: A systematic review. *Journal of psychiatric research*. 2016;75:107-15. PMID: 26828370
18. Washington State Health Care Authority, Health Technology Assessment: Nonpharmacologic Treatments for Treatment-Resistant Depression. [cited 04/09/2026]. 'Available from:' <https://www.hca.wa.gov/assets/program/Revised-TRD-final-findings-decision.pdf>.
19. Liu X, Peng Z, Cheng F, et al. Efficacy and Safety of Accelerated Intermittent Theta Burst Stimulation for Adolescents With Major Depressive Disorder: A Randomized, Double-Blind, Sham-Controlled Study. *Biol Psychiatry*. 2026;99(3):218-26. PMID: 40738417
20. Qin Y, Chen H, Liu F, et al. Intermittent theta burst stimulation for non-suicidal self-injury in adolescents with major depressive disorder: a randomized, sham-controlled trial. *Mol Psychiatry*. 2026;31(2):860-68. PMID: 40883451
21. Dalhuisen I, van Oostrom I, Spijker J, et al. rTMS as a Next Step in Antidepressant Nonresponders: A Randomized Comparison With Current Antidepressant Treatment Approaches. *Am J Psychiatry*. 2024;181(9):806-14. PMID: 39108161
22. Papakostas GI, Trivedi MH, Shelton RC, et al. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. *Mol Psychiatry*. 2024;29(8):2287-95. PMID: 38454079

23. Wang X, Fan X, Zhang L, et al. Repetitive transcranial magnetic stimulation in the treatment of middle-aged and elderly major depressive disorder: A randomized controlled trial. *Medicine (Baltimore)*. 2023;102(35):e34841. PMID: 37657019
24. Zangen A, Zibman S, Tendler A, et al. Pursuing personalized medicine for depression by targeting the lateral or medial prefrontal cortex with Deep TMS. *JCI Insight*. 2023;8(4). PMID: 36692954
25. Bulteau S, Laurin A, Pere M, et al. Intermittent theta burst stimulation (iTBS) versus 10 Hz high-frequency repetitive transcranial magnetic stimulation (rTMS) to alleviate treatment-resistant unipolar depression: A randomized controlled trial (THETA-DEP). *Brain Stimul*. 2022;15(3):870-80. PMID: 35609816
26. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry*. 2006;163(11):1905-17. PMID: 17074942
27. Rush AJ, South C, Jha MK, et al. What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study. *J Clin Psychiatry*. 2020;81(5). PMID: 32780949
28. Yip AG, George MS, Tendler A, et al. 61% of unmedicated treatment resistant depression patients who did not respond to acute TMS treatment responded after four weeks of twice weekly deep TMS in the Brainsway pivotal trial. *Brain Stimul*. 2017;10(4):847-49. PMID: 28330592
29. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. *Lancet (London, England)*. 2018;391(10131):1683-92. PMID: 29726344
30. Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2004;75(8):1171-4. PMID: 15258224
31. Poulet E, Brunelin J, Boeuvre C, et al. Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. *Eur Psychiatry*. 2004;19(6):382-3. PMID: 15363481
32. Fitzgerald PB, Benitez J, de Castella A, et al. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. *Am J Psychiatry*. 2006;163(1):88-94. PMID: 16390894
33. Isenberg K, Downs D, Pierce K, et al. Low frequency rTMS stimulation of the right frontal cortex is as effective as high frequency rTMS stimulation of the left frontal cortex for antidepressant-free, treatment-resistant depressed patients. *Ann Clin Psychiatry*. 2005;17(3):153-9. PMID: 16433057
34. Avery DH, Holtzheimer PE, 3rd, Fawaz W, et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. *Biol Psychiatry*. 2006;59(2):187-94. PMID: 16139808
35. Rossini D, Magri L, Lucca A, et al. Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial. *J Clin Psychiatry*. 2005;66(12):1569-75. PMID: 16401159
36. Avery DH, Isenberg KE, Sampson SM, et al. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. *J Clin Psychiatry*. 2008;69(3):441-51. PMID: 18294022

37. Myczkowski ML, Dias AM, Luvisotto T, et al. Effects of repetitive transcranial magnetic stimulation on clinical, social, and cognitive performance in postpartum depression. *Neuropsychiatric disease and treatment*. 2012;8:491-500. PMID: 23118543
38. Anderson IM, Delvai NA, Ashim B, et al. Adjunctive fast repetitive transcranial magnetic stimulation in depression. *Br J Psychiatry*. 2007;190:533-4. PMID: 17541116
39. Mogg A, Pluck G, Eranti SV, et al. A randomized controlled trial with 4-month follow-up of adjunctive repetitive transcranial magnetic stimulation of the left prefrontal cortex for depression. *Psychol Med*. 2008;38(3):323-33. PMID: 17935639
40. Fitzgerald PB, Hoy K, McQueen S, et al. Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. *J Clin Psychopharmacol*. 2008;28(1):52-8. PMID: 18204341
41. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. *Brain Stimul*. 2010;3(4):187-99. PMID: 20965447
42. Ullrich H, Kranaster L, Sigges E, et al. Ultra-high-frequency left prefrontal transcranial magnetic stimulation as augmentation in severely ill patients with depression: a naturalistic sham-controlled, double-blind, randomized trial. *Neuropsychobiology*. 2012;66(3):141-8. PMID: 22948250
43. Dang T, Avery DH, Russo J. Within-session mood changes from TMS in depressed patients. *J Neuropsychiatry Clin Neurosci*. 2007;19(4):458-63. PMID: 18070851
44. Jorge RE, Moser DJ, Acion L, et al. Treatment of vascular depression using repetitive transcranial magnetic stimulation. *Arch Gen Psychiatry*. 2008;65(3):268-76. PMID: 18316673
45. Wang YM, Li N, Yang LL, et al. Randomized controlled trial of repetitive transcranial magnetic stimulation combined with paroxetine for the treatment of patients with first-episode major depressive disorder. *Psychiatry Res*. 2017;254:18-23. PMID: 28441583
46. Triggs WJ, Ricciuti N, Ward HE, et al. Right and left dorsolateral pre-frontal rTMS treatment of refractory depression: a randomized, sham-controlled trial. *Psychiatry Res*. 2010;178(3):467-74. PMID: 20643486
47. Levkovitz Y, Harel EV, Roth Y, et al. Deep transcranial magnetic stimulation over the prefrontal cortex: evaluation of antidepressant and cognitive effects in depressive patients. *Brain Stimul*. 2009;2(4):188-200. PMID: 20633419
48. Sobis J, Jarzab M, Hese RT, et al. Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression. *J Affect Disord*. 2010;123(1-3):321-6. PMID: 19896204
49. Hoeppner J, Padberg F, Domes G, et al. Influence of repetitive transcranial magnetic stimulation on psychomotor symptoms in major depression. *Eur Arch Psychiatry Clin Neurosci*. 2010;260(3):197-202. PMID: 19680706
50. Bares M, Kopecek M, Novak T, et al. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study. *J Affect Disord*. 2009;118(1-3):94-100. PMID: 19249105
51. Ray S, Nizamie SH, Akhtar S, et al. Efficacy of adjunctive high frequency repetitive transcranial magnetic stimulation of left prefrontal cortex in depression: a randomized sham controlled study. *J Affect Disord*. 2011;128(1-2):153-9. PMID: 20621361
52. Anderson BS, Kavanagh K, Borckardt JJ, et al. Decreasing procedural pain over time of left prefrontal rTMS for depression: initial results from the open-label phase of a multi-site trial (OPT-TMS). *Brain Stimul*. 2009;2(2):88-92. PMID: 20161310

53. Dolberg OT, Dannon PN, Schreiber S, et al. Transcranial magnetic stimulation in patients with bipolar depression: a double blind, controlled study. *Bipolar Disord.* 2002;4 Suppl 1:94-5. PMID: 12479689
54. Janicak PG, O'Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. *J Clin Psychiatry.* 2008;69(2):222-32. PMID: 18232722
55. Lisanby SH, Husain MM, Rosenquist PB, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. *Neuropsychopharmacology.* 2009;34(2):522-34. PMID: 18704101
56. Zheng W, Lan XJ, Qin ZJ, et al. Low-frequency repetitive transcranial magnetic stimulation for children and adolescents with first-episode and drug-naïve major depressive disorder: A systematic review. *Front Psychiatry.* 2023;14:1111754. PMID: 36911139
57. Sun CH, Mai JX, Shi ZM, et al. Adjunctive repetitive transcranial magnetic stimulation for adolescents with first-episode major depressive disorder: a meta-analysis. *Front Psychiatry.* 2023;14:1200738. PMID: 37593451
58. Majumder P, Balan S, Gupta V, et al. The Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in the Treatment of Major Depression Among Children and Adolescents: A Systematic Review. *Cureus.* 2021;13(4):e14564. PMID: 34026380
59. Croarkin PE, Elmaadawi AZ, Aaronson ST, et al. Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial. *Neuropsychopharmacology.* 2021;46(2):462-69. PMID: 32919400
60. Kedzior KK, Reitz SK, Azorina V, et al. Durability of the antidepressant effect of the high-frequency repetitive transcranial magnetic stimulation (rTMS) in the absence of maintenance treatment in major depression: a systematic review and meta-analysis of 16 double-blind, randomized, sham-controlled trials. *Depression and anxiety.* 2015;32(3):193-203. PMID: 25683231
61. Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. *J Clin Psychiatry.* 2014;75(12):1394-401. PMID: 25271871
62. Richieri R, Guedj E, Michel P, et al. Maintenance transcranial magnetic stimulation reduces depression relapse: a propensity-adjusted analysis. *J Affect Disord.* 2013;151(1):129-35. PMID: 23790811
63. Connolly KR, Helmer A, Cristancho MA, et al. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. *J Clin Psychiatry.* 2012;73(4):e567-73. PMID: 22579164
64. Konstantinou G, Hui J, Ortiz A, et al. Repetitive transcranial magnetic stimulation (rTMS) in bipolar disorder: A systematic review. *Bipolar Disord.* 2022;24(1):10-26. PMID: 33949063
65. Tee MMK, Au CH. A Systematic Review and Meta-Analysis of Randomized Sham-Controlled Trials of Repetitive Transcranial Magnetic Stimulation for Bipolar Disorder. *Psychiatr Q.* 2020;91(4):1225-47. PMID: 32860557
66. Dellink A, Hebbrecht K, Zeeuws D, et al. Continuous theta burst stimulation for bipolar depression: A multicenter, double-blind randomized controlled study exploring treatment

- efficacy and predictive potential of kynurenine metabolites. *J Affect Disord.* 2024;361:693-701. PMID: 38936704
67. Novák T, Kostýlková L, Bareš M, et al. Right ventrolateral and left dorsolateral 10 Hz transcranial magnetic stimulation as an add-on treatment for bipolar I and II depression: a double-blind, randomised, three-arm, sham-controlled study. *World J Biol Psychiatry.* 2024;25(5):304-16. PMID: 38785073
 68. Sheline YI, Makhoul W, Batzdorf AS, et al. Accelerated Intermittent Theta-Burst Stimulation and Treatment-Refractory Bipolar Depression: A Randomized Clinical Trial. *JAMA Psychiatry.* 2024;81(9):936-41. PMID: 38985492
 69. Mallik G, Mishra P, Garg S, et al. Safety and Efficacy of Continuous Theta Burst "Intensive" Stimulation in Acute-Phase Bipolar Depression: A Pilot, Exploratory Study. *The journal of ECT.* 2023;39(1):28-33. PMID: 35815855
 70. Torres IJ, Ge R, McGirr A, et al. Effects of intermittent theta-burst transcranial magnetic stimulation on cognition and hippocampal volumes in bipolar depression. *Dialogues Clin Neurosci.* 2023;25(1):24-32. PMID: 36924413
 71. Zengin G, Topak OZ, Atesci O, et al. The Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment-Resistant Bipolar Depression. *Psychiatr Danub.* 2022;34(2):236-44. PMID: 35772133
 72. Myczkowski ML, Fernandes A, Moreno M, et al. Cognitive outcomes of TMS treatment in bipolar depression: Safety data from a randomized controlled trial. *J Affect Disord.* 2018;235:20-26. PMID: 29631203
 73. Tavares DF, Myczkowski ML, Alberto RL, et al. Treatment of Bipolar Depression with Deep TMS: Results from a Double-Blind, Randomized, Parallel Group, Sham-Controlled Clinical Trial. *Neuropsychopharmacology.* 2017;42(13):2593-601. PMID: 28145409
 74. McGirr A, Karmani S, Arsappa R, et al. Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression. *World Psychiatry.* 2016;15(1):85-86. PMID: PMC4780310
 75. Fitzgerald PB, Hoy KE, Elliot D, et al. A negative double-blind controlled trial of sequential bilateral rTMS in the treatment of bipolar depression. *J Affect Disord.* 2016;198:158-62. PMID: 27016659
 76. Nahas Z, Kozel FA, Li X, et al. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. *Bipolar Disord.* 2003;5(1):40-7. PMID: 12656937
 77. Brown R, Cherian K, Jones K, et al. Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults. *Cochrane Database Syst Rev.* 2024;8(8):Cd015040. PMID: 39092744
 78. Cui H, Jiang L, Wei Y, et al. Efficacy and safety of repetitive transcranial magnetic stimulation for generalised anxiety disorder: A meta-analysis. *Gen Psychiatr.* 2019;32(5):e100051. PMID: 31673675
 79. Cirillo P, Gold AK, Nardi AE, et al. Transcranial magnetic stimulation in anxiety and trauma-related disorders: A systematic review and meta-analysis. *Brain Behav.* 2019;9(6):e01284. PMID: 31066227
 80. Trevizol AP, Barros MD, Silva PO, et al. Transcranial magnetic stimulation for posttraumatic stress disorder: an updated systematic review and meta-analysis. *Trends in psychiatry and psychotherapy.* 2016;38(1):50-5. PMID: 27074341
 81. Yuan H, Liu B, Li F, et al. Effects of intermittent theta-burst transcranial magnetic stimulation on post-traumatic stress disorder symptoms: A randomized controlled trial. *Psychiatry Res.* 2023;329:115533. PMID: 37826976

82. Isserles M, Tendler A, Roth Y, et al. Deep Transcranial Magnetic Stimulation Combined With Brief Exposure for Posttraumatic Stress Disorder: A Prospective Multisite Randomized Trial. *Biol Psychiatry*. 2021;90(10):721-28. PMID: 34274108
83. Chen H, Li J, Jia X, et al. Efficacy of high-frequency transcranial magnetic stimulation to improve negative symptoms in patients with Schizophrenia: A meta-analysis of randomized controlled trials. *Psychiatry Res*. 2026;356:116868. PMID: 41343889
84. Blyth SH, Cruz Bosch C, Raffoul JJ, et al. Safety of rTMS for Schizophrenia: A Systematic Review and Meta-analysis. *Schizophr Bull*. 2025;51(2):392-400. PMID: 39278637
85. Marzouk T, Winkelbeiner S, Azizi H, et al. Transcranial Magnetic Stimulation for Positive Symptoms in Schizophrenia: A Systematic Review. *Neuropsychobiology*. 2019:1-13. PMID: 31505508
86. Iimori T, Nakajima S, Miyazaki T, et al. Effectiveness of the prefrontal repetitive transcranial magnetic stimulation on cognitive profiles in depression, schizophrenia, and Alzheimer's disease: A systematic review. *Progress in neuro-psychopharmacology & biological psychiatry*. 2019;88:31-40. PMID: 29953934
87. He H, Lu J, Yang L, et al. Repetitive transcranial magnetic stimulation for treating the symptoms of schizophrenia: A PRISMA compliant meta-analysis. *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology*. 2017;128(5):716-24. PMID: 28315614
88. Dollfus S, Lecardeur L, Morello R, et al. Placebo Response in Repetitive Transcranial Magnetic Stimulation Trials of Treatment of Auditory Hallucinations in Schizophrenia: A Meta-Analysis. *Schizophr Bull*. 2016;42:301-8. PMID: 26089351
89. Dougall N, Maayan N, Soares-Weiser K, et al. Transcranial magnetic stimulation (TMS) for schizophrenia. *Cochrane Database Syst Rev*. 2015;8:CD006081. PMID: 26289586
90. TEC Assessment "Transcranial magnetic stimulation for the treatment of schizophrenia." BlueCross BlueShield Association Technology Evaluation Center, Vol. 26, Tab 6.
91. Kumar N, Vishnubhatla S, Wadhawan AN, et al. A randomized, double blind, sham-controlled trial of repetitive transcranial magnetic stimulation (rTMS) in the treatment of negative symptoms in schizophrenia. *Brain Stimul*. 2020;13(3):840-49. PMID: 32289715
92. Zhuo K, Tang Y, Song Z, et al. Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial. *Neuropsychiatric disease and treatment*. 2019;15:1141-50. PMID: 31190822
93. Guan HY, Zhao JM, Wang KQ, et al. High-frequency neuronavigated rTMS effect on clinical symptoms and cognitive dysfunction: a pilot double-blind, randomized controlled study in Veterans with schizophrenia. *Transl Psychiatry*. 2020;10(1):79. PMID: 32098946
94. Jin Y, Tong J, Huang Y, et al. Effectiveness of accelerated intermittent theta burst stimulation for social cognition and negative symptoms among individuals with schizophrenia: A randomized controlled trial. *Psychiatry Res*. 2023;320:115033. PMID: 36603383
95. Hu Q, Jiao X, Zhou J, et al. Low-frequency repetitive transcranial magnetic stimulation over the right orbitofrontal cortex for patients with first-episode schizophrenia: A randomized, double-blind, sham-controlled trial. *Psychiatry Res*. 2023;330:115600. PMID: 37992513

96. Hua Q, Wang L, He K, et al. Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations in Schizophrenia: A Randomized Clinical Trial. *JAMA Netw Open*. 2024;7(11):e2444215. PMID: 39527055
97. Joseph JT, Vishwanath R, Praharaj SK. Efficacy and safety of accelerated transcranial magnetic stimulation for obsessive-compulsive disorder: A systematic review and meta-analysis. *Asian J Psychiatr*. 2025;106:104420. PMID: 40081086
98. Vicheva P, Osborne C, Krieg SM, et al. Transcranial magnetic stimulation for obsessive-compulsive disorder and post-traumatic stress disorder: A comprehensive systematic review and analysis of therapeutic benefits, cortical targets, and psychopathophysiological mechanisms. *Progress in neuro-psychopharmacology & biological psychiatry*. 2025;136:111147. PMID: 39293504
99. Ramakrishnan D, Farhat LC, Vattimo EFQ, et al. An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis. *Journal of psychiatric research*. 2024;173:387-97. PMID: 38598877
100. Kar SK, Agrawal A, Silva-Dos-Santos A, et al. The Efficacy of Transcranial Magnetic Stimulation in the Treatment of Obsessive-Compulsive Disorder: An Umbrella Review of Meta-Analyses. *CNS Spectr*. 2024;29(2):109-18. PMID: 38053347
101. Grassi G, Moradei C, Cecchelli C. Will Transcranial Magnetic Stimulation Improve the Treatment of Obsessive-Compulsive Disorder? A Systematic Review and Meta-Analysis of Current Targets and Clinical Evidence. *Life (Basel)*. 2023;13(7). PMID: 37511869
102. Pellegrini L, Garg K, Enara A, et al. Repetitive transcranial magnetic stimulation (r-TMS) and selective serotonin reuptake inhibitor-resistance in obsessive-compulsive disorder: A meta-analysis and clinical implications. *Compr Psychiatry*. 2022;118:152339. PMID: 35917621
103. Fitzsimmons S, van der Werf YD, van Campen AD, et al. Repetitive transcranial magnetic stimulation for obsessive-compulsive disorder: A systematic review and pairwise/network meta-analysis. *J Affect Disord*. 2022;302:302-12. PMID: 35041869
104. Suhas S, Malo PK, Kumar V, et al. Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomised controlled trials. *World J Biol Psychiatry*. 2023;24(2):162-77. PMID: 35615998
105. Perera MPN, Mallawaarachchi S, Miljevic A, et al. Repetitive Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Meta-analysis of Randomized, Sham-Controlled Trials. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2021;6(10):947-60. PMID: 33775927
106. Liang K, Li H, Bu X, et al. Efficacy and tolerability of repetitive transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. *Transl Psychiatry*. 2021;11(1):332. PMID: 34050130
107. Carmi L, Tendler A, Bystritsky A, et al. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. *American Journal of Psychiatry*. 2019;176(11):931-38. PMID:
108. Zhou DD, Wang W, Wang GM, et al. An updated meta-analysis: Short-term therapeutic effects of repeated transcranial magnetic stimulation in treating obsessive-compulsive disorder. *J Affect Disord*. 2017;215:187-96. PMID: 28340445
109. Trevizol AP, Shiozawa P, Cook IA, et al. Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: An Updated Systematic Review and Meta-analysis. *The journal of ECT*. 2016;32(4):262-66. PMID: 27327557

110. Ozer U, Yucens B, Tumkaya S. Efficacy of accelerated deep transcranial magnetic stimulation with double cone coil in obsessive-compulsive disorder: A double-blind, placebo-controlled study. *Journal of psychiatric research*. 2024;171:325-31. PMID: 38342033
111. Jiang J, Wan K, Liu Y, et al. A Controlled Clinical Study of Accelerated High-Dose Theta Burst Stimulation in Patients with Obsessive-Compulsive Disorder. *Neural Plast*. 2023;2023:2741287. PMID: 38099081
112. Roth Y, Tendler A, Arikan MK, et al. Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites. *Journal of psychiatric research*. 2021;137:667-72. PMID: 33183769
113. Meek BP, Fotros A, Abo Aoun M, et al. Improvements in error-monitoring and symptoms following low-frequency rTMS of dorsal anterior cingulate cortex in obsessive compulsive disorder; a randomized, sham-controlled study. *Brain Cogn*. 2021;154:105809. PMID: 34619574
114. Fu B, Zhou X, Zhou X, et al. Efficacy and Safety of Transcranial Magnetic Stimulation for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-Analysis. *Brain Behav*. 2025;15(1):e70246. PMID: 39829146
115. Smith JR, DiSalvo M, Green A, et al. Treatment Response of Transcranial Magnetic Stimulation in Intellectually Capable Youth and Young Adults with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. *Neuropsychol Rev*. 2023;33(4):834-55. PMID: 36161554
116. Westwood SJ, Radua J, Rubia K. Noninvasive brain stimulation in children and adults with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. *J Psychiatry Neurosci*. 2021;46(1):E14-e33. PMID: 33009906
117. Mostafavi SA, Khaleghi A, Mohammadi MR. Noninvasive brain stimulation in alcohol craving: A systematic review and meta-analysis. *Progress in neuro-psychopharmacology & biological psychiatry*. 2020;101:109938. PMID: 32234509
118. Barahona-Correa JB, Velosa A, Chainho A, et al. Repetitive Transcranial Magnetic Stimulation for Treatment of Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. *Frontiers in integrative neuroscience*. 2018;12:27. PMID: 30038561
119. Li H, Wang J, Li C, et al. Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults. *Cochrane Database Syst Rev*. 2014;9:CD009083. PMID: 25230088
120. Konstantinou GN, Trevizol AP, Downar J, et al. Repetitive transcranial magnetic stimulation in patients with borderline personality disorder: A systematic review. *Psychiatry Res*. 2021;304:114145. PMID: 34358761
121. Torres-Castaño A, Rivero-Santana A, Perestelo-Pérez L, et al. Transcranial Magnetic Stimulation for the Treatment of Cocaine Addiction: A Systematic Review. *J Clin Med*. 2021;10(23). PMID: 34884297
122. Zou M, Broadbear JH, Rao S. Exploring the Utility of Neurostimulation Therapies in the Treatment of Borderline Personality Disorder: A Systematic Literature Review. *The journal of ECT*. 2023. PMID: 36988515
123. Amerio A, Baccino C, Breda GS, et al. Effects of transcranial magnetic stimulation on cocaine addiction: A systematic review of randomized controlled trials. *Psychiatry Res*. 2023;329:115491. PMID: 37783092
124. Rosa MO, Gattaz WF, Rosa MA, et al. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. *J Clin Psychiatry*. 2007;68(10):1528-32. PMID: 17960967

125. Prikryl R, Kasperek T, Skotakova S, et al. Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study. *Schizophr Res.* 2007;95(1-3):151-7. PMID: 17689931
126. Mogg A, Purvis R, Eranti S, et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study. *Schizophr Res.* 2007;93(1-3):221-8. PMID: 17478080
127. Walpoth M, Hoertnagl C, Mangweth-Matzek B, et al. Repetitive transcranial magnetic stimulation in bulimia nervosa: preliminary results of a single-centre, randomised, double-blind, sham-controlled trial in female outpatients. *Psychother Psychosom.* 2008;77(1):57-60. PMID: 18087209
128. Mantovani A, Aly M, Dagan Y, et al. Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. *J Affect Disord.* 2013;144(1-2):153-9. PMID: 22858212
129. Watts BV, Landon B, Groft A, et al. A sham controlled study of repetitive transcranial magnetic stimulation for posttraumatic stress disorder. *Brain Stimul.* 2012;5(1):38-43. PMID: 22264669
130. Kaptan A, Yaroslavsky Y, Applebaum J, et al. Right prefrontal TMS versus sham treatment of mania: a controlled study. *Bipolar Disord.* 2003;5(1):36-9. PMID: 12656936
131. Cohen H, Kaplan Z, Kotler M, et al. Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in posttraumatic stress disorder: a double-blind, placebo-controlled study. *Am J Psychiatry.* 2004;161(3):515-24. PMID: 14992978
132. Isserles M, Shalev AY, Roth Y, et al. Effectiveness of deep transcranial magnetic stimulation combined with a brief exposure procedure in post-traumatic stress disorder - A pilot study. *Brain Stimul.* 2012. PMID: 22921765
133. Schonfeldt-Lecuona C, Gron G, Walter H, et al. Stereotaxic rTMS for the treatment of auditory hallucinations in schizophrenia. *Neuroreport.* 2004;15(10):1669-73. PMID: 15232304
134. Weaver L, Rostain AL, Mace W, et al. Transcranial magnetic stimulation (TMS) in the treatment of attention-deficit/hyperactivity disorder in adolescents and young adults: a pilot study. *The journal of ECT.* 2012;28(2):98-103. PMID: 22551775
135. Elbeh KA, Elserogy YM, Khalifa HE, et al. Repetitive transcranial magnetic stimulation in the treatment of obsessive-compulsive disorders: Double blind randomized clinical trial. *Psychiatry Res.* 2016;238:264-9. PMID: 27086243
136. Deppermann S, Vennewald N, Diemer J, et al. Neurobiological and clinical effects of fNIRS-controlled rTMS in patients with panic disorder/agoraphobia during cognitive-behavioural therapy. *Neuroimage Clin.* 2017;16:668-77. PMID: 29085773
137. Prahara SK, Ram D, Arora M. Efficacy of high frequency (rapid) suprathreshold repetitive transcranial magnetic stimulation of right prefrontal cortex in bipolar mania: a randomized sham controlled study. *J Affect Disord.* 2009;117(3):146-50. PMID: 19178948
138. Ni HC, Chen YL, Chao YP, et al. Intermittent theta burst stimulation over the posterior superior temporal sulcus for children with autism spectrum disorder: A 4-week randomized blinded controlled trial followed by another 4-week open-label intervention. *Autism.* 2021;25(5):1279-94. PMID: 33631943
139. Rabey JM, Dobronevsky E, Aichenbaum S, et al. Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: a randomized, double-blind study. *J Neural Transm.* 2012. PMID: 23076723

140. Bloch Y, Harel EV, Aviram S, et al. Positive effects of repetitive transcranial magnetic stimulation on attention in ADHD Subjects: a randomized controlled pilot study. *World J Biol Psychiatry*. 2010;11(5):755-8. PMID: 20521875
141. Cordes J, Thunker J, Agelink MW, et al. Effects of 10 Hz repetitive transcranial magnetic stimulation (rTMS) on clinical global impression in chronic schizophrenia. *Psychiatry Res*. 2010;177(1-2):32-6. PMID: 20378181
142. Mishra BR, Nizamie SH, Das B, et al. Efficacy of repetitive transcranial magnetic stimulation in alcohol dependence: a sham-controlled study. *Addiction*. 2010;105(1):49-55. PMID: 20078462
143. Van den Eynde F, Claudino AM, Mogg A, et al. Repetitive transcranial magnetic stimulation reduces cue-induced food craving in bulimic disorders. *Biol Psychiatry*. 2010;67(8):793-5. PMID: 20060105
144. Boggio PS, Rocha M, Oliveira MO, et al. Noninvasive brain stimulation with high-frequency and low-intensity repetitive transcranial magnetic stimulation treatment for posttraumatic stress disorder. *J Clin Psychiatry*. 2010;71(8):992-9. PMID: 20051219
145. Sokhadze E, Baruth J, Tasman A, et al. Low-frequency repetitive transcranial magnetic stimulation (rTMS) affects event-related potential measures of novelty processing in autism. *Appl Psychophysiol Biofeedback*. 2010;35(2):147-61. PMID: 19941058
146. Mantovani A, Simpson HB, Fallon BA, et al. Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder. *Int J Neuropsychopharmacol*. 2010;13(2):217-27. PMID: 19691873
147. Vercammen A, Knegtering H, Bruggeman R, et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory-verbal hallucinations in schizophrenia: a randomized controlled trial. *Schizophr Res*. 2009;114(1-3):172-9. PMID: 19679450
148. Amiaz R, Levy D, Vainiger D, et al. Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption. *Addiction*. 2009;104(4):653-60. PMID: 19183128
149. Paz Y, Friedwald K, Levkovitz Y, et al. Randomised sham-controlled study of high-frequency bilateral deep transcranial magnetic stimulation (dTMS) to treat adult attention hyperactive disorder (ADHD): Negative results. *World J Biol Psychiatry*. 2018;19(7):561-66. PMID: 28090806
150. Khedr EM, Abo-Elfetoh N, Rothwell JC. Treatment of post-stroke dysphagia with repetitive transcranial magnetic stimulation. *Acta Neurol Scand*. 2009;119(3):155-61. PMID: 18771521
151. Gay A, Jaussent I, Sigaud T, et al. A Lack of Clinical Effect of High-frequency rTMS to Dorsolateral Prefrontal Cortex on Bulimic Symptoms: A Randomised, Double-blind Trial. *European eating disorders review : the journal of the Eating Disorders Association*. 2016;24(6):474-81. PMID: 27633286
152. Garza-Villarreal EA, Alcala-Lozano R, Fernandez-Lozano S, et al. Clinical and Functional Connectivity Outcomes of 5-Hz Repetitive Transcranial Magnetic Stimulation as an Add-on Treatment in Cocaine Use Disorder: A Double-Blind Randomized Controlled Trial. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2021;6(7):745-57. PMID: 33508499
153. Wang B, Wang Y, Yang F, et al. The effect of repetitive transcranial magnetic stimulation on immediate and long-term cognitive functions in Alzheimer's dementia and mild cognitive impairment: a meta-analysis. *J Neuroeng Rehabil*. 2025;22(1):262. PMID: 41398677

154. Xiu H, Liu F, Hou Y, et al. High-frequency repetitive transcranial magnetic stimulation (HF-rTMS) on global cognitive function of elderly in mild to moderate Alzheimer's disease: a systematic review and meta-analysis. *Neurol Sci.* 2024;45(1):13-25. PMID: 37749398
155. Huang P, Lin L, Zhang J, et al. Efficacy analysis of three brain stimulation techniques for Alzheimer's disease: a meta-analysis of repeated transcranial magnetic stimulation, transcranial direct current stimulation, and deep brain stimulation. *Expert Rev Neurother.* 2024;24(1):117-27. PMID: 38088070
156. Miller A, Allen RJ, Juma AA, et al. Does repetitive transcranial magnetic stimulation improve cognitive function in age-related neurodegenerative diseases? A systematic review and meta-analysis. *International journal of geriatric psychiatry.* 2023;38(8):e5974. PMID: 37526325
157. Teselink J, Bawa KK, Koo GK, et al. Efficacy of non-invasive brain stimulation on global cognition and neuropsychiatric symptoms in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review. *Ageing Res Rev.* 2021;72:101499. PMID: 34700007
158. Wang X, Mao Z, Yu X. The role of noninvasive brain stimulation for behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. *Neurol Sci.* 2020. PMID: 31925612
159. Vacas SM, Stella F, Loureiro JC, et al. Noninvasive brain stimulation for behavioural and psychological symptoms of dementia: A systematic review and meta-analysis. *International journal of geriatric psychiatry.* 2018. PMID: 30246461
160. Cheng CPW, Wong CSM, Lee KK, et al. Effects of repetitive transcranial magnetic stimulation on improvement of cognition in elderly patients with cognitive impairment: a systematic review and meta-analysis. *International journal of geriatric psychiatry.* 2018;33(1):e1-e13. PMID: 28493371
161. Koch G, Casula EP, Bonni S, et al. Effects of 52 weeks of precuneus rTMS in Alzheimer's disease patients: a randomized trial. *Alzheimers Res Ther.* 2025;17(1):69. PMID: 40176122
162. Koch G, Casula EP, Bonni S, et al. Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial. *Brain.* 2022;145(11):3776-86. PMID: 36281767
163. Gupta MR, Bablu Lal; Bhatia, Dinesh; Mukherjee, Arun Transcranial Magnetic Stimulation Therapy in Spastic Cerebral Palsy Children Improves Motor Activity. *Journal of Neuroinfectious Diseases* 2016;7(4):1-4. PMID:
164. Mishra A, Maiti R, Mishra BR, et al. Effect of Repetitive Transcranial Magnetic Stimulation on Seizure Frequency and Epileptiform Discharges in Drug-Resistant Epilepsy: A Meta-Analysis. *J Clin Neurol.* 2020;16(1):9-18. PMID: 31942753
165. Walton D, Spencer DC, Nevitt SJ, et al. Transcranial magnetic stimulation for the treatment of epilepsy. *Cochrane Database of Systematic Reviews.* 2021(4). PMID: CD011025
166. Pereira LS, Muller VT, da Mota Gomes M, et al. Safety of repetitive transcranial magnetic stimulation in patients with epilepsy: A systematic review. *Epilepsy & behavior : E&B.* 2016;57(Pt A):167-76. PMID: 26970993
167. Wang YY, Ma L, Shi XJ, et al. Cerebellar transcranial magnetic stimulation to treat drug-resistant epilepsy: A randomized, controlled, crossover clinical trial. *Epilepsia.* 2025;66(1):240-52. PMID: 39513971
168. Ahmed I, Mustafaoglu R, Memon AR, et al. Comparative Effectiveness of Noninvasive Brain Stimulation for the Treatment of Pain, Fatigue, and Sleep Quality in Fibromyalgia.

- A Systematic Review With Network Meta-Analysis. *Clin J Pain*. 2025;41(5). PMID: 40091857
169. Su YC, Guo YH, Hsieh PC, et al. Efficacy of Repetitive Transcranial Magnetic Stimulation in Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Clin Med*. 2021;10(20). PMID: 34682790
 170. Sun P, Fang L, Zhang J, et al. Repetitive Transcranial Magnetic Stimulation for Patients with Fibromyalgia: A Systematic Review with Meta-Analysis. *Pain Med*. 2022;23(3):499-514. PMID: 34542624
 171. Saltychev M, Laimi K. Effectiveness of repetitive transcranial magnetic stimulation in patients with fibromyalgia: a meta-analysis. *International journal of rehabilitation research Internationale Zeitschrift fur Rehabilitationsforschung Revue internationale de recherches de readaptation*. 2017;40(1):11-18. PMID: 27977465
 172. Knijnik LM, Dussan-Sarria JA, Rozisky JR, et al. Repetitive Transcranial Magnetic Stimulation for Fibromyalgia: Systematic Review and Meta-Analysis. *Pain practice : the official journal of World Institute of Pain*. 2016;16(3):294-304. PMID: 25581213
 173. Marlow NM, Bonilha HS, Short EB. Efficacy of transcranial direct current stimulation and repetitive transcranial magnetic stimulation for treating fibromyalgia syndrome: a systematic review. *Pain practice : the official journal of World Institute of Pain*. 2013;13(2):131-45. PMID: 22631436
 174. Badr MY, Ahmed GK, Amer RA, et al. Effects of transcranial magnetic stimulation on sleep quality in fibromyalgia: A double-blind randomized clinical trial. *Sleep Med*. 2024;124:354-61. PMID: 39378544
 175. Saltychev M, Juhola J. Effectiveness of High-Frequency Repetitive Transcranial Magnetic Stimulation in Migraine: A Systematic Review and Meta-analysis. *Am J Phys Med Rehabil*. 2022;101(11):1001-06. PMID: 35034064
 176. Subramonian A, Argáez C. CADTH Rapid Response Reports. Non-invasive Nerve Stimulation Modalities for Migraine Pain: A Review of Clinical Effectiveness and Cost-effectiveness. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Copyright © 2020 Canadian Agency for Drugs and Technologies in Health., 2020.
 177. Feng Y, Zhang B, Zhang J, et al. Effects of Non-invasive Brain Stimulation on Headache Intensity and Frequency of Headache Attacks in Patients With Migraine: A Systematic Review and Meta-Analysis. *Headache*. 2019;59(9):1436-47. PMID: 31535368
 178. Treatment of chronic migraine and chronic tension-type headache: Final evidence report. Olympia (WA): Washington State Health Care Authority; 2017 April 14. [cited 04/09/2026]. 'Available from:' <https://www.hca.wa.gov/assets/program/chronic-migraine-final-rpt-20170417.pdf>.
 179. Stilling JM, Monchi O, Amoozegar F, et al. Transcranial Magnetic and Direct Current Stimulation (TMS/tDCS) for the Treatment of Headache: A Systematic Review. *Headache*. 2019;59(3):339-57. PMID: 30671941
 180. Lan L, Zhang X, Li X, et al. The efficacy of transcranial magnetic stimulation on migraine: a meta-analysis of randomized controlled trails. *J Headache Pain*. 2017;18(1):86. PMID: 28831756
 181. Granato A, Fantini J, Monti F, et al. Dramatic placebo effect of high frequency repetitive TMS in treatment of chronic migraine and medication overuse headache. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia*. 2019;60:96-100. PMID: 30316627

182. Leung A, Shukla S, Fallah A, et al. Repetitive Transcranial Magnetic Stimulation in Managing Mild Traumatic Brain Injury-Related Headaches. *Neuromodulation : journal of the International Neuromodulation Society*. 2016;19(2):133-41. PMID: 26555886
183. Rapinesi C, Del Casale A, Scatena P, et al. Add-on deep Transcranial Magnetic Stimulation (dTMS) for the treatment of chronic migraine: A preliminary study. *Neurosci Lett*. 2016;623:7-12. PMID: 27132086
184. Che X, Cash RFH, Luo X, et al. High-frequency rTMS over the dorsolateral prefrontal cortex on chronic and provoked pain: A systematic review and meta-analysis. *Brain Stimul*. 2021;14(5):1135-46. PMID: 34280583
185. Ramger BC, Bader KA, Davies SP, et al. Effects of Non-Invasive Brain Stimulation on Clinical Pain Intensity and Experimental Pain Sensitivity Among Individuals with Central Post-Stroke Pain: A Systematic Review. *J Pain Res*. 2019;12:3319-29. PMID: 31853195
186. Hamid P, Malik BH, Hussain ML. Noninvasive Transcranial Magnetic Stimulation (TMS) in Chronic Refractory Pain: A Systematic Review. *Cureus*. 2019;11(10):e6019. PMID: 31824787
187. Attal N, Poindessous-Jazat F, De Chauvigny E, et al. Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial. *Brain*. 2021;144(11):3328-39. PMID: 34196698
188. Ambriz-Tututi M, Alvarado-Reynoso B, Drucker-Colin R. Analgesic effect of repetitive transcranial magnetic stimulation (rTMS) in patients with chronic low back pain. *Bioelectromagnetics*. 2016. PMID: 27548757
189. Malavera A, Silva FA, Fregni F, et al. Repetitive Transcranial Magnetic Stimulation for Phantom Limb Pain in Land Mine Victims: A Double-Blinded, Randomized, Sham-Controlled Trial. *The journal of pain : official journal of the American Pain Society*. 2016;17(8):911-8. PMID: 27260638
190. Shimizu T, Hosomi K, Maruo T, et al. Efficacy of deep rTMS for neuropathic pain in the lower limb: a randomized, double-blind crossover trial of an H-coil and figure-8 coil. *J Neurosurg*. 2017;127(5):1172-80. PMID: 28156250
191. Conte D, Roman A, Beorchia Y, et al. The effects of transcranial magnetic stimulation in motor symptoms of Parkinson's disease: an overview of systematic reviews with meta-analysis. *Neurol Sci*. 2025;46(8):3405-18. PMID: 40237970
192. Li R, He Y, Qin W, et al. Effects of Repetitive Transcranial Magnetic Stimulation on Motor Symptoms in Parkinson's Disease: A Meta-Analysis. *Neurorehabil Neural Repair*. 2022;36(7):395-404. PMID: 35616427
193. Cheng B, Zhu T, Zhao W, et al. Effect of Theta Burst Stimulation-Patterned rTMS on Motor and Nonmotor Dysfunction of Parkinson's Disease: A Systematic Review and Metaanalysis. *Front Neurol*. 2021;12:762100. PMID: 35095722
194. Jiang Y, Guo Z, McClure MA, et al. Effect of rTMS on Parkinson's cognitive function: a systematic review and meta-analysis. *BMC Neurol*. 2020;20(1):377. PMID: 33076870
195. Kim YW, Shin IS, Moon HI, et al. Effects of non-invasive brain stimulation on freezing of gait in parkinsonism: A systematic review with meta-analysis. *Parkinsonism & related disorders*. 2019;64:82-89. PMID: 30902526
196. Qin B, Chen H, Gao W, et al. Effectiveness of high-frequency repetitive transcranial magnetic stimulation in patients with depression and Parkinson's disease: a meta-analysis of randomized, controlled clinical trials. *Neuropsychiatric disease and treatment*. 2018;14:273-84. PMID: 29391800

197. Wagle Shukla A, Shuster JJ, Chung JW, et al. Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy in Parkinson Disease: A Meta-Analysis. *PM & R : the journal of injury, function, and rehabilitation*. 2016;8(4):356-66. PMID: 26314233
198. Chou YH, Hickey PT, Sundman M, et al. Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis. *JAMA neurology*. 2015;72(4):432-40. PMID: 25686212
199. Shirota Y, Ohtsu H, Hamada M, et al. Supplementary motor area stimulation for Parkinson disease: a randomized controlled study. *Neurology*. 2013;80:1400-5. PMID: 23516319
200. Elahi B, Chen R. Effect of transcranial magnetic stimulation on Parkinson motor function--systematic review of controlled clinical trials. *Mov Disord*. 2009;24(3):357-63. PMID: 18972549
201. Feng Z, Li M, Zheng Y, et al. Efficacy of low-frequency repetitive transcranial magnetic stimulation in the treatment of sleep disorders in the early stage of Parkinson disease: A single-center double-blind controlled study. *Medicine (Baltimore)*. 2025;104(38):e44780. PMID: 40988161
202. Romero JP, Moreno-Verdú M, Arroyo-Ferrer A, et al. Clinical and neurophysiological effects of bilateral repetitive transcranial magnetic stimulation and EEG-guided neurofeedback in Parkinson's disease: a randomized, four-arm controlled trial. *J Neuroeng Rehabil*. 2024;21(1):135. PMID: 39103947
203. He W, Wang JC, Tsai PY. Theta Burst Magnetic Stimulation Improves Parkinson's-Related Cognitive Impairment: A Randomised Controlled Study. *Neurorehabil Neural Repair*. 2021;35(11):986-95. PMID: 34467796
204. Cohen OS, Rigbi A, Yahalom G, et al. Repetitive Deep TMS for Parkinson Disease: A 3-Month Double-Blind, Randomized Sham-Controlled Study. *J Clin Neurophysiol*. 2018;35(2):159-65. PMID: 29373395
205. Makkos A, Pal E, Aschermann Z, et al. High-Frequency Repetitive Transcranial Magnetic Stimulation Can Improve Depression in Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study. *Neuropsychobiology*. 2016;73:169-77. PMID: 27093063
206. Benninger DH, Iseki K, Kranick S, et al. Controlled study of 50-Hz repetitive transcranial magnetic stimulation for the treatment of Parkinson disease. *Neurorehabil Neural Repair*. 2012;26(9):1096-105. PMID: 22593114
207. Yang YR, Tseng CY, Chiou SY, et al. Combination of rTMS and treadmill training modulates corticomotor inhibition and improves walking in Parkinson disease: a randomized trial. *Neurorehabil Neural Repair*. 2013;27(1):79-86. PMID: 22785003
208. Zhang K, Zhao Y, Hu Q, et al. Theta burst stimulation effectively improves post-stroke aphasia: A systematic review and meta-analysis of randomized controlled trials. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia*. 2026;144:111793. PMID: 41401734
209. Zhang JJY, Ang J, Saffari SE, et al. Repetitive Transcranial Magnetic Stimulation for Motor Recovery After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Low Risk of Bias. *Neuromodulation : journal of the International Neuromodulation Society*. 2025;28(1):16-42. PMID: 39320286
210. Duan X, Huang D, Zhong H, et al. Efficacy of rTMS in treating functional impairment in post-stroke patients: a systematic review and meta-analysis. *Neurol Sci*. 2024;45(8):3887-99. PMID: 38512529
211. Ahmed I, Mustafaoglu R, Rossi S, et al. Non-invasive Brain Stimulation Techniques for the Improvement of Upper Limb Motor Function and Performance in Activities of Daily

- Living After Stroke: A Systematic Review and Network Meta-analysis. *Arch Phys Med Rehabil.* 2023;104(10):1683-97. PMID: 37245690
212. Chen G, Wu M, Chen J, et al. Non-invasive brain stimulation effectively improves post-stroke sensory impairment: a systematic review and meta-analysis. *J Neural Transm (Vienna).* 2023;130(10):1219-30. PMID: 37495840
 213. Xie YJ, Chen Y, Tan HX, et al. Repetitive transcranial magnetic stimulation for lower extremity motor function in patients with stroke: a systematic review and network meta-analysis. *Neural Regen Res.* 2021;16(6):1168-76. PMID: 33269766
 214. Dionisio A, Duarte IC, Patricio M, et al. Transcranial Magnetic Stimulation as an Intervention Tool to Recover from Language, Swallowing and Attentional Deficits after Stroke: A Systematic Review. *Cerebrovasc Dis.* 2018;46(3-4):178-85. PMID: 30343304
 215. Zhang L, Xing G, Fan Y, et al. Short- and Long-term Effects of Repetitive Transcranial Magnetic Stimulation on Upper Limb Motor Function after Stroke: a Systematic Review and Meta-Analysis. *Clinical rehabilitation.* 2017;31(9):1137-53. PMID: 28786336
 216. Sebastianelli L, Versace V, Martignago S, et al. Low-frequency rTMS of the unaffected hemisphere in stroke patients: A systematic review. *Acta Neurol Scand.* 2017;136(6):585-605. PMID: 28464421
 217. McIntyre A, Mirkowski M, Thompson S, et al. A Systematic Review and Meta-Analysis on the Use of Repetitive Transcranial Magnetic Stimulation for Spasticity Poststroke. *PM & R : the journal of injury, function, and rehabilitation.* 2017. PMID: 29045857
 218. Fan J, Li Y, Yang Y, et al. Efficacy of Noninvasive Brain Stimulation on Unilateral Neglect After Stroke: A Systematic Review and Meta-analysis. *Am J Phys Med Rehabil.* 2017. PMID: 28953034
 219. Graef P, Dadalt MLR, Rodrigues D, et al. Transcranial magnetic stimulation combined with upper-limb training for improving function after stroke: A systematic review and meta-analysis. *J Neurol Sci.* 2016;369:149-58. PMID: 27653882
 220. Liao X, Xing G, Guo Z, et al. Repetitive transcranial magnetic stimulation as an alternative therapy for dysphagia after stroke: a systematic review and meta-analysis. *Clinical rehabilitation.* 2017;31:289-98. PMID: 27113337
 221. Li Y, Qu Y, Yuan M, et al. Low-frequency repetitive transcranial magnetic stimulation for patients with aphasia after stroke: A meta-analysis. *J Rehabil Med.* 2015;47(8):675-81. PMID: 26181486
 222. Le Q, Qu Y, Tao Y, et al. Effects of repetitive transcranial magnetic stimulation on hand function recovery and excitability of the motor cortex after stroke: a meta-analysis. *Am J Phys Med Rehabil.* 2014;93(5):422-30. PMID: 24429509
 223. Hao Z, Wang D, Zeng Y, et al. Repetitive transcranial magnetic stimulation for improving function after stroke. *Cochrane Database Syst Rev.* 2013;5:CD008862. PMID: 23728683
 224. Liu Y, Ai Y, Cao J, et al. High-Frequency rTMS Broadly Ameliorates Working Memory and Cognitive Symptoms in Stroke Patients: A Randomized Controlled Trial. *Neurorehabil Neural Repair.* 2024;38(10):729-41. PMID: 39162240
 225. Dai M, Qiao J, Shi Z, et al. Effect of cerebellar transcranial magnetic stimulation with double-cone coil on dysphagia after subacute infratentorial stroke: A randomized, single-blinded, controlled trial. *Brain Stimul.* 2023;16(4):1012-20. PMID: 37301470
 226. Zhong L, Wen X, Liu Z, et al. Effects of bilateral cerebellar repetitive transcranial magnetic stimulation in poststroke dysphagia: A randomized sham-controlled trial. *NeuroRehabilitation.* 2023;52(2):227-34. PMID: 36641691
 227. Choi GS, Chang MC. Effects of high-frequency repetitive transcranial magnetic stimulation on reducing hemiplegic shoulder pain in patients with chronic stroke: a

- randomized controlled trial. *The International journal of neuroscience*. 2018;128(2):110-16. PMID: 28805107
228. Forogh B, Ahadi T, Nazari M, et al. The Effect of Repetitive Transcranial Magnetic Stimulation on Postural Stability After Acute Stroke: A Clinical Trial. *Basic Clin Neurosci*. 2017;8(5):405-11. PMID: 29167727
 229. Huang YZ, Lin LF, Chang KH, et al. Priming with 1-Hz rTMS over contralesional leg motor cortex does not increase the rate of regaining ambulation within 3 months of stroke: A randomized controlled trial. *Am J Phys Med Rehabil*. 2017. PMID: 29023249
 230. Guan YZ, Li J, Zhang XW, et al. Effectiveness of repetitive transcranial magnetic stimulation (rTMS) after acute stroke: A one-year longitudinal randomized trial. *CNS neuroscience & therapeutics*. 2017;23(12):940-46. PMID: 28971620
 231. RTI International–University of North Carolina Evidence-based Practice Center. Tinnitus: Non-invasive, Non-pharmacologic Treatments. Olympia (WA): Washington State Health Care Authority; 2020 April 10. [cited 04/09/2026]. 'Available from:' <https://www.hca.wa.gov/assets/program/tinnitus-final-rpt-20200410.pdf>.
 232. Sahlsten H, Virtanen J, Joutsa J, et al. Electric field-navigated transcranial magnetic stimulation for chronic tinnitus: a randomized, placebo-controlled study. *International journal of audiology*. 2017;56(9):692-700. PMID: 28415897
 233. Landgrebe M, Hajak G, Wolf S, et al. 1-Hz rTMS in the treatment of tinnitus: A sham-controlled, randomized multicenter trial. *Brain Stimul*. 2017;10(6):1112-20. PMID: 28807845
 234. Lehner A, Schecklmann M, Greenlee MW, et al. Triple-site rTMS for the treatment of chronic tinnitus: a randomized controlled trial. *Sci Rep*. 2016;6:22302. PMID: 26927363
 235. Defrin R, Grunhaus L, Zamir D, et al. The effect of a series of repetitive transcranial magnetic stimulations of the motor cortex on central pain after spinal cord injury. *Arch Phys Med Rehabil*. 2007;88(12):1574-80. PMID: 18047871
 236. Saitoh Y, Hirayama A, Kishima H, et al. Reduction of intractable deafferentation pain due to spinal cord or peripheral lesion by high-frequency repetitive transcranial magnetic stimulation of the primary motor cortex. *J Neurosurg*. 2007;107(3):555-9. PMID: 17886555
 237. Passard A, Attal N, Benadhiria R, et al. Effects of unilateral repetitive transcranial magnetic stimulation of the motor cortex on chronic widespread pain in fibromyalgia. *Brain*. 2007;130(Pt 10):2661-70. PMID: 17872930
 238. Pomeroy VM, Cloud G, Tallis RC, et al. Transcranial magnetic stimulation and muscle contraction to enhance stroke recovery: a randomized proof-of-principle and feasibility investigation. *Neurorehabil Neural Repair*. 2007;21(6):509-17. PMID: 17409389
 239. Malcolm MP, Triggs WJ, Light KE, et al. Repetitive transcranial magnetic stimulation as an adjunct to constraint-induced therapy: an exploratory randomized controlled trial. *Am J Phys Med Rehabil*. 2007;86(9):707-15. PMID: 17709994
 240. Valle AC, Dionisio K, Pitskel NB, et al. Low and high frequency repetitive transcranial magnetic stimulation for the treatment of spasticity. *Dev Med Child Neurol*. 2007;49(7):534-8. PMID: 17593127
 241. Khedr EM, Rothwell JC, Ahmed MA, et al. Effect of daily repetitive transcranial magnetic stimulation for treatment of tinnitus: comparison of different stimulus frequencies. *J Neurol Neurosurg Psychiatry*. 2008;79(2):212-5. PMID: 18202212
 242. Rossi S, De Capua A, Olivelli M, et al. Effects of repetitive transcranial magnetic stimulation on chronic tinnitus: a randomised, crossover, double blind, placebo controlled study. *J Neurol Neurosurg Psychiatry*. 2007;78(8):857-63. PMID: 17314192

243. Kirton A, Chen R, Friefeld S, et al. Contralesional repetitive transcranial magnetic stimulation for chronic hemiparesis in subcortical paediatric stroke: a randomised trial. *Lancet Neurol.* 2008;7(6):507-13. PMID: 18455961
244. Andre-Obadia N, Mertens P, Gueguen A, et al. Pain relief by rTMS: differential effect of current flow but no specific action on pain subtypes. *Neurology.* 2008;71(11):833-40. PMID: 18779511
245. Hamada M, Ugawa Y, Tsuji S. High-frequency rTMS over the supplementary motor area for treatment of Parkinson's disease. *Mov Disord.* 2008;23(11):1524-31. PMID: 18548577
246. Gabis L, Shklar B, Baruch YK, et al. Pain reduction using transcranial electrostimulation: a double blind "active placebo" controlled trial. *J Rehabil Med.* 2009;41(4):256-61. PMID: 19247545
247. Takeuchi N, Tada T, Toshima M, et al. Inhibition of the unaffected motor cortex by 1 Hz repetitive transcranial magnetic stimulation enhances motor performance and training effect of the paretic hand in patients with chronic stroke. *J Rehabil Med.* 2008;40(4):298-303. PMID: 18382826
248. Kranz G, Shamim EA, Lin PT, et al. Transcranial magnetic brain stimulation modulates blepharospasm: a randomized controlled study. *Neurology.* 2010;75(16):1465-71. PMID: 20956792
249. Chang WH, Kim YH, Bang OY, et al. Long-term effects of rTMS on motor recovery in patients after subacute stroke. *J Rehabil Med.* 2010;42(8):758-64. PMID: 20809058
250. Soler MD, Kumru H, Pelayo R, et al. Effectiveness of transcranial direct current stimulation and visual illusion on neuropathic pain in spinal cord injury. *Brain.* 2010;133(9):2565-77. PMID: 20685806
251. Anders M, Dvorakova J, Rathova L, et al. Efficacy of repetitive transcranial magnetic stimulation for the treatment of refractory chronic tinnitus: a randomized, placebo controlled study. *Neuro Endocrinol Lett.* 2010;31(2):238-49. PMID: 20424590
252. Kim BR, Kim DY, Chun MH, et al. Effect of repetitive transcranial magnetic stimulation on cognition and mood in stroke patients: a double-blind, sham-controlled trial. *Am J Phys Med Rehabil.* 2010;89(5):362-8. PMID: 20407301
253. Martiny K, Lunde M, Bech P. Transcranial low voltage pulsed electromagnetic fields in patients with treatment-resistant depression. *Biol Psychiatry.* 2010;68(2):163-9. PMID: 20385376
254. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. *Lancet Neurol.* 2010;9(4):373-80. PMID: 20206581
255. Filipovic SR, Rothwell JC, Bhatia K. Low-frequency repetitive transcranial magnetic stimulation and off-phase motor symptoms in Parkinson's disease. *J Neurol Sci.* 2010;291(1-2):1-4. PMID: 20153482
256. Kumru H, Murillo N, Samso JV, et al. Reduction of spasticity with repetitive transcranial magnetic stimulation in patients with spinal cord injury. *Neurorehabil Neural Repair.* 2010;24(5):435-41. PMID: 20053952
257. Takeuchi N, Tada T, Toshima M, et al. Repetitive transcranial magnetic stimulation over bilateral hemispheres enhances motor function and training effect of paretic hand in patients after stroke. *J Rehabil Med.* 2009;41(13):1049-54. PMID: 19894000
258. Khedr EM, Abo-Elfetoh N. Therapeutic role of rTMS on recovery of dysphagia in patients with lateral medullary syndrome and brainstem infarction. *J Neurol Neurosurg Psychiatry.* 2010;81(5):495-9. PMID: 19828479

259. Kang BS, Shin HI, Bang MS. Effect of repetitive transcranial magnetic stimulation over the hand motor cortical area on central pain after spinal cord injury. *Arch Phys Med Rehabil.* 2009;90(10):1766-71. PMID: 19801069
260. Khedr EM, Abdel-Fadeil MR, Farghali A, et al. Role of 1 and 3 Hz repetitive transcranial magnetic stimulation on motor function recovery after acute ischaemic stroke. *Eur J Neurol.* 2009;16(12):1323-30. PMID: 19780802
261. Arfeller C, Vonthein R, Plontke SK, et al. Efficacy and safety of bilateral continuous theta burst stimulation (cTBS) for the treatment of chronic tinnitus: design of a three-armed randomized controlled trial. *Trials.* 2009;10:74. PMID: 19698089
262. Di Lazzaro V, Pilato F, Profice P, et al. Motor cortex stimulation for ALS: a double blind placebo-controlled study. *Neurosci Lett.* 2009;464(1):18-21. PMID: 19682544
263. Khedr EM, Etraby AE, Hemeda M, et al. Long-term effect of repetitive transcranial magnetic stimulation on motor function recovery after acute ischemic stroke. *Acta Neurol Scand.* 2010;121(1):30-7. PMID: 19678808
264. Loo CK, Sainsbury K, Mitchell P, et al. A sham-controlled trial of left and right temporal rTMS for the treatment of auditory hallucinations. *Psychol Med.* 2010;40(4):541-6. PMID: 19656432
265. Marcondes RA, Sanchez TG, Kii MA, et al. Repetitive transcranial magnetic stimulation improve tinnitus in normal hearing patients: a double-blind controlled, clinical and neuroimaging outcome study. *Eur J Neurol.* 2010;17(1):38-44. PMID: 19614962
266. Borckardt JJ, Smith AR, Reeves ST, et al. A pilot study investigating the effects of fast left prefrontal rTMS on chronic neuropathic pain. *Pain Med.* 2009;10(5):840-9. PMID: 19594842
267. Jayaram G, Stinear JW. The effects of transcranial stimulation on paretic lower limb motor excitability during walking. *J Clin Neurophysiol.* 2009;26(4):272-9. PMID: 19584748
268. Brighina F, Palermo A, Panetta ML, et al. Reduced cerebellar inhibition in migraine with aura: a TMS study. *Cerebellum.* 2009;8(3):260-6. PMID: 19156474
269. Arias P, Vivas J, Grieve KL, et al. Double-blind, randomized, placebo controlled trial on the effect of 10 days low-frequency rTMS over the vertex on sleep in Parkinson's disease. *Sleep Med.* 2010;11(8):759-65. PMID: 20674489
270. Lorenz I, Muller N, Schlee W, et al. Short-term effects of single repetitive TMS sessions on auditory evoked activity in patients with chronic tinnitus. *J Neurophysiol.* 2010;104(3):1497-505. PMID: 20592125
271. Emara TH, Moustafa RR, Elnahas NM, et al. Repetitive transcranial magnetic stimulation at 1Hz and 5Hz produces sustained improvement in motor function and disability after ischaemic stroke. *Eur J Neurol.* 2010;17(9):1203-9. PMID: 20402755
272. Short EB, Borckardt JJ, Anderson BS, et al. Ten sessions of adjunctive left prefrontal rTMS significantly reduces fibromyalgia pain: a randomized, controlled pilot study. *Pain.* 2011;152(11):2477-84. PMID: 21764215
273. Ahmed MA, Darwish ES, Khedr EM, et al. Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer's dementia. *J Neurol.* 2012;259(1):83-92. PMID: 21671144
274. Kim L, Chun MH, Kim BR, et al. Effect of repetitive transcranial magnetic stimulation on patients with brain injury and Dysphagia. *Annals of rehabilitation medicine.* 2011;35(6):765-71. PMID: 22506204
275. Fang J, Zhou M, Yang M, et al. Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. *Cochrane Database Syst Rev.* 2013;5:CD008554. PMID: 23728676

276. O'Connell NE, Wand BM, Marston L, et al. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev*. 2014;4:CD008208. PMID: 24729198
277. Jansen JM, Daams JG, Koeter MW, et al. Effects of non-invasive neurostimulation on craving: a meta-analysis. *Neuroscience and biobehavioral reviews*. 2013;37(10 Pt 2):2472-80. PMID: 23916527
278. O'Connell NE, Wand BM, Marston L, et al. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev*. 2010(9):CD008208. PMID: 20824873
279. Gunduz A, Rothwell J, Vidal J, et al. Non-invasive brain stimulation to promote motor and functional recovery following spinal cord injury. *Neural Regen Res*. 2017;12(12):1933-38. PMID: 29323025
280. Koch G, Bonni S, Pellicciari MC, et al. Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer's disease. *NeuroImage*. 2017;169:302-11. PMID: 29277405
281. Kohutova B, Fricova J, Klirova M, et al. Theta burst stimulation in the treatment of chronic orofacial pain: a randomized controlled trial. *Physiol Res*. 2017;66(6):1041-47. PMID: 28937248
282. Goudra B, Shah D, Balu G, et al. Repetitive Transcranial Magnetic Stimulation in Chronic Pain: A Meta-analysis. *Anesth Essays Res*. 2017;11(3):751-57. PMID: 28928582
283. Umezaki Y, Badran BW, DeVries WH, et al. The Efficacy of Daily Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) for Burning Mouth Syndrome (BMS): A Randomized Controlled Single-blind Study. *Brain Stimul*. 2016;9(2):234-42. PMID: 26597930
284. Nardone R, Versace V, Sebastianelli L, et al. Transcranial magnetic stimulation in subjects with phantom pain and non-painful phantom sensations: A systematic review. *Brain research bulletin*. 2019;148:1-9. PMID: 30862485
285. Neville IS, Zaninotto AL, Hayashi CY, et al. Repetitive TMS does not improve cognition in patients with TBI: A randomized double-blind trial. *Neurology*. 2019;93(2):e190-e99. PMID: 31175209
286. Rao V, Bechtold K, McCann U, et al. Low-Frequency Right Repetitive Transcranial Magnetic Stimulation for the Treatment of Depression After Traumatic Brain Injury: A Randomized Sham-Controlled Pilot Study. *J Neuropsychiatry Clin Neurosci*. 2019;31(4):306-18. PMID: 31018810
287. Ma T, Sun Y, Ku Y. Effects of Non-invasive Brain Stimulation on Stimulant Craving in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-Analysis. *Frontiers in neuroscience*. 2019;13:1095. PMID: 31680830
288. Elbanna ST, Elshennawy S, Ayad MN. Noninvasive Brain Stimulation for Rehabilitation of Pediatric Motor Disorders Following Brain Injury: Systematic Review of Randomized Controlled Trials. *Arch Phys Med Rehabil*. 2019;100(10):1945-63. PMID: 31078616
289. Liu M, Fan S, Xu Y, et al. Non-invasive brain stimulation for fatigue in multiple sclerosis patients: A systematic review and meta-analysis. *Multiple sclerosis and related disorders*. 2019;36:101375. PMID: 31491597
290. Chou YH, Ton That V, Sundman M. A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer's disease. *Neurobiology of aging*. 2020;86:1-10. PMID: 31783330
291. Zucchella C, Mantovani E, De Icco R, et al. Non-invasive Brain and Spinal Stimulation for Pain and Related Symptoms in Multiple Sclerosis: A Systematic Review. *Frontiers in neuroscience*. 2020;14:547069. PMID: 33328843

292. Mollica A, Safavifar F, Fralick M, et al. Transcranial Magnetic Stimulation for the Treatment of Concussion: A Systematic Review. *Neuromodulation : journal of the International Neuromodulation Society*. 2020. PMID: 33184973
293. Gao F, Chu H, Li J, et al. Repetitive transcranial magnetic stimulation for pain after spinal cord injury: a systematic review and meta-analysis. *J Neurosurg Sci*. 2016. PMID: 27603408
294. Shen Z, Li Z, Ke J, et al. Effect of non-invasive brain stimulation on neuropathic pain following spinal cord injury: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2020;99(34):e21507. PMID: 32846761
295. Tsai PY, Chen YC, Wang JY, et al. Effect of repetitive transcranial magnetic stimulation on depression and cognition in individuals with traumatic brain injury: a systematic review and meta-analysis. *Sci Rep*. 2021;11(1):16940. PMID: 34417481
296. Zhang X, Lan X, Chen C, et al. Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Mild Cognitive Impairment: A Meta-Analysis of Randomized Controlled Trials. *Front Hum Neurosci*. 2021;15:723715. PMID: 34764859
297. Li L, Huang H, Yu Y, et al. Non-invasive Brain Stimulation for Neuropathic Pain After Spinal Cord Injury: A Systematic Review and Network Meta-Analysis. *Frontiers in neuroscience*. 2021;15:800560. PMID: 35221889
298. Lyon DE, Schubert C, Taylor AG. Pilot study of cranial stimulation for symptom management in breast cancer. *Oncol Nurs Forum*. 2010;37(4):476-83. PMID: 20591807
299. Speyer R, Sutt AL, Bergström L, et al. Neurostimulation in People with Oropharyngeal Dysphagia: A Systematic Review and Meta-Analysis of Randomised Controlled Trials- Part II: Brain Neurostimulation. *J Clin Med*. 2022;11(4). PMID: 35207265
300. Kan RLD, Xu GXJ, Shu KT, et al. Effects of non-invasive brain stimulation in multiple sclerosis: systematic review and meta-analysis. *Ther Adv Chronic Dis*. 2022;13:20406223211069198. PMID: 35126965
301. Chang CH, Liou MF, Liu CY, et al. Efficacy of Repetitive Transcranial Magnetic Stimulation in Patients With Methamphetamine Use Disorder: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. *Front Psychiatry*. 2022;13:904252. PMID: 35711590
302. Jiang X, Yan W, Wan R, et al. Effects of repetitive transcranial magnetic stimulation on neuropathic pain: A systematic review and meta-analysis. *Neuroscience and biobehavioral reviews*. 2022;132:130-41. PMID: 34826512
303. Alhindi YA, Khalifa N, Al-Khyatt W, et al. The use of non-invasive brain stimulation techniques to reduce body weight and food cravings: A systematic review and meta-analysis. *Clin Obes*. 2023;13(6):e12611. PMID: 37577814
304. Knorst GRS, Souza PR, Araújo A, et al. Transcranial magnetic stimulation in the treatment of phantom limb pain: a systematic review. *Arq Neuropsiquiatr*. 2024;82(1):1-10. PMID: 38286434
305. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. *Movement Disorders*. 2019;34(2):180-98. PMID:
306. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. *Movement Disorders*. 2018;33(8):1248-66. PMID:
307. Shprecher D, Kurlan R. The management of tics. *Mov Disord*. 2009;24(1):15-24. PMID: 19170198
308. Walter HJ, Abright AR, Bukstein OG, et al. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent

- Depressive Disorders. *J Am Acad Child Adolesc Psychiatry*. 2023;62(5):479-502. PMID: 36273673
309. McClintock SM, Reti IM, Carpenter LL, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. *The Journal of clinical psychiatry*. 2018;79(1). PMID:
 310. Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2016;87(24):2585-93. PMID: PMC5206998
 311. VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder. Washington, DC: U.S. Government Printing Office. [cited 04/09/2026]. 'Available from:' <https://www.healthquality.va.gov/guidelines/MH/bd/VA-DoD-CPG-BD-Full-CPGFinal508.pdf>.
 312. VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder. [cited 04/09/2026]. 'Available from:' <https://www.healthquality.va.gov/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Full-CPGAug242023>.
 313. Washington DUSGPO. VA/DoD Clinical Practice Guideline. (2022). The Management of Major Depressive Disorder. [cited 04/09/2026]. 'Available from:' <https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf>.
 314. VA/DoD Clinical Practice Guidelines. The Management of Stroke Rehabilitation (2019). [cited 11/3/2025]. 'Available from:' https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/Rehab/stroke/VADOD-2024-Stroke-Rehab-CPG-Full-CPG_final_508.pdf.
 315. VA/DoD Clinical Practice Guidelines. The Primary Care Management of Headache (2020). [cited 04/09/2026]. 'Available from:' <https://www.healthquality.va.gov/guidelines/Pain/headache/>.
 316. VA/DoD Clinical Practice Guideline for the Management and Rehabilitation of Post-Acute Mild Traumatic Brain Injury (2021). [cited 04/09/2026]. 'Available from:' <https://www.healthquality.va.gov/guidelines/Rehab/mtbi/VADoDmTBICPGFinal508.pdf>.

CODES

Codes	Number	Description
CPT	0858T	Externally applied transcranial magnetic stimulation with concomitant measurement of evoked cortical potentials with automated report
	0889T	Personalized target development for accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation derived from a structural and resting-state functional MRI, including data preparation and transmission, generation of the target, motor threshold-starting location, neuronavigation files and target report, review and interpretation
	0890T	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including target assessment, initial motor threshold determination, neuronavigation, delivery and management, initial treatment day
	0891T	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent treatment day
	0892T	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent

Codes	Number	Description
		motor threshold redetermination with delivery and management, per treatment day
	0997T	Precuneus magnetic stimulation; treatment planning using magnetic resonance imaging-guided neuronavigation to determine optimal location, dose, and intensity for magnetic stimulation therapy, derived from evoked potentials from single pulses of electromagnetic energy recorded by 64-channel electroencephalogram, including automated data processing, transmission, analysis, generation of treatment parameters with review, interpretation, and report
	0998T	Precuneus magnetic stimulation; personalized treatment delivery of magnetic stimulation therapy to a prespecified target area derived from analysis of evoked potentials within the precuneus, utilizing magnetic resonance imaging-based
	90867	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management
	90868	;subsequent delivery and management, per session
	90869	;subsequent motor threshold re-determination with delivery and management
HCPCS	None	

Date of Origin: April 2022